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 Traumatic brain injury (TBI) affects 1.5 million Americans annually and is a 
major health concern.  Increasing evidence suggests that the brain extracellular 
environment regulates plasticity and synaptic recovery following TBI.  Here we 
have focused on phosphacan/RPTPβ, an alternatively spliced group of 
chondroitin sulfate proteoglycans which are prominent within the mature brain 
extracellular matrix (ECM).  Previous studies show that phosphacan/RPTPβ 
influences neuronal migration, adhesion, neurite outgrowth, and morphogenesis.  
However, our understanding of how these important ECM components are 
involved in recovery from brain trauma remains unclear.  In the present study, we 
  xiv
used unilateral entorhinal cortex lesion (UEC), a model which induces robust 
hippocampal reactive plasticity, to investigate the role(s) of phosphacan/RPTPβ 
isoforms in adaptive synaptogenesis after TBI.  Using detailed protein and mRNA 
quantification, immunohistochemistry, and qualitative ultrastructural analyses, we 
show elevated phosphacan expression in the deafferented hippocampus at the 
early degenerative phase and during the subsequent period of active sprouting.  
By contrast, the receptor variant sRPTPβ is persistently elevated in hippocampus 
over the first two weeks following UEC.  We have further characterized a process 
for validating appropriate reference genes for quantitative real-time RT-PCR 
studies of plasticity and recovery after TBI.  From these studies we conclude that 
injury model, brain region, survival period and correlative protein expression are 
critical factors which must be considered for reference gene selection.  Finally, 
we investigated functional implications of sRPTPβ increase during reactive 
synaptogenesis, showing that the sRPTPβ substrate β-catenin, an important 
cytoskeletal regulator, is altered in hippocampus during injury-induced plasticity.  
Together, these results support a role for phosphacan/RPTPβ in both 
degenerative and regenerative phases of reactive synaptogenesis.  Phosphacan 
may promote adaptive plasticity at earlier post-injury phases through interactions 
with adhesion molecules or growth factors in the extracellular space.  The 
prolonged increase in sRPTPβ after UEC, along with its localization at 
postsynaptic profiles, suggests that this isoform may work with intracellular 
substrates to influence spine morphogenesis and/or stabilization of new 
  xv
synapses.  Gaining a better understanding of the roles of ECM components in 
recovery from TBI will be an essential part of defining the difference between 
injuries where recovery is successful, and those where recovery fails. 
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CHAPTER 1 
 INTRODUCTION 
 
 
General Introduction: Traumatic Brain Injury 
Traumatic brain injury (TBI) is an enormous health concern in the United 
States and around the world.  Every year at least 1.5 million people in this 
country sustain a TBI (Langlois et al., 2006; Rutland-Brown et al., 2006; Centers 
for Disease Control and Prevention, 2006), and since this statistic excludes mild 
TBI and unreported cases it is likely to be a significant underestimate of the true 
incidence of brain trauma.  The U.S. Centers for Disease Control and Prevention 
reported that in the year 2003 alone, TBI claimed 51,000 lives, and resulted in 
300,000 hospitalizations and more than 1.2 million emergency department visits 
(Rutland-Brown et al., 2006).  Persons under the age of 24 and over the age of 
75 are at the highest risk of acquiring brain trauma, and males are affected 
nearly twice as often as females (Thurman & Guerrero, 1999; Langlois et al., 
2006; Centers for Disease Control and Prevention, 2006).  In recent years TBI 
has come to be known as the “signature injury” among U.S. military personnel 
serving in Iraq and Afghanistan; in 2005 it was estimated that more than 20% of 
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all service personnel who were injured in Iraq had sustained a TBI (Okie 2005).  
Beyond the impact on U.S. citizens, TBI has been identified as a growing 
problem around the world (Hyder et al., 2007).  The World Health Organization 
has estimated that by the year 2020, injury will surpass many diseases to 
account for 20% of the global burden of death and disability (Murray & Lopez, 
1997).   
 For survivors of brain trauma and for the families that support them, TBI-
related deficits in motor, sensory, and cognitive functioning present considerable 
challenges which may last for years.  Finkelstein and colleagues (2006) recently 
reported that 1 in 5 hospitalized survivors of brain trauma were unable to return 
to work one year after TBI due to injury-related disabilities, and this analysis 
concluded that the total productivity loss from TBI is higher than from any other 
type of injury.  Considering both direct costs for medical treatment and indirect 
costs such as lost productivity, the annual financial burden of TBI approaches 
$60 billion dollars (Finkelstein et al. 2006).  Given the magnitude of the problem, 
a better understanding of the pathobiological mechanisms underlying the 
morbidity and mortality of TBI could help to identify therapies with the potential to 
improve many lives. 
 
Pathobiological Mechanisms of TBI 
 Clearly the high incidence of TBI has enormous personal, social, and 
economic ramifications.  Yet despite decades of research, there are still no 
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approved therapies to ameliorate outcomes for TBI patients.  The reasons behind 
this are complex, but undoubtedly one factor which has made it more difficult to 
develop effective therapeutic approaches is the heterogeneity of TBI pathology.  
A TBI may involve focal tissue damage such as contusion or hematoma, or 
diffuse tissue damage such as diffuse axonal  injury (DAI) or diffuse damage to 
the microvasculature (Povlishock & Katz, 2005).  While this delineation of focal 
versus diffuse injury is of use conceptually, in actuality most TBI patients present 
with elements of both focal and diffuse pathologies.  Furthermore the effects of 
overt tissue damage may be compounded by secondary effects of the traumatic 
insult, including widespread changes in cell metabolism, edema and elevated 
intracranial pressure, hypoxia, ischemia, and inflammatory responses (Yoshino 
et al., 1991; Vespa et al., 2004; Marmarou 2003; Gennarelli 1993; Morganti-
Kossmann et al., 2001).  For example, focal injuries may result in greatly reduced 
regional cerebral blood flow, causing ischemic and hypoxic damage which 
contribute to a broader zone of neuronal cell death surrounding the area of initial 
injury (Gaetz et al., 2004; Muller et al., 2004).  Edema is also an important factor 
in secondary brain injury, causing increased intracranial pressure (ICP) and 
decreased cerebral perfusion and oxygen delivery.  Numerous mediators are 
released from damaged brain tissue which can enhance both cytotoxic and 
vasogenic edema, including glutamate, K+ ions, Ca++ ions, and oxygen free 
radicals (Marmarou 2003; Unterberg et al., 2004).  The resulting elevation in ICP 
worsens TBI outcome, and in the most extreme cases can lead to brain 
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herniation and death.  Thus it is clear that the pathophysiological components of 
initial and delayed tissue damage following TBI can be varied and complex.  
However at its simplest level, the pathology of each individual trauma case will 
include two core components, namely, some amount of cellular death, and some 
degree of axonal injury (Parikh et al., 2007; Gaetz et al., 2004). 
 
TBI-induced Cell Death 
 Cell death occurs after brain injury both in the regions directly affected by 
a focal insult (typically cortical), and in more widespread areas including 
thalamus, hippocampus, and cerebellum (Reviewed in Farkas & Povlishock, 
2007; Raghupathi 2004).  In both cases, necrotic and apoptotic death pathways 
appear to contribute to the total cellular loss.  Necrotic pathways are likely 
induced by disruption of ionic homeostasis, due at least in part to trauma-induced 
mechanical disruption of the plasmolemma (Farkas et al. 2006).  The resulting 
rise in intracellular Ca++ can activate several enzymes which contribute to 
cytotoxicity.  One important example is the cysteine protease calpain, which 
degrades intracellular proteins and plays a key role in the cascade which 
ultimately leads to necrotic cell death (Kermer et al., 1999; Raghupathi 2004).  By 
contrast, apoptotic cell death after TBI primarily occurs as a result of injury-
induced excitotoxic neurotransmitter release.  Abnormally high levels of 
extracellular glutamate act on several types of receptors to produce an influx of 
Ca++  and to initiate multiple intracellular signaling cascades.  Shifts in 
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intracellular levels of Bcl-2 family members regulate the release of cytochrome c 
from mitochondria, which helps to activate apoptosis-promoting caspases 
(McIntosh et al., 1998; Raghupathi 2004; Yakovlev & Faden 2004).  While injury-
induced neuronal loss has received the most attention in clinical and 
experimental studies, astrocytes and oligodendrocytes also appear to undergo 
apoptosis after TBI (Conti et al., 1998; Newcomb et al., 1999).  Thus it may be 
that a loss of adequate glial support further contributes to the functional deficits 
associated with brain trauma.  
 
Traumatic Axonal Injury in TBI 
 In addition to cell death, diffuse traumatic axonal injury (TAI) is a major 
contributor to TBI-associated morbidity (Genarelli et al., 1982; Adams et al., 
1991; Smith et al., 2003; Buki & Povlishock, 2006).  The definitive diagnosis of 
TAI is based on histological observation of axonal swellings at autopsy, so it is 
difficult to determine the true prevalence of TAI among survivors of mild-to-
moderate brain injury.  However findings in experimental models of TBI suggest 
that TAI is likely to be a component of most brain injuries, from the mildest to the 
most severe, and its prevalence is probably under-diagnosed in patients 
(Povlishock & Katz, 2005; Povlishock et al., 1992).  While previously it was 
thought that TAI reflected the overt tearing of axons due to mechanical shear at 
the moment of impact, this view has been expanded to include the occurrence of 
both immediate “primary axotomy”, as well as “secondary axotomy” which 
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develops progressively over the course of hours to days after the initial injury 
(Maxwell et al., 1993).  It is now generally accepted that the majority of TAI falls 
in the latter category, where transient local perturbations of the axolemma initiate 
intracellular cascades including activation of calpain and caspase, leading to 
collapse of the axonal cytoskeletal, impairment of axonal transport, and 
eventually to complete disconnection of the proximal axon stump (Povlishock et 
al., 1983; Povlishock & Becker, 1985; Christman et al., 1994).  A devastating 
component of TBI pathology, axonal injury is a major contributor to the morbidity 
and mortality seen in head-injured patients without mass lesions (Meythaler et 
al., 2001).  However the mechanism posited to underlie TAI-associated functional 
deficits—the deafferentation of target neurons and resulting transneuronal 
effects—has been generally underappreciated (Povlishock & Katz, 2005).    
 
 
Neuroplasticity and Recovery from Injury 
The death of cells and the degeneration of axons which occur in TBI 
produce a shared downstream effect, namely, the deafferentation of brain areas 
targeted by those cells or axons (Povlishock et al., 1992; Buki & Povlishock, 
2006).  However in numerous experimental models and in human patients, 
evidence indicates that deafferentation is capable of inducing some amount of 
compensatory neuronal growth (Steward 1989; Nadler & Cotman, 1978; Grady et 
al., 1989; Stein & Hoffman, 2003; Deller et al., 2006).  This phenomenon of 
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injury-induced or ‘reactive’ neuroplasticity was initially demonstrated after focal 
lesions which disrupted input to specific brain regions, e.g. the septal nuclei 
(Raisman 1969), superior colliculus (Lund & Lund, 1971), and hippocampal 
dentate gyrus (Steward et al., 1976).  Later, it was also shown that a similar 
reactive plasticity could be induced by the scattered axonal damage that arose 
from diffuse brain injury (Erb & Povlishock 1991; Christman et al. 1997).  In a 
clinically relevant model of diffuse brain trauma Christman et al.(1997) observed, 
in the same regions showing histological features of TAI, “evidence of a 
sustained regenerative attempt,” including axons stained with the growth-
associated protein GAP-43, and ultrastructural changes consistent with adaptive 
sprouting and tissue reorganization.   
 Whether such injury-induced axonal growth and synaptogenesis can 
support meaningful functional recovery has been the focus of many experimental 
studies, and recent developments in functional neuroimaging have opened up 
the possibility of examining this question in the clinical setting as well.  In several 
recent reviews on the topic (Ramirez 2001; Stein & Hoffman, 2003; Nudo 2007) 
the common consensus has been that reactive plasticity is a likely mechanism for 
observed post-injury functional recovery under at least some conditions.  For 
example, homotypic axonal sprouting and reactive synaptogenesis after 
deafferentation of the hippocampus show a clear temporal correlation with 
changes in hippocampus-dependent behavior (Reeves and Smith,1987).  
Moreover, manipulations which affect synaptogenesis have been shown to 
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produce concomitant changes in behavioral outcomes (Phillips et al., 1997; Falo 
et al., 2006).  Rats tested in a learned alternation task, and mice tested in a water 
maze—both measures of hippocampal-dependent spatial learning—showed 
initial postlesion impairments which recovered along the same time course as 
compensatory axonal sprouting (Loesche & Steward, 1977; Hardman et al., 
1997).  A subsequent transection of the sprouted pathway in rats reinstated the 
behavioral deficit (Loesche & Steward, 1977).  Furthermore, progressive EC 
lesions, an experimental manipulation known to accelerate the axonal sprouting 
response, was also shown to accelerate the post-injury recovery of learned 
alternation performance (Ramirez et al., 1996).  However it is also clear that not 
all reactive sprouting is equally supportive for behavioral recovery.  Much 
depends on the definition of “functional recovery” and the demands that the 
particular behavioral test places on the damaged/sprouted pathways (Ramirez 
2001).  Animals given bilateral entorhinal lesions demonstrate sprouting of 
heterotypic inputs to the hippocampus, which correlate with some measures of 
recovery such as open-field locomotor activity (Lasher & Steward, 1981), but not 
with other measures like the radial arm maze (Olton et al., 1978), water maze 
(Skelton & McNamara, 1992), or operant non-matching to position task (Kirkby & 
Higgins, 1998).  Overall these data led Ramirez (2001) to suggest the ‘principle 
of isomorphism’ as a guiding rule in the attempt to define the relationship 
between reactive sprouting and behavioral recovery.  This posits that the greater 
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the similarity between the injured pathway and the sprouting pathway, the greater 
the probability that sprouting will contribute to meaningful functional recovery. 
 Axonal sprouting is by nature a spatially limited process, so that 
successful synaptogenesis following injury is most likely to occur when there are 
intact fiber systems near the deafferented sites.  Diffuse or multifocal brain 
trauma is likely to damage some axons within a functional tract, while leaving 
some adjacent fibers intact.  Thus Steward noted in his comprehensive review on 
injury-induced neuronal reorganization (1989) that in fact, the diffuse denervation 
caused by TAI in the majority of naturally occurring brain traumata may be the 
optimal type of insult for inducing successful sprouting—and, hopefully, 
meaningful brain repair.  Since the evidence points to a role for sprouting and 
synaptogenesis in functional recovery after TBI, any therapeutic treatment 
capable of directing or enhancing these processes would be worthy of attention.  
Particular interest has arisen in the effects of the extracellular environment on 
axonal sprouting and synaptic reorganization, with the idea that manipulations of 
this environment could help support a functionally adaptive plasticity response. 
 
Extracellular Matrix in the Brain 
 For much of the 20th century, the idea that an appreciable amount of 
extracellular matrix (ECM) was present in the adult mammalian central nervous 
system (CNS) remained out of favor among most neuroscientists.  However with 
improved histological and biochemical research techniques, it has now come to 
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be widely recognized that ECM not only comprises a significant portion of the 
volume of brain and spinal cord, but also that it plays a vital role in the 
development and normal functioning of the nervous system (Celio 1999).  
Extracellular tracer diffusion studies have consistently demonstrated the volume 
fraction of the extracellular space to be around 20% of mature brain (Nicholson & 
Sykova, 1998).  This space is occupied by an extracellular matrix that is secreted 
by both neurons and glia, and is biochemically unique compared to the ECM of 
other body tissues.  Specifically, compared to the ECM of other organs, matrix in 
the brain and spinal cord contains unusually low levels of fibrous proteins such 
as collagen and elastin, and unusually high levels of glycosaminoglycans (GAGs; 
Novak & Kaye, 2000).   
 
ECM Composition and Structure 
 While the composition of nervous system ECM is highly complex and 
heterogeneous, its major components may be considered in the framework of 
three broad groups of molecules: hyaluronan, matrix proteins, and proteoglycans.  
Hyaluronan is the simplest form of GAG, a linear chain of repeating disaccharide 
units which may reach sizes up to 106 or 107 kilodaltons (kD).  Hyaluronan is 
believed to serve as a “backbone” in the structural organization of nervous 
system matrix, binding and connecting other ECM components (Margolis et al., 
1975; Rauch  2004; see Figure 1.1).  Matrix proteins comprise the second broad 
group, including link protein, which stabilizes the bond between hyaluronan some 
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proteoglycans, and several glycoproteins such as tenascin, fibronectin, laminin, 
thrombospondin, and reelin.  The third group of ECM components, the 
proteoglycans, are large multidomain molecules which exhibit a great amount of 
structural diversity (Galtrey & Fawcett, 2007).  Proteoglycans consist of a protein 
core, to which some variable number of sulfated GAG chains are covalently 
attached.  Classification of proteoglycans rests on the type of attached GAGs.  
Proteoglycans carrying chondroitin sulfate (CS) are the most abundant in brain 
ECM, followed by heparin sulfate (HS), dermatan sulfate (DS), and keratan 
sulfate (KS).  Altogether, these proteoglycans, proteins, and hyaluronan chains 
form a complex, interconnected structure surrounding the cellular components of 
the nervous system.  Both the physical parameters of the ECM (its volume 
fraction and tortuosity), and its specific biochemical composition, are altered over 
the course of development and after CNS injury (Pearlman & Sheppard 1996; 
Oohira 2000; Grimpe et al. 2002; Garwood et al. 2002).   
 
Proposed Functions of ECM in the CNS  
 ECM in the brain serves both a structural role and a cell signaling role.  In 
terms of its structural function, ECM influences the formation and stabilization of 
the cytoarchitecture and synapses.  Perineuronal nets (PNNs) are condensed 
regions of extracellular matrix surrounding the cell bodies and proximal dendrites 
of specific subsets of neurons in the brain and spinal cord (Celio & Blumcke, 
1994; Celio et al., 1998).  Important insights about the role of these discrete ECM 
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Figure 1.1 Proteoglycan Structure & Organization of Brain ECM  
(A) Transmission electron micrograph showing the classical proteoglycan 
structure where both protein core and GAG side chains are clearly visible.  (B) In 
vivo, proteoglycans are not typically found in isolation, but are bound to other 
matrix molecules in complex aggregates.  In brain ECM, hyaluronan is believed 
to act as an organizing “backbone”, connecting many different proteoglycan 
molecules.  (C) Chemical structures of the disaccharide building blocks of GAG 
chains.   
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structures came from a study by Pizzorusso et al. (2002) in the cat visual cortex.  
This group showed that PNNs first appear in visual cortex at the end of the 
critical period for developmental plasticity, and that dark-rearing the animals to 
prolong the critical period also correspondingly delayed PNN formation.  Finally, 
they showed that an in vivo treatment to degrade the ECM of perineuronal nets 
was able to re-activate developmental plasticity in adult animals.  Thus PNNs 
have been proposed to surround synapses in the mature CNS, where they serve 
to stabilize synaptic cytoarchitecture (Fox & Caterson, 2002; Murakami & 
Ohtsuka, 2003). 
 The cell signaling properties of ECM are initiated when a matrix molecule 
binds to a specific receptor on the plasma membrane of a neuronal or glial cell.  
This activates intracellular pathways which may influence a plethora of cellular 
behaviors, including migration, differentiation, survival, neurite outgrowth, 
fasciculation, synapse formation, and synaptic plasticity.  Integrins, a class of 
heterodimeric cell surface receptors which bind to molecules in the extracellular 
matrix, may be responsible for mediating many of the signaling functions of ECM 
in the CNS (Dityatev & Schachner, 2006).  For example, the matrix glycoproteins 
thrombospondin 1 and 2 (TSP1 and TSP2) are posited to induce synapse 
formation through a mechanism that involves binding to neuronal integrins and 
the intracellular activation of protein kinase C (Hama et al., 2004).  TSP1 and 
TSP2 were each shown to elicit formation of synapses in neuronal cultures, and 
double knock-out mice develop about 30% fewer synapses than age-matched 
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wild type mice (Christopherson et al., 2005).  The many studies examining 
knockout animals deficient in integrins or in various specific matrix components 
have helped our understanding of the vital importance of ECM-integrin receptor 
interactions for normal development and functioning of the CNS (Chan et al., 
2003; McCarty et al., 2005). 
 
Regulation of ECM by Extracellular Proteolysis 
 Functions of ECM in the brain in vivo are under constant dynamic 
regulation through the activity of extracellular proteases.  These important 
enzymes not only control constitutive turnover of matrix molecules, but also 
actively sculpt extracellular microenvironments to allow for cell growth and 
morphogenesis, and control the concentration and type of ECM constituents 
which are made available to specific cells.  Major classes of matrix-regulating 
enzymes include the matrix metalloprotease (MMP) family and the plasminogen 
activator/plasmin cascade.  
 MMPs are zinc-dependent proteases which constitute an ever-growing 
family of now nearly 30 members (Ethell & Ethell, 2007).  Together, the MMPs 
are capable of degrading all components of the ECM.  MMPs play a role in tissue 
remodeling during development, and they are expressed by neural progenitor 
cells and oligodendrocyte precursor cells (Agrawal et al., 2008; Frolichsthal-
Schoeller et al., 1999; Oh et al., 1999).  Neurite extension through the 
extracellular matrix is aided by secretion of MMPs at the leading edge of the 
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growth cone (Yong et al., 2001).  In the mature nervous system most MMPs are 
expressed at very low levels, and once expressed there are multiple mechanisms 
in place to ensure the precise regulation of their activity.  First, MMPs are 
secreted into the extracellular compartment as inactive zymogens, which must be 
cleaved by either by plasmin or by other MMPs in order to be activated in situ.  
Second, TIMPs (tissue inhibitors of metalloproteinases) are co-expressed with 
MMPs in the nervous system.  TIMPs bind MMPs in a one-to-one ratio, 
occupying the active zinc-binding sites on MMPs to inhibit their activity (Gomis-
Ruth et al., 1997).  Despite their low constitutive activity, MMP expression and 
activity can be rapidly up-regulated by CNS insult or by degenerative diseases 
such as Alzheimers disease (AD), multiple sclerosis (MS), many types of 
invasive cancers, stroke, and brain trauma (Kim et al., 2005; Falo et al., 2006; 
Vilalta et al., 2008; reviewed in Agrawal et al., 2008).  Additional types of 
proteases in the MMP family include the membrane-type MMPs (MT-MMPs), 
ADAM (a disintegrin and metalloproteinase), and ADAMTS (ADAM proteins with 
a thrombospondin-like domain).  ADAMs are thought to be involved mainly in 
proteolysis and ectodomain shedding of cell surface receptors in the brain, but 
possible additional roles for these proteases are still emerging (Novak 2004; 
Mayer et al., 2005; Yang et al., 2006).   
Tissue plasminogen activator (tPA) is a plasma serine protease, best 
known for its role in blood clot lysis through the conversion of plasminogen to the 
active protease plasmin.  However, tPA is also expressed in brain parenchyma, 
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where it is posited that its primary role is not fibrinolysis but degradation of 
specific substrates in the ECM.  tPA is secreted by neurons and its ECM-
degrading activity is thought to contribute to developmental neurite outgrowth 
and plasticity-associated tissue reorganization (Pittman & Buettner, 1989; 
Baranes et al., 1998).  Like MMPs, the activity of tPA in normal CNS tissue is 
tightly regulated, both at the level of restricted protein translation and post-
translationally.  Neuroserpin is a endogenous inhibitor of tPA, which is co-
expressed with tPA during development and in the adult (Yepes & Lawrence, 
2004).  While this helps to maintain low constitutive activity of tPA, expression 
and activity can be rapidly increased under pathological conditions such as 
seizures (Qian et al., 1993), ischemia and associated breakdown of the BBB 
(Yepes et al., 2000, 2003), and MS (Teesalu et al., 2002).  Also studies with 
knockout animals have demonstrated that tPA can mediate excitotoxic cell death 
through a plasmin-dependent cascade that involves cleavage of the end-
substrate laminin (Chen & Strickland, 1997).  Plasmin generated by tPA can 
activate MMP zymogens, thus providing a link between these two major 
proteolytic systems in ECM of the nervous system (Lo et al., 2002). 
 While much progress has been made in the last two decades as interest in 
CNS extracellular matrix has grown, much still remains to be learned about the 
expression patterns, interactions, regulation, and precise functional roles of many 
matrix components in the normal brain and in neuropathological conditions.  
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Recently, the class of ECM molecules called the chondroitin sulfate 
proteoglycans (CSPGs) has begun to attract particular attention. 
 
Phosphacan/RPTPβ as Important Components of Nervous 
System ECM   
 
 CSPGs are an abundant component of ECM in the brain and spinal cord.  
As a group, CSPGs are generally considered inhibitory for neurite growth and 
structural plasticity, yet there is also evidence to indicate that not all of these 
proteoglycans are strictly inhibitory.  Phosphacan is one example of a CSPG 
whose functional role in the CNS appears to be more versatile (Faissner et al. 
2003; Dobbertin et al. 2003).  Phosphacan (also known as 6B4 proteoglycan, or 
DSD-1 PG in the mouse) is a major component of adult brain ECM, comprising 
approximately 20% of the total CSPG content (Rauch et al 1991).  It has been 
reported to both inhibit and promote neurite outgrowth under different conditions, 
and studies have shown that phosphacan may be both upregulated and 
downregulated in the injured CNS (Faissner et al. 1994; Garwood et al 1999; 
McKeon et al 1999; Jones et al. 2003; Tang et al. 2003).  Phosphacan and its 
related splice variants will be described in detail below, including consideration of 
structure, expression patterns, ligands, and putative functional roles of these 
proteoglycans in the normal and injured CNS.   
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Structural Characterization of RPTPβ Splice Variants  
 Molecular cloning studies have identified phosphacan as an alternative 
splice variant of receptor protein tyrosine phosphatase beta (RPTPβ).  The full-
length RPTPβ (also known as protein tyrosine phosphatase receptor type Z, 
PTPRz, or PTPζ) is a single-pass transmembrane protein (see Figure 1.2 for a 
structural comparison of RPTPβ splice variants).  The extracellular domain of 
RPTPβ contains an N-terminal carbonic anhydrase sequence (CA), followed by a 
single fibronectin type III domain (FnIII), a 360 amino acid ‘spacer’ region, and an 
intervening sequence (IS) of approximately 860 amino acids.  Additionally, 
RPTPβ has a short membrane-spanning domain and two intracellular tyrosine 
phosphatase sites, termed D1 and D2 (Levy et al., 1993).  All phosphatase 
activity can be attributed to the membrane-proximal D1 site; the D2 domain is 
rendered catalytically inactive by deletion of a single cysteine (Krueger & Saito, 
1992).  The shorter transmembrane splice variant (termed sRPTPβ) has most of 
the IS region deleted (Levy et al., 1993).  Phosphacan is the primary extracellular 
variant, and is structurally identical to the entire extracellular portion of RPTPβ 
(Maurel et al., 1994).  Finally, another secreted extracellular isoform termed 
phosphacan short isoform (PSI) has recently been identified.  PSI corresponds to 
the N-terminal portion of phosphacan but lacks the IS sequence and half of the 
spacer region (Garwood et al., 2003).  In this document we will use the term 
"phosphacan/RPTPβ" to refer collectively to the three major splice variants 
investigated in these studies: phosphacan, RPTPβ, and sRPTPβ.   
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Figure 1.2  RPTPβ splice variants.  The receptor-type protein tyrosine 
phosphatase β (RPTPβ) gene is alternatively spliced into several different 
isoforms.  RPTPβ is a transmembrane receptor with an extracellular carbonic 
anhydrase (CA) domain, a fibronectin type III (FnIII) domain, a spacer region (S), 
and a membrane-proximal intervening sequence (IS) which contains many of the 
predicted glycosaminoglycan (GAG) attachment sites.  RPTPβ also has a short 
transmembrane region and two intracellular tyrosine phosphatase domains, only 
one of which is catalytically active.  A shorter transmembrane splice variant, 
sRPTPβ, retains the intracellular tyrosine phosphatase but lacks the extracellular 
IS region.  Phosphacan is the major secreted splice variant, and its structure is 
identical to the entire extracellular domain of the full-length RPTPβ.  Phosphacan 
short isoform (PSI) is a secreted non-proteoglycan which contains the CA and 
FNIII domains, and part of the S region.  Figure modified from Harris et al., 2005. 
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Phosphacan splice variants are highly decorated with different types of 
post-translational modifications.  The extracellular IS region of 860 amino acids is 
of particular importance since it contains most of the putative attachment sites for  
the GAG chains.  The isoforms which express this region—phosphacan and 
RPTPβ—are heavily glycosylated with long, sulfated CS-GAG chains.  Since 
sRPTPβ lacks the IS region it is less heavily glycosylated, but still exists in 
mature brain as a CSPG (Nishiwaki et al., 1998).  Phosphacan and RPTPβ may 
also sometimes carry KS-GAGs (Rauch et al., 1991; Maeda et al., 1995).  All of 
the phosphacan/RPTPβ splice variants also contain numerous sites for 
attachment of small N- and O-linked oligosaccharides (Maeda et al., 1995).   
   
Developmental Expression and Localization of Phosphacan/RPTPβ 
 Expression of all the RPTPβ variants is largely restricted to the nervous 
system (Shintani et al., 1998; Engel et al., 1996; Meyer-Puttlitz et al., 1996).  In 
the rodent brain, phosphacan is first detectable in tissue homogenates at 
embryonic day 20 (E20), with levels rising steadily thereafter to peak in the 
second postnatal week.  Phosphacan accounts for around 20% of the total 
soluble CSPG in adult rat brain, and is thus a major component of mature 
nervous system ECM (Rauch et al., 1991).  Keratan sulfate is not present in 
embryonic brain, but after birth it becomes detectable and its concentration 
increases gradually to peak in the third postnatal week (Sakurai et al., 1996; 
Meyer-Puttlitz et al., 1995; Meyer-Puttlitz et al., 1996).  This increase in KS is 
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believed to be attributable solely to chains attached to phosphacan; no other 
KSPGs have been identified which are expressed postnatally in the nervous 
system (Rauch et al., 1991; Maurel et al., 1994).   Because KS concentration and 
phosphacan concentration peak at different times, it appears that the GAGs 
attached to phosphacan are regulated independently of the core protein during 
development.  In fact, many structural features of phosphacan/RPTPβ are altered 
as the nervous system matures, including the number of GAG chains, their 
length and sulfation pattern, and the number of N- and O-linked oligosaccharides 
(Rauch et al., 1991; Meyer-Puttlitz et al., 1995; Mace et al., 2002).  Since the 
enzyme chondroitinase ABC (chABC), which is known to digest the CS chains 
attached to proteoglycans in mature tissue, cannot efficiently digest CS on 
embryonic and early postnatal phosphacan (Mace et al., 2002), it has been 
suggested that the fine structure of these CS-GAGs may be altered during 
development.  Milev et al. (1998) found a developmental shift in the position of 
sulfation on phosphacan CS chains, which may account for the difference in 
susceptibility to degradation.  Since specific functions of RPTPβ can be attributed 
to distinct structural domains, the regulation of structural features suggests a 
dynamic role for these molecules over the course of CNS development. 
Immunostaining for phosphacan in the nervous system shows a wider 
distribution than that shown by in situ hybridization, consistent with its 
characterization as a secreted molecule which could be transported or 
redistributed in the extracellular space.  In the embryonic rodent CNS, 
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phosphacan transcript is largely confined to areas of active cell proliferation, such 
as the ventricular zone and ependymal layer surrounding the central canal of 
spinal cord (Engel et al., 1996).  Immunoreactivity for phosphacan core protein is 
also very prominent in the ventricular zone, and diffuse staining is seen in many 
areas of the cerebrum, brainstem, cerebellum, dorsal root ganglia, and in grey 
and white matter of the spinal cord (Meyer-Puttlitz et al., 1996).  Postnatally, 
strong phosphacan staining is seen surrounding radial glia in the developing 
cortex and Bergmann glia in the cerebellum (Meyer-Puttlitz et al., 1996; Rauch et 
al., 1991).  Since phosphacan is known to bind to numerous cell adhesion 
molecules, it may assist in developmental migration of neurons along these glial 
scaffolds. 
 The localization of the transmembrane variants appears to be less 
widespread than phosphacan in the nervous system.  RPTPβ and sRPTPβ are 
detected predominantly in the subventricular zone in embryonic brain (Canoll et 
al., 1996; Snyder et al., 1996).  Expression of the full-length form all but 
disappears postnatally, while expression of the short form sRPTPβ declines but 
remains at steady lower levels in the adult CNS (Sakurai et al., 1996; Dobbertin 
et al., 2003; Lorente et al., 2005).   
 Immunoblotting of primary cell cultures and in situ hybridization studies 
have indicated that astroglia (Canoll et al., 1996; Engel et al., 1996) as well as 
certain neuronal populations (Snyder et al., 1996; Hayashi et al., 2005; Shintani 
et al., 1998) express sRPTPβ and phosphacan.  02A cells secrete high levels of 
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phosphacan and RPTPβ, but expression of both disappears as these cells 
differentiate into mature oligodendrocytes.  While several cell populations appear 
capable of producing phosphacan, astrocytes in culture were shown to secrete 
much higher levels of this proteoglycan than other cell types (Snyder et al., 1996; 
Canoll et al., 1996; Dobbertin et al., 2003).  By contrast, O2A cells expressed 
more RPTPβ than astrocytes or neurons (Dobbertin et al., 2003). 
 Recent investigations have also explored the ultrastructural localization of 
RPTPβ family members.  Electron microscopy revealed that sRPTPβ and 
phosphacan are present on the surface of postmitotic migrating neurons and on 
the surface of radial glia (Hayashi et al., 2005).  In adult hypothalamus, 
immunoreactivity for all variants was also seen surrounding axons and astrocytic 
processes (Miyata et al., 2004).  Cultured neurons from embryonic cortex first 
express sRPTPβ and phosphacan on somata, axons, and dendrites.  However, 
as these cells mature in vitro, the staining selectively disappears from axonal 
surfaces, suggesting that the cellular localization of RPTPβ/phosphacan may 
shift during development, at least in some neuronal types (Hayashi et al., 2005).  
While localization of the transmembrane forms at the plasma membrane is 
anticipated, presumably the phosphacan immunostaining observed near the cell 
surface was due to its interactions with membrane-associated molecules.  
Binding partners of phosphacan include a number of surface cell adhesion 
molecules (CAMs), which will be considered in detail below. 
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Descriptions of RPTPβ/phosphacan localization in developing and adult 
hippocampus have been contradictory.  Some studies have reported that all 
neuropil layers show gradually increasing immunoreactivity from birth, with the 
strongest staining developing in the stratum lucidum of the CA subfields, and in 
the polymorphic layer and middle third of the molecular layer in the dentate gyrus 
(Bruckner et al., 2003; Wilson & Snow, 2000).  In contrast, others have found a 
distinct absence of immunoreactivity in the stratum lucidum, and the strongest 
staining in the inner third of the molecular layer (Okamoto et al., 2001; Okamoto 
et al., 2003).  The discrepancies may be due to the use of antibodies recognizing 
epitopes on different subsets of the RPTPβ family.  Additionally, the substantial 
changes in the GAG and oligosaccharide epitopes on phosphacan and RPTPβ 
which occur during development could potentially alter antibody recognition sites 
at different ages.  Overall, the expression of phosphacan/RPTPβ is regulated on 
many levels during development, and the spatial and temporal patterns of 
expression suggest a potential involvement in cell migration, differentiation, and 
synaptogenesis (Faissner et al., 2006). 
 
Ligands of Phosphacan/RPTPβ 
Extracellular Ligands 
 Studies over the last decade have identified a host of molecules which 
bind to extracellular regions of the RPTPβ family.  These may generally be 
divided into three categories: cell surface-associated molecules, molecules of the 
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extracellular matrix, and diffusable extracellular growth/differentiation factors.  
The CA domain of the core protein, which is shared by all RPTPβ splice variants, 
has been shown to bind to the cell surface adhesion molecule F3/contactin 
(Peles et al., 1995), the transmembrane glycoprotein Caspr/paranodin (Peles et 
al., 1997), and to the extracellular portion of voltage-activated Na+ channels.  
The FnIII domain, also shared by all RPTPβ isoforms, binds to the ECM molecule 
Tenascin-C (Adamsky et al., 2001).  The S region, which is truncated in PSI but 
present in all other isoforms, binds several members of the immunoglobulin 
superfamily of cell adhesion molecules (Sakurai et al., 1997).  In addition, 
Tenascin-R and basic fibroblast growth factor (FGF-2) each bind to some part of 
the extracellular core protein, but the specific binding sites have not been 
identified for these ligands (Milev et al., 1998a; Milev et al., 1998b).   
 The chondroitin sulfate and keratan sulfate GAGs appear to be 
responsible for modulating phosphacan/RPTPβ binding affinity to certain ligands.  
Binding of phosphacan to FGF-2, for example, is reduced by 35% after in vitro 
treatment with chABC to digest CS GAGs on phosphacan (Milev et al., 1998b).  
The CS chains also serve as the primary binding sites for some ligands including 
the adhesion molecule TAG-1/axonin-1, and the growth factors amphoterin, 
midkine, and pleiotrophin/HB-GAM (Milev et al., 1996; Milev et al., 1998a; Maeda 
et al., 1999).  Small oligosaccharides attached to the CA and FnIII regions also 
enhance binding affinity to N-CAM, Ng-CAM, and Tenascin-C, since treatment of 
phosphacan with peptide N-glycosidase can substantially reduce binding to these 
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molecules (Milev et al., 1995).  Immunological studies have shown extensive 
overlap between the expression of RPTPβ isoforms and expression of many of 
the ligands discussed above, underscoring the biological importance of these 
interactions in vivo.  It should also be emphasized that in nervous system tissue, 
rarely would phosphacan/RPTPβ encounter only one of these extracellular 
binding partners in isolation.  Rather, it is likely that the presence of certain 
ligands can influence association of phosphacan with other binding partners, 
possibly by steric alteration of binding sites, thereby adding another layer of 
complexity to the interactions of phosphacan/RPTPβ in vivo. 
 
Intracellular Ligands  
While earlier studies focused on identifying ligands for 
phosphacan/RPTPβ in the extracellular domain, a number of more recent reports 
have described novel ligand interactions with intracellular regions of the receptor 
forms.  These ligands include both intracellular proteins and transmembrane 
receptors.  Intriguingly, many are enriched at post-synaptic profiles and have 
been functionally linked to structural plasticity or synaptogenesis.  Intracellular 
binding partners of full-length and short RPTPβ include PSD-95 (Kawachi et al., 
1999), β-catenin (Meng et al., 2000), β-adducin (Pariser et al., 2005), p190 
RhoGAP (Tamura et al., 2006), ErbB4 (Fujikawa et al., 2007), and TrkA (Shintani 
et al., 2008).  Most of the studies which identified these interactions have used in 
vitro models to demonstrate that RPTPβ binding is linked to dephosphorylation of 
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the ligands at tyrosine residues.  For example, the D1 catalytic domain of RPTPβ 
co-precipitates from glioblastoma cells with β-catenin, a key regulator of the 
neuronal cytoskeleton (Meng et al., 2000).  Furthermore, binding of pleiotrophin 
to the extracellular domain of RPTPβ was shown reduce the intracellular 
phosphatase activity and increase detection of phosphorylated β-catenin, 
providing compelling evidence that β-catenin is a substrate for RPTPβ.  RPTPβ 
and sRPTPβ can also interact through their cytosolic D1 domain with voltage-
gated sodium channels (Ratcliffe et al., 2000).  This interaction was shown to 
regulate tyrosine phosphorylation of the sodium channel α subunit, and when 
both α subunit and the intracellular portion of RPTPβ were co-expressed in tsa-
201 cells, an increase in whole-cell sodium current was observed.  While an 
interaction with sodium channels has yet to be demonstrated in neurons, these 
findings suggest that RPTPβ phosphatase activity might be capable of 
modulating cell excitability.   
 
Interaction of RPTPβ Isoforms: Potential Competition for Common Ligands 
 Because of the sequence homology shared by RPTPβ variants, it is likely 
that wherever multiple isoforms are co-expressed, they can compete for common 
ligands.  One could easily imagine a scenario where the transmembrane forms 
respond to extracellular signals and activate intracellular signaling, while the 
secreted forms regulate this activity by competing for ligand binding in the 
extracellular space.  In this context, there may be special significance in the 
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relative spatial and temporal expression of the different RPTPβ splice variants.  
Shifts in the relative expression of phosphacan/RPTPβ isoforms are likely to be 
one way that these proteoglycans influence neuronal and glial adhesion, 
migration, and neurite growth during CNS development and after injury.   
 An important way in which competition for common ligands might 
influence cell behavior is through regulation of the tyrosine phosphatase activity 
of full-length or short RPTPβ.  It has been shown that pleiotrophin binding to the 
extracellular domain of RPTPβ reduces the activity of the intracellular D1 
phosphatase.  Specifically, in both RPTPβ-expressing glioblastoma cells and Sf9 
insect cells transfected with RPTPβ, application of pleiotrophin increased the 
phosphorylation of the putative intracellular substrate β-catenin; this effect 
appeared to be specific because β-catenin phosphorylation was unchanged in 
untransfected Sf9 cells which do not express any RPTPβ variants (Meng et al. 
2000).  Since both phosphacan and RPTPβ can bind pleiotrophin, an increase in 
extracellular phosphacan could increase competition and reduce binding of this 
ligand to the transmembrane receptor. This would reduce ligand-induced 
receptor inactivation and thus cause a net increase in phosphatase activity.  One 
in vitro study has suggested that such an increase in phosphatase activity might 
support neuronal migration.  Pleiotrophin stimulated migration of RPTPβ-
expressing neurons along coated glass fibers, and this effect was blocked by 
application of soluble phosphacan to the culture medium (Maeda & Noda, 1998).  
In the same assay, migration was blocked by tyrosine phosphatase inhibition, 
  31
although it was unclear whether the halt in migration resulted from reduced 
RPTPβ activity, or reduced activity of other tyrosine phosphatases. 
Maeda and colleagues showed that adding phosphacan to neuronal 
cultures caused a transient increase in phosphorylated-tyrosine on an 85kD 
protein, which correlated closely with induction of neurite growth from these cells 
(Maeda & Noda, 1996).  In contrast with the experimental model described 
above, in this case the data suggest that competition by phosphacan may reduce 
phosphatase activity.  An alternative interpretation is that phosphacan may 
influence the phosphorylation of different effector molecules through multiple 
pathways, including but not limited to its effects on RPTPβ phosphatase activity.  
Another possibility is that different extracellular ligands may differentially 
influence the catalytic activity of RPTPβ.  Pleiotrophin binding is known to 
suppress RPTPβ phosphatase activity, but it is conceivable that other yet-
unidentified ligands might have the opposite effect.  If this is the case, then when 
phosphacan competes with the transmembrane variants for ligands, the net 
effect could be either an increase or a decrease in catalytic activity.  Evidently, 
further studies are needed to better characterize the influence of different ligands 
on RPTPβ phosphatase activity, as well as the downstream effects on cellular 
function.  Figure 1.3 summarizes the potential effects of binding competition on 
RPTPβ phosphatase activity and cell signaling. 
The influence of the RPTPβ family on intracellular signaling pathways 
could extend beyond simply those effectors which are altered directly via  
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Figure 1.3  Potential effects of binding competition on RPTPβ phosphatase 
activity and cell signaling.  The structural similarity between phosphacan and 
RPTPβ/sRPTPβ means that these splice variants share many common ligands.  
In the mature brain, phosphacan is found in the extracellular space while 
RPTPβ/sRPTPβ are primarily located on the surface of neuronal dendrites and 
spines (Hayashi et al., 2005; see also Figure 2.3).  Ligand binding to the 
extracellular portion of RPTPβ/sRPTPβ may enhance or reduce activity of the 
phosphatase and transduction of intracellular signals in postsynaptic neurons.  
Phosphacan competition for ligand binding would modulate these effects.  If the 
ligand in question is a surface receptor on another cell (e.g. a CAM) then these 
interactions could impact on bi-directional cell signaling in both the neuron 
expressing RPTPβ and the neighboring cell expressing the CAM (CAM = cell 
adhesion molecule; Figure modified from Sakurai et al., 1997).
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dephosphorylation.  A second way in which phosphacan/RPTPβ can affect cell 
behavior is by modifying the activity of other cell surface receptors.  This 
influence may be direct, via cis or trans interactions of other receptors with an 
RPTPβ isoform.  For example, RPTPβ may influence the intracellular signaling 
pathways initiated by transmembrane CAMs to which it binds.  If soluble 
phosphacan interacts with a surface adhesion molecule, it would generate a uni-
directional signal from the extracellular ligand to the CAM-expressing cell.  
However bi-directional signaling could also result from a trans interaction 
between RPTPβ and CAMs on adjacent cells, when both of these receptors 
transduce intracellular signals after binding (Peles et al., 1995; Oohira et al., 
2000; see again Figure 1.3).  
Additionally, phosphacan/RPTPβ could influence cell signaling in a more 
indirect manner, by altering the availability of soluble extracellular ligands.  
RPTPβ and phosphacan are known to bind to various growth and differentiation 
factors, which may bring these factors into closer proximity to their respective 
surface receptors, thereby potentiating their effects.  Indeed, it has been shown 
that when phosphacan binds to FGF-2, the mitogenic effects of this growth factor 
is nearly doubled (Milev et al., 1998).  RPTPβ may not always augment growth 
factor signaling, however.  In some cases phosphacan in the ECM could 
sequester growth factors, limiting their accessibility to receptors on the surface of 
neurons (McKeon et al., 1999). 
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In vitro Studies Suggest a Complex Influence of Phosphacan/ 
RPTPβ on Neuronal Behavior  
 
 Unlike many other CSPGs, which are generally considered to be inhibitory 
to neuronal adhesion and axon growth (Davies et al., 1997; Fawcett & Asher, 
1999), studies on the effects of phosphacan splice variants on neuronal function 
in vitro have produced mixed results.  As discussed above, phosphacan/RPTPβ 
can interact with ligands through binding sites on the protein core, on the GAG 
chains, and on the N- and O-linked oligosaccharides.  With so many potential 
interactions in vivo, it is perhaps not surprising that RPTPβ isoforms have been 
implicated in many aspects of nervous system function, nor that the results of 
different in vitro assays may at times appear contradictory.   
 
Phosphacan/RPTPβ and Cell Adhesion 
 Since the RPTPβ family members are high-affinity ligands for a number of 
different CAMs, it is logical to suggest that they might play a role in modulating 
cell adhesion.  In vitro studies have shown that phosphacan is a repulsive 
substrate for cortical and thalamic neurons (Maeda & Noda, 1996) and for U373 
astrocytoma cells (Lorente et al., 2005).  Soluble phosphacan can interfere with 
adhesion of neurons to Ng-CAM coated plates in a dose-dependent manner 
(Milev et al., 1994).  Moreover, it has been demonstrated that simply the purified 
CS and KS epitopes of phosphacan are sufficient to prevent adhesion of 
mesencephalic neurons (Mace et al., 2002).  Interestingly though, the repulsive 
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effect of CS as an isolated culture substrate stands in direct contrast to its effect 
in an in situ assay where neurons were cultured on top of whole brain slices.  
Neurons did adhere to the brain slice; however when the slice was pre-treated 
with chABC, all neuronal adhesion to it was abolished, indicating that in this 
experimental paradigm the CS acts as a permissive substrate (Mace et al., 
2002).   
 Adhesion experiments may report different results for phosphacan/RPTPβ 
when different cell types are tested.  For example, the isolated extracellular 
domain of sRPTPβ is repulsive to U373 cells (Lorente et al., 2005) but 
permissive for adhesion of neurons (Sakurai et al., 1997).  Moreover, it appears 
that details of the experimental protocol can affect the conclusions of in vitro 
adhesion assays.  Most adhesion studies use a traditional gravity assay where a 
cell suspension is added to a flat substrate-coated plate and allowed to incubate 
while gravity settles the cells onto the substrate.  The plate is washed to remove 
unbound cells, and those remaining are counted.  By contrast, in a centrifugation 
assay a cell suspension is added to a U-shaped well coated with substrate, and 
centrifugation is the force which brings suspended cells briefly into contact with 
the substrate-bound surface.  After the centrifugation step, cells which have 
adhered to the sides of the well are counted.  The short-term centrifugation assay 
is a better reflection of the strength of molecular interactions upon initial cell 
contact, while the gravity assay reflects the capacity of a substrate to allow cell 
spreading.  Since phosphacan can bind to cells but also seems to exhibit some 
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repulsive properties, a centrifugation assay would be more likely to identify it as 
‘adhesive’ (e.g. Grumet et al., 1993) while a gravity assay is more likely to report 
that no adhesion was observed (e.g. Maeda & Noda, 1996). 
 
Phosphacan/RPTPβ and Neurite Outgrowth 
 Phosphacan has been found to promote neurite outgrowth from embryonic 
cortical, mesencephalic, and hippocampal neurons (Faissner et al., 1994; 
Garwood et al., 1999; Maeda et al., 1995; Dobbertin et al., 2003).  PSI also 
promotes neurite outgrowth from cortical neurons, though the effect is less potent 
than that of phosphacan (Garwood et al., 2003).  However in contrast with these 
findings, are other studies showing that phosphacan inhibits neurite extension 
from dorsal root ganglion explants (Garwood et al., 1999), retinal ganglion cells 
(Inatani et al., 2001), neurons from embyronic chick brain (Milev et al., 1994), 
and PC12D cells (Oohira et al., 1991).  It may be that the inhibitory effect is due 
to the core protein, while the promoting effect is due to an epitope present on the 
CS chains.  In support of this, outgrowth promotion is abolished by degradation 
of CS-GAGs or by antibodies to the “DSD-1” epitope on CS (Faissner et al., 
1994; Garwood et al., 1999; Dobbertin et al., 2003).  Conversely, inhibition of 
neurite outgrowth is either unaltered or enhanced by removal of the CS chains 
(Garwood et al., 1999; Inatani et al., 2001).   
 However, a model where CS is permissive and the protein core is 
inhibitory is probably too simplistic.  Instead, specific domains within the protein 
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core may mediate different effects on neurite extension.  A fusion protein 
containing all extracellular regions of the short receptor form sRPTPβ can 
promote neurite extension from chick tectal neurons (Sakurai et al., 1997), thus 
suggesting that inhibitory epitopes may be contained within the IS region, which 
sRPTPβ lacks.  If different domains within phosphacan/RPTPβ can mediate 
different effects on neurite outgrowth, then the presence of binding partners—
growth factors and cytokines, ECM molecules, and/or cell surface-associated 
cues—may cause either promoting or inhibiting effects to dominate.  Overall, 
these findings from studies in vitro suggest that cell adhesion and axon guidance 
are likely to be governed by a tightly regulated balance between the growth-
promoting and growth-inhibiting influences of RPTPβ splice variants, along with 
the influences of other ECM and cell-surface signals.   
 
Phosphacan/RPTPβ in the CNS Injury Response 
 The role of RPTPβ splice variants has been studied in the context of 
several different CNS injury models.  As with the in vitro studies discussed 
above, here too the results are complex.  RPTPβ mRNA expression is induced in 
rodent hippocampus after deafferentation by a knife lesion to the fimbria-fornix 
and entorhinal cortex, while both phosphacan and  RPTPβ transcript are 
increased directly surrounding the lesion sites (Snyder et al., 1996).  Nigrostriatal 
axotomy, another type of mechanical deafferenting lesion which induces axonal 
sprouting and glial scarring, produces an increase in both phosphacan core 
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protein and KS-phosphacan (Moon et al., 2002).  Animal models of 
epileptogenesis induced by Pilocarpine and Domoate have also demonstrated 
increases in RPTPβ and phosphacan in the hippocampus after seizure (Naffah-
Mazzacoratti et al., 1999; Heck et al., 2004).  Similarly, brain tissue resected from 
human patients with intractable temporal lobe epilepsy showed elevated RPTPβ 
staining compared to age-matched autopsy controls (Perosa et al., 2002).  By 
contrast, a reduction in phosphacan has been repeatedly demonstrated in 
studies of kainate-induced seizures (Wu et al., 2000; Matsui et al., 2002; 
Okamoto et al., 2003) and cortical stab wounding (Dobbertin et al., 2003).  
Finally, in a filter implantation model to induce reactive gliosis, McKeon et al 
(1999) found both an increase in phosphacan mRNA in the glial scar and a 
simultaneous decrease in phosphacan protein.   
 The pathology of different injury models may involve significant variations 
in the extent of cell loss, blood-brain barrier compromise, induction of cytokines 
and other inflammatory factors, activation of microglia, astrocytes, 
oligodendrocyte precursor cells (OPCs), and neuronal precursor cells (NPCs) are 
activated.  It seems likely that these injury variations can at least partially account 
for the range of RPTPβ/phosphacan responses observed.  Dobbertin and 
colleagues (2003) showed that in vitro a number of inflammatory cytokines can 
influence glial expression of RPTPβ isoforms.  In particular, IFNγ and TNFα 
cause astrocytes to downregulate phosphacan production, while EGF and TGFα 
strongly upregulate production of phosphacan, RPTPβ, and sRPTPβ.  Microglia 
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are a major source of TNFα in the injured nervous system, and lymphocytes 
infiltrating at sites of BBB disruption are a major source of IFNγ (Uno et al., 1997; 
Popko et al., 1997).  However, injured neurons and astrocytes are known to 
produce EGF and TGFα (Junier 2000).  Therefore the relative activities of 
microglia, lymphocytes, injured neurons, and astrocytes could influence ambient 
levels of RPTPβ after nervous system insult. 
 Post-translational features of phosphacan/RPTPβ may be regulated 
independently from the core proteins following injury.  Dobbertin and colleagues 
(2003) found that after a cortical stab injury, CS and KS GAG epitopes specific to 
phosphacan exhibited a transient decrease (1-4 days) corresponding to a 
decrease in phosphacan core protein.  However, at later time points (7-28 days) 
this parallel regulation diverged: the chondroitin sulfate epitope was increased 
relative to phosphacan core, while keratan sulfate levels were decreased relative 
to the core.  Considering the influences of CS on ligand binding, such changes in 
the GAG composition of phosphacan/ RPTPβ after injury could modify the 
function of these proteoglycans. 
 Four enzymes have been identified which are expressed in the CNS and 
can degrade phosphacan/RPTPβ in isolated in vitro assays.  Interestingly, all of 
these enzymes have been implicated in the pathobiology of brain injury.  First, 
MMP-3 can digest phosphacan in vitro (Muir et al., 2002) and is upregulated in 
the hippocampus after traumatic brain injury (Muir et al., 2002; Kim et al., 2005; 
Falo et al., 2006).  MMP-3 is an extracellular protease which cleaves a range of 
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ECM components including laminin, agrin, tenascin, and several CSPGs.  It 
appears that MMP-3 degradation of ECM components may contribute to an 
environment which is permissive for morphological plasticity, since it is activated 
in regions where synaptic plasticity occurs after traumatic brain injury.  Moreover 
this activation is reduced in animals treated with a pharmacological agent which 
reduces cell death and degeneration after injury (Falo et al., 2006).  Second, 
plasmin can also degrade phosphacan in vitro (Wu et al., 2000).  Plasmin is an 
extracellular serine protease expressed in brain parenchyma, where its 
substrates include the ECM components laminin and phosphacan (Tsirka et al., 
1997; Tsirka, 2002; Wu et al., 2000).  In mice lacking the gene for plasminogen 
(the inactive precursor to plasmin), aberrant accumulation of phosphacan was 
found in hippocampus, coincident with an abnormal build-up of Timm-stained 
mossy fiber terminals after KA-induced seizures.  Further, in vitro assays showed 
that mossy fibers would not grow across a border of native phosphacan, while 
pre-incubating the phosphacan with plasmin abolished the inhibitory effect (Wu et 
al., 2000).  These data suggest that cleavage of phosphacan by plasmin may be 
required for the mossy fiber growth and aberrant synaptic reorganization induced 
by epileptic seizures.  Finally, a recent study showed that the metalloproteinases 
ADAM-17 and MMP-9 can also cleave long and short RPTPβ (Chow et al., 
2008).  Both enzymes cleaved a membrane-proximal sequence of RPTPβ in 
CHO cells, resulting in shedding of the receptor ectodomain.  While relatively 
little is known about ADAM-17 expression after TBI, increases in MMP-9 activity 
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following brain injury have been well documented (Romanic et al., 1998; Wang et 
al., 2000; Vilalta et al., 2008).  It remains to be verified whether cleavage in vivo 
by MMP-9, MMP-3, and/or plasmin might regulate phosphacan/RPTPβ following 
brain injury.   
 Due to the complex and sometime contradictory results from previous 
studies of phosphacan/RPTPβ following CNS injuries, it has been difficult thus far 
to clearly define what role these important matrix components might play during 
recovery from TBI.  In order to investigate this question directly, we have 
conducted a series of studies using unilateral entorhinal cortex lesion (UEC), a 
model of injury-induced plasticity and adaptive synaptic recovery.  
 
Unilateral Entorhinal Cortex Lesion 
 Many animal models have been developed to mimic the pathological 
sequelae and cognitive effects of TBI in humans, and different models are useful 
to researchers in different ways.  Experimental models such as impact 
acceleration (Marmarou et al., 1994), inertial acceleration (Gennarelli et al., 1982; 
Ross et al., 1994), and fluid percussion injury (Dixon et al., 1987) reliably 
reproduce many of the features of human closed-head injury including the TAI 
frequently associated with it.  However, the diffuse nature of this type of injury 
makes it difficult to study the reactive axonal sprouting and synaptogenesis 
induced by TAI.  A more suitable experimental model which has been used to 
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study the phenomenon of reactive synaptogenesis in a more targeted manner is 
unilateral entorhinal cortex lesion (UEC; see Figure 1.4).   
 The entorhinal cortex (EC) provides approximately 90% of the afferents to 
granule cells of the dentate gyrus, so that UEC produces a very significant 
deafferentation of granule cell dendrites within the ipsilateral outer molecular 
layer (OML).  This lesion induces robust tissue restructuring, sprouting of axon 
collaterals, and synaptogenesis which is spatially restricted to the OML, and 
which has been well defined temporally in a number of detailed studies.  
Specifically, reactive synaptogenesis occurs in a series of stages over 
approximately the first two weeks following UEC.  In the first 2 days post lesion, 
synaptic boutons in the OML degenerate (Steward et al., 1976; Steward et al., 
1988) and the resulting cellular debris is cleared by activated microglia (Morgan 
et al., 1993).  We have designated this period the “degenerative phase” of 
reactive synaptogenesis after UEC.  The removal of afferent terminals induces 
morphological changes in the postsynaptic granule cell dendrites in the 
denervated OML, which first shrink and then reorganize to form new synaptic 
contacts with axonal sprouts from the crossed entorhinal-dentate projection 
(Cotman et al., 1977).  Tissue remodeling and synaptogenesis continue for an 
extended period, but the rate of plasticity sees its greatest rise at 7-8 days post 
lesion (Steward et al., 1988).  Thus we have termed 7 days after UEC to be the 
“reorganization phase” of reactive synaptogenesis.  By 15 days post lesion, the 
rate of tissue reorganization has greatly declined and many of the newly formed 
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synapses have begun to assume a stable, mature phenotype; thus we have 
designated this period the “stabilization phase” of reactive plasticity after UEC.  
These stages of degeneration, reorganization/regeneration, and recovery have 
been documented with histological staining of the tissue, ultrastructural analyses, 
electrophysiological recordings, and hippocampus-dependent behavioral testing 
(Lynch et al., 1972; Matthews et al., 1976a,b; Steward et al., 1976; Reeves & 
Steward, 1986; Loesche & Steward, 1977).   
 Importantly, the reactive synaptogenesis induced by UEC leads to 
successful functional recovery.  Physiological recordings have shown that the 
amplitude of evoked potentials in the crossed temporo-dentate (CTD) projection 
to the denervated OML increases in parallel with sprouting of CTD axon 
terminals, and with recovery of T-maze behavioral performance (Steward et al., 
1976; Reeves & Smith, 1987).  The capacity for LTP—thought to be a 
physiological correlate of learning and memory—also emerges in the CTD 
pathway around 2 weeks post-lesion as the newly sprouted synapses mature 
(Reeves & Steward, 1986).  In sum, the discrete and targeted nature of the 
deafferentation in UEC, and the well-defined cell biology of each phase of the 
ensuing reactive synaptogenesis, make this an ideal model to investigate the 
role(s) of phosphacan/RPTPβ in adaptive plasticity after TBI. 
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Figure 1.4  Unilateral entorhinal cortex lesion.  (A) Diagram of a horizontal 
section through hippocampus and adjacent entorhinal cortex.  Entorhinal neurons 
send projections to the outer molecular layer of the dentate gyrus, where they 
synapse on granule cell dendrites.  (B) Surgical ablation of the entorhinal cortex 
deprives the outer molecular layer of approximately 90% of its normal input, and 
induces sprouting of remaining intact afferents.  (C) A horizontal section from one 
of our rats 7 days after UEC, with visible necrosis, hemorrhage, and complete 
severance of the entorhinal-hippocampal connections.  (D) UEC lesion 
placement.  At each point marked, 1.5 mA current is passed through the 
electrode tip for 30 seconds. 
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Summary 
 In this introduction, we have framed the work to be presented herein within 
the context of the ongoing search to better understand mechanisms of plasticity 
and recovery after TBI.  Extracellular matrix undoubtedly influences structural 
plasticity and synaptogenesis, but many of the details regarding specific 
functions of individual ECM components are still lacking.  Phosphacan/RPTPβ is 
an important CSPG in brain ECM which, unlike many other CSPGs, may not be 
straightforwardly inhibitory for axon growth and plasticity.  We have described the 
structure of RPTPβ and its alternative splice variants, and their patterns of 
expression during development.  We have reviewed the putative functions of the 
different RPTPβ variants in the nervous system, which include the regulation of 
cell adhesion, neurite outgrowth, and a potential role in morphogenesis and 
structural plasticity.  Phosphacan/RPTPβ variants have been studied in neuronal 
cultures and examined in animal models of epilepsy, penetrating brain injury, and 
spinal cord injury.  However, our understanding of how exactly these important 
ECM components are involved in recovery from brain trauma remains unclear.  
In the following chapters, we will take advantage of the unique features of the 
UEC model to investigate the role of phosphacan/RPTPβ during the process of 
injury-induced reactive plasticity.  Through detailed protein and mRNA 
quantification studies, immunohistochemistry, and qualitative ultrastructural 
analyses, Chapter 2 will characterize the expression of phosphacan/RPTPβ 
during synaptogenesis after UEC.  In Chapter 3 we will examine an important 
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methodological issue prompted by our quantitative mRNA studies, namely, the 
identification of a valid approach to data normalization for real-time RT-PCR 
studies of experimental TBI.  Chapter 4 begins to explore mechanisms by which 
sRPTPβ might influence the structural plasticity of dendritic spines during 
reactive synaptogenesis, focusing on changes in the sRPTPβ substrate β-
catenin.  It is our hope that the findings in this dissertation will help improve our 
understanding of how ECM influences recovery from brain injury, and will 
therefore aid in the development of therapies to promote improved recovery in 
TBI patients. 
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CHAPTER 2 
 
EVIDENCE FOR PHOSPHACAN/RPTPβ MEDIATION OF INJURY-
INDUCED SYNAPTOGENESIS 
 
 
 
Introduction 
 Functional recovery after traumatic brain injury (TBI) requires axonal 
sprouting and synaptic reorganization (Ramirez 2001; Stein & Hoffman, 2003; 
Nudo 2007).  There is increasing evidence that these processes are regulated by 
molecules within the extracellular environment of the brain.  The extracellular 
matrix (ECM) in the brain is particularly enriched in proteoglycans, with a major 
type being the chondroitin sulfate proteoglycans (CSPGs).  Structurally, CSPGs 
consist of a core protein containing variable number of chondroitin sulfate type 
glycosaminoglycan (CS-GAG) side chains.  As a group, CSPGs were initially 
described as inhibitory regulators of axon growth and plasticity.  For example, 
they impede axon extension in vitro and in vivo (Snow et al., 1990; Oohira et al., 
1991; Grumet et al., 1993; Davies et al., 1999), and are major components of the 
inhibitory glial scar which forms after lesions to the brain or spinal cord (reviewed 
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in Properzi et al., 2003).  More recently, it has been shown that enzymes which 
degrade CS-GAGs enhance axon regeneration and synaptic plasticity (Moon et 
al., 2001; Bradbury et al., 2002; Pizzorusso et al., 2002; Huang et al., 2006).  By 
contrast, some CSPG family members have been shown to interact in a positive 
way with cell adhesion molecules and soluble growth factors, resulting in 
enhanced axonal sprouting (Faissner et al., 1994; Sakurai et al., 1997; Bicknese 
et al., 1994). These interactions may be complex and show that CSPG function is 
not only growth inhibitory, but in some cases may serve to support regenerative 
plasticity.  The CSPG phosphacan and its related splice variants constitute one 
group whose members may play a supportive role in neuronal plasticity 
processes.     
Phosphacan (6B4 proteoglycan, or DSD-1 proteoglycan in the mouse) is a 
secreted alternative splice variant of the full length receptor protein tyrosine 
phosphatase β (RPTPβ), a transmembrane receptor with intracellular tyrosine 
phosphatase activity (Maurel et al., 1994).  A third form of the CSPG, the short 
transmembrane receptor (sRPTPβ), lacks the extracellular membrane-proximal 
sequence but retains the full intracellular phosphatase.  Recently, a fourth splice 
variant, phosphacan short isoform, was identified (Garwood et al., 2003) as a 
non-proteoglycan variant found in the extracellular space.  Secreted phosphacan 
and transmembrane sRPTPβ are the two most prominent forms found in adult 
brain (Sakurai et al., 1996; Dobbertin et al., 2003).  In vitro, phosphacan can 
either inhibit or promote axon growth depending on the neuronal lineage 
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(Garwood et al., 1999).   Produced and secreted by both neurons and glia 
(Snyder et al., 1996; Hayashi et al., 2005), phosphacan is a major component of 
brain ECM.  In normal brain, ultrastructural studies have shown the majority of 
RPTPβ/sRPTPβ expression restricted to post-synaptic dendrites and spines 
(Hayashi et al., 2005).  The phosphacan splice variant is secreted into the ECM 
and assumes a more diffuse distribution, observed surrounding synaptic profiles, 
but absent from the synaptic active zone (Miyata et al., 2004).   
In contrast to other CSPGs (e.g. neurocan, versican, NG2) which are up-
regulated after CNS trauma (Asher et al., 2000; Asher et al., 2002; Morgenstern 
et al., 2002; Jones et al., 2003), phosphacan expression after injury can vary 
significantly.  For example, phosphacan is reduced acutely following spinal cord 
injury (Jones et al., 2003; Tang et al., 2003), attenuated after cortical stab injury 
(Dobbertin et al., 2003) and is lowered following filter implant-induced glial 
scarring (McKeon et al., 1999).  In contrast, other studies have reported 
phosphacan increases after experimental stroke (Carmichael et al., 2005) and 
fimbria/fornix lesion (Snyder et al., 1996).  While one recent study did profile 
phosphacan mRNA expression after deafferentation lesion (Snyder et al., 2008), 
a systematic analysis of phosphacan splice variants during injury-induced 
reactive synaptic plasticity has not been made.  Phosphacan/RPTPβ expression 
is clearly regulated following CNS trauma, and these molecules are well 
positioned in the cytoarchitecture to potentially regulate axon regeneration and 
synaptic recovery. 
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 Several recent studies support a role for RPTPβ in synaptic plasticity in 
the uninjured mature brain.  Hippocampal long term potentiation (LTP) and 
hippocampus-dependent spatial learning are two processes which rely on 
synaptic plasticity and appear to be influenced by phosphacan CSPGs.  RPTPβ 
knockout mice (lacking all phosphacan splice variants) display age-dependent 
abnormalities in hippocampal LTP, as well as impairments in spatial learning and 
contextual fear conditioning (Niisato et al., 2005; Tamura et al., 2006).  A number 
of intracellular targets for the RPTPβ phosphatase have been identified (Kawachi 
et al., 1999; Meng et al., 2000; Pariser et al., 2005; Tamura et al., 2006), many of 
which function in neurite morphogenesis, synapse regeneration, and/or 
stabilization (e.g. β-catenin, β-adducin, PSD-95, p190 RhoGAP, etc.).  These 
results suggest that there may be multiple signaling pathways through which 
RPTPβ can influence structural plasticity at synapses.   
 In the present study we have documented the spatial and temporal 
expression of three phosphacan CSPG variants (phosphacan, RPTPβ and 
sRPTPβ) during synaptic regeneration following brain injury.  Here we will use 
the term “phosphacan/RPTPβ” to collectively refer to all three of these splice 
variants.  We have used unilateral entorhinal cortex lesion (UEC), a well-
characterized rodent model of reactive plasticity which leads to successful 
functional recovery (Steward et al., 1988).  One advantage of the UEC lesion 
model is that a robust reactive synaptogenesis occurs within the ipsilateral outer 
molecular layer (OML) of the dentate gyrus during the first two weeks post-lesion.  
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This temporal profile permits the examination of phosphacan splice variant 
mRNA and protein change during three distinct post-lesion phases of injury-
induced plasticity: degeneration of perforant path axon terminals (2d), afferent 
sprouting and establishment of new synaptic contacts (7d), and stabilization of 
newly formed synapses (15d).  We report that hippocampal sRPTPβ protein and 
mRNA are persistently elevated over the first two weeks after UEC.  In contrast, 
phosphacan protein is elevated in whole hippocampus during the acute 
degenerative phase (2d) and in ML-enriched samples during active synapse 
regeneration (7d), while its mRNA is increased during sprouting and synapse 
formation (7d).  These results support a role for phosphacan/RPTPβ in both the 
degenerative and regenerative phases of reactive synaptogenesis.   
 
 
Methods 
Animals and Surgical Procedures 
 Adult male Sprague-Dawley rats (300-390g) were subjected to entorhinal 
cortical lesion after the method of Loesche and Steward (1977).  Rats were 
randomly divided into three experimental groups:  2d (n = 18), 7d (n = 23) and 
15d (n = 12) survival.  All animals were surgically prepared under isoflurane 
anesthesia delivered via nose cone (2.25% in carrier gas of 70% N2O, 30% O2).  
During all surgical procedures body temperature was maintained at 37°C.  Rats 
were placed in a stereotaxic frame and an area of skull was removed above the 
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entorhinal cortex of the right hemisphere.  Lesion current was passed (1.5 mA for 
30 sec) through a Teflon-insulated wire electrode, 10° to perpendicular, at eight 
stereotaxic sites:  1.5 mm anterior to the transverse sinus, 3mm lateral to midline, 
at 2mm, 4mm, and 6 mm ventral to the brain surface; then 4mm lateral to midline 
at 2mm, 4mm, and 6mm ventral; and finally 5 mm lateral to midline at 2mm and 4 
mm ventral (see Figure 1.4).  After lesions were completed, the electrode was 
removed, the scalp was sutured closed, and   topical antibiotic was applied to the 
surgical site.  Animals were placed in a warmed holding cage and monitored 
during recovery, after which they were returned to their home cages.  All animal 
protocols were approved by the Institutional Animal Care and Use Committee. 
 
Protein Extraction and Western Blotting 
 Two rapid dissection procedures were performed for isolation of ipsilateral 
and contralateral samples.  Whole hippocampi were removed from one subset of 
animals at 2d (n = 6), 7d (n = 9), or 15d (n = 6) post-lesion, and a dentate 
molecular layer enriched fraction was removed from a second subset of rats at 
2d (n = 3) and 7d (n = 4) post-lesion.  For the whole hippocampal tissue, a serial 
extraction protocol was adapted from Dobbertin et al. (2003) in order to separate 
soluble extracellular phosphacan from transmembrane RPTPβ and sRPTPβ.  
Brains were removed from the skull, divided by a mid-sagittal cut, and whole 
hippocampi (including dentate gyrus and Ammon's horn) were dissected from 
each hemisphere.  Each hippocampus was homogenized  in 1.75 ml detergent-
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free extraction buffer (50mM Tris, 150mM NaCl, 40mM Na Acetate) containing 
protease inhibitors (Roche complete cocktail plus 2μg/ml Pepstatin).  
Homogenates were centrifuged for 20 min at 100,000 x g and 4°C.  Supernatant 
was removed and stored at -80°C as the saline fraction.  Pellets were re-
homogenized in 1.75ml extraction buffer containing 1% Triton X-100, and 
agitated  for 1 h at 4°C prior to centrifugation for 20 min at 100,000 x g and 4°C.  
Supernatant was removed and stored at -80°C as the detergent fraction.  In order 
to expose antigenic sites and maximize efficiency of antibody recognition, all 
protein samples were treated with chondroitinase ABC (chABC; Seikagaku 
America; East Falmouth, MA) to remove chondroitin sulfate GAG chains from 
proteoglycans (see Appendix B).  Aliquots of 540 ul for each sample were 
removed, buffered to pH 8 by addition of 400 mM Tris, and mixed with an 
additional protease inhibitor (Roche complete cocktail plus 2μg/ml Pepstatin).  
The resulting preparation (600μl volume) was incubated with 0.3 U chABC for 3 
h, shaking at 37°C.  Reaction was stopped by returning samples to -80°C.  
Protein concentration of the treated samples was determined by 
spectrophotometry (Shimadzu UV-160; Shimadzu Scientific Instruments; 
Colombia, MD).  For phosphacan Western blots, samples were heat denatured in 
XT sample buffer (Bio-Rad Laboratories; Hercules CA), 5μg separated on 
Criterion XT 3-8% gels (Invitrogen; Carlsbad, CA) and protein transferred to 
PVDF membrane.   In Western blotting of RPTP-β/sRPTP-β, samples were heat 
denatured in sample buffer and18μg separated on 3-8% gels (Bio-Rad 
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Laboratories; Hercules CA) before transfer to PVDF membrane.  Blots were 
probed with monoclonal antibodies 3F8 (Developmental Studies Hybridoma  
Bank; University of Iowa) or anti-RPTPβ (BD Biosciences; San Jose, CA). 
A second subset of animals at 2d (n = 3) and 7d (n = 4) postlesion were 
prepared for enriched molecular layer extraction.  Fresh brain was rapidly 
blocked into thick coronal sections, and the dentate molecular layer and adjacent 
granule cell laminae were excised from the ventral leaf of the dentate gyrus.  
These ML-enriched tissues were pooled from several adjacent thick sections, 
homogenized in a 100μl volume of T-PER (Thermo Scientific; Waltham, MA), and 
centrifuged for 5 min at 8,000xg and 4°C.  Supernatant was removed and stored 
at -80°C.   As for the whole hippocampal protein extracts, 5μg of protein was 
separated on Criterion XT 3-8% gels and transferred to PVDF membrane prior to 
probing for phosphacan using the 3F8 antibody.  Immunopositive bands on each 
blot were detected using Supersignal West  Dura (Pierce Biotechnology; 
Rockford, IL) and images were captured with the G:Box ChemiHR system for 
densitometric analysis using GeneSnap software (SynGene; Frederick, MD).  
Measurements from tissue ipsilateral to UEC were compared to homologous 
contralateral control regions and results expressed as percent of contralateral 
value.   
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Fluorescent Immunohistochemistry   
 At 2d (n = 3) or 7d (n = 3) post-lesion, groups of rats were deeply 
anesthetized with sodium pentobarbital (60 mg/kg, i.p.) and sacrificed by 
transcardiac perfusion of 0.9% saline, followed by 4% paraformaldehyde 
(Electron Microscopy Sciences; Fort Washington, PA) in 0.1M phosphate buffer 
(PB), pH 7.2.  Brains were removed and post-fixed overnight at 4°C.  Coronal 
sections (40 μm) were collected in 0.1 M PB, and immunohistochemistry (IHC) 
was performed for phosphacan (3F8 antibody; Developmental Studies 
Hybridoma Bank) or RPTPβ and sRPTPβ (anti-RPTPβ, BD Biosciences) which 
targets an intracellular domain common to both receptor forms.  On some 
sections, colocalization studies were performed with rabbit-anti-PSD-95 
(Invitrogen; Camarillo, CA) or with rabbit-anti-GFAP (Dako North America Inc.; 
Carpinteria, CA) to identify astrocytes as a possible source of phosphacan.  
Since the binding site for 3F8 is partially masked by CS-GAGs attached to the 
core protein (Dobbertin et al. 2003), we treated brain sections with chABC prior 
to phosphacan immunodetection.  These sections were incubated for 1 h at 37°C 
with chABC (0.1 U/mL in Tris Acetate buffer; 100 mM Tris-HCl, 30 mM Na-
Acetate, pH 8.0), then washed 3 x 10 min in phosphate buffered saline (PBS; 
Bio-Rad Laboratories) before subsequent  immunodetection.  Free-floating 
sections were then blocked for 30 min in peroxidase, washed 3 x 10 min in PBS 
and placed in blocking buffer (fish gelatin in PBS + 0.05% Triton X-100) for 30 
min.  Next, the tissue sections were incubated in primary antibody (3F8 1:100, 
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anti-RPTPβ 1:500, or GFAP 1:5,000) overnight at 4°C.  After primary antibody 
exposure, sections were washed 3 x 10 min in PBS, blocked again for 30 min 
and incubated with the appropriate fluorescent secondary antibody (Alexa 488 
goat-anti-mouse, Alexa 594 goat-anti-chicken, or Alexa 594 donkey anti-rabbit; 
Invitrogen; Carlsbad, CA) for 2 h.  After a final series of PBS washes, sections 
were mounted onto Probe On Plus glass slides (Fisher Scientific), and 
coverslipped with Vectashield (Vector Laboratories).  Minus primary controls 
were processed in parallel to confirm signal specificity.  Images were captured 
with a Leica TCS-SP2 confocal microscope for qualitative analysis of protein 
distribution. 
 
EM Immunohistochemistry 
At 7d, a subset of animals (n = 2) were deeply anesthetized with sodium 
pentobarbital (60 mg/kg, i.p.) and sacrificed by transcardiac perfusion of 0.9% 
saline, followed by mixed aldehyde fixative (4% paraformaldehyde and 0.2% 
glutaraldehyde; Electron Microscopy Sciences) in 0.1M PB, pH 7.2.  Brains were 
removed and post-fixed overnight at 4°C.  Coronal sections (40 μm) were 
collected in 0.1 M PB and processed for immunostaining with anti-RPTPβ 
antibody (BD Biosciences) as indicated above, or with MAB 5210 (Chemicon) to 
detect all phosphacan splice variants.  Antibody binding was visualized with DAB 
as described previously (Phillips et al., 1994).  Tissue was then placed in 1% 
osmium (0.1M phosphate buffer, pH 7.2) and processed in resin prior to being 
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flat-embedded on plastic slides.  After the plastic had cured, sample regions of 
mid-dorsal hippocampus containing the CA1 and dentate gyrus were excised and 
a series of thick and thin sections cut on an Leica EM UC6i ultramicrotome (Leica 
Microsystems).  The thin sections were collected on membrane-coated slotted 
grids and observed on a Jeol JEM-1230 electron microscope (Tokyo) equipped 
with a Gatan UltraScan 4000SP CCD camera.  The granule cell and molecular 
layers of the dentate gyrus, both ipsilateral and contralateral to the lesion, were 
systematically photographed at 5-10,000x magnification for qualitative analysis.  
 
RNA Isolation and qRT-PCR 
 Whole hippocampi (including dentate gyrus and Ammon's horn) were 
rapidly dissected from a subset of animals at 2d (n = 6), 7d (n = 5), or 15d (n = 6) 
post-lesion, and RNA extraction was performed under nuclease-free conditions.  
Each hippocampus (~100mg) was homogenized in 1ml Trizol Reagent 
(Invitrogen), mixed with 0.2 ml chloroform, and centrifuged for 15 min at 12,000 x 
g.  RNA in the upper phase was removed and precipitated with 0.5 ml isopropyl 
alcohol.  After centrifugation for 10 min at 12,000 x g, supernatant was removed 
and RNA pellets were washed in 75% ethanol.  The pellets were dissolved in 
PCR-grade water (Ambion) and incubated at 55°C for 10 min.  All samples were 
DNase treated (DNA-free DNase kit; Ambion) according to the manufacturer’s 
protocol in order to remove residual DNA contamination and then stored at -
80°C.  Total RNA integrity and concentration was assessed with the Experion 
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automated electrophoresis system (Bio-Rad).  Electropherogram traces for all 
samples indicated good quality RNA, with clear peaks at 18s and 28s and minor 
RNA degradation.  Sample concentrations measured with Experion were also 
verified with spectrophotometry (ND-1000; Nanodrop Technologies).  Equal 
amounts of total RNA were prepared in PCR-grade water (Ambion) for 
quantitative real time RT-PCR on the ABI prism 7900 Sequence Detection 
system (Applied Biosystems).  Taqman primers were designed with Primer 
Express software (Applied Biosystems) to span exon-exon boundaries.  
Sequences for specific primers and Taqman probes are shown Table 2.1.  
Reactions were run in triplicate and relative mRNA quantities were derived from 
CT values by the standard curve method.  All reactions were found to have an 
efficiency of >88% as determined by the slope of the standard curves.  Negative 
controls on each plate included no-amplification and no-template control 
conditions.  For subsequent data analysis, the mean of each mRNA triplicate was 
calculated and ipsilateral values were expressed as percent of contralateral 
controls for each gene.  Four widely used reference genes (β-actin, cyclophilin A, 
GAPDH, and 18s rRNA) were screened to assess their suitability as controls in 
our injury paradigm.  Only cyclophilin showed no differences in expression 
between ipsilateral and contralateral hippocampi at any given time point, no 
change over time postinjury, and the lowest variability of expression within each 
group.  Given these results, we grouped our RT-PCR data in two ways, first with 
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target gene expression normalized to total RNA content, and second with 
expression normalized to cyclophilin levels for each sample.  
 
Statistical Analysis 
 The significance of densitometric values from Western blot immunobinding 
was analyzed using the Student’s t-test.  For quantitative RT-PCR data, both 
normalized and non-normalized group means were analyzed using specific 
planned comparisons between experimental groups, implemented using simple 
main effects tests (SPSS v11 MANOVA syntax).  A probability of less than 0.05 
was considered statistically significant for all tests. 
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Table 2.1  Taqman Sequences 
 
 
 
 
     gene 
 
            Oligo sequence 
 
phosphacan forward 5’- GGGCATTCAGGAGTATCCAACA-3’ 
phosphacan reverse 5’- TCCGTGACTCTTCTATTTTTACTTTCAT-3’ 
phosphacan probe 5’- TCAGCACATCTCGTTCTATCCCTTTGCTCA-3’ 
  
RPTPβ forward 5’- GCAGAGGCCAGTAATAGTAGCCAT-3’ 
RPTPβ reverse 5’- TAGATGAGAATACCAACAAGAACCACTAG-3’ 
RPTPβ probe 5’- ACACGATCACAAGGGGTATAACCGCCTT-3’ 
  
sRPTPβ forward 5’-ACAATGAGGCCAGTAATAGTAGCCAT-3’ 
sRPTPβ reverse 5’- TAGATGAGAATACCAACAAGAACCACTAG -3’ 
sRPTPβ probe 3’- AGACACGATCACAAGGGGTATAACCGCCT -5’
  
cyclophilin A forward 5’- CTGTTTGCAGACAAAGTTCCAAA -3’ 
cyclophilin A reverse 5’- AGGAACCCTTATAGCCAAATCCTT -3' 
cyclophilin A probe 5’- CAGCAGAAAACTTTCGTGCTCTGAGCACT -3' 
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Results 
Expression of phosphacan/RPTPβ protein after UEC 
 Western blot analysis of phosphacan in hippocampal homogenates 
extracted without detergent (saline fraction enriched in soluble extracellular 
proteins) was performed using the 3F8 antibody.  In the untreated saline extracts 
from 2, 7 and 15d cases, we observed a broad high molecular weight signal, 
migrating at greater than 600 kD.  After the samples were treated with chABC, a 
discrete band at approximately 450 kD was resolved with the 3F8 antibody (see 
Appendix B).  This band, corresponding to the phosphacan splice variant 
(Dobbertin et al., 2003), was significantly increased in the ipsilateral 
hippocampus at 2d (Figure 2.1 A; 114.4 ± 6.9%, p<0.05), but was not different 
from contralateral control samples at either 7 or 15d survival.  By contrast, when 
hippocampal homogenates extracted with 1% Triton (detergent fraction enriched 
in transmembrane proteins) were probed for RPTPβ and sRPTPβ using antibody 
to the intracellular c-terminal epitope, we observed a 250 kD band corresponding 
to sRPTPβ (Dobbertin et al., 2003, which was significantly increased at 2, 7, and 
15d after UEC (Figure 2.1 B; 116.6 ± 8.2%, p<0.05; 118.4 ± 9.5% and 120.2 ± 
10.4%, p<0.001).  Consistent with the reported low expression of full length 
RPTPβ in adult brain, we failed to detect RPTPβ in our samples.  These results 
show that reactive synaptogenesis alters the protein expression of both 
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Figure 2.1  Hippocampal phosphacan and sRPTPβ protein after UEC.  
Protein was extracted from whole hippocampi at 2, 7, or 15d following UEC 
lesion and Western blotting was performed for phosphacan (3F8 antibody) or 
RPTPβ/sRPTPβ (anti-RPTPβ antibody).  The developmentally prominent full-
length RPTPβ protein was not detected in our samples from adult brain.  In (A) 
phosphacan in the saline fraction (enriched in soluble extracellular proteins) is 
increased in ipsilateral hippocampus at 2d post lesion (114.4 ± 6.9%, *p<0.02).  
In (B) sRPTPβ in the detergent fraction (enriched in transmembrane proteins) is 
persistently increased in ipsilateral hippocampus at 2, 7, and 15d post lesion 
(116.6 ± 8.2%, *p<0.02; 118.4 ± 9.5% and 120.2 ± 10.4%, **p<0.001). 
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Figure 2.1 
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phosphacan and sRPTPβ and that the temporal pattern of change is different for 
the two proteins.  Such differences suggest that phosphacan may selectively 
affect an earlier phase of synapse reorganization after brain injury.  
 
Phosphacan/RPTPβ immunohistochemistry 
 Having established the quantitative differences in phosphacan/RPTPβ 
expression after UEC, we examined the cellular localization of these 
proteoglycans with the same antibodies used in the Western blot experiments.  
IHC analysis of phosphacan was focused on the acute 2d post-injury period, 
where significant elevation in protein expression was observed.  Diffuse low level 
staining for phosphacan was evident in the contralateral molecular layer (ML), 
with denser aggregates of the protein (arrows) surrounding the cell bodies of 
dentate granule cells (Figure 2.2 A).  By contrast, immunoreactivity specifically 
within the outer ML (arrows) was upregulated ipsilateral to UEC when compared 
to contralateral controls (Figure 2.2 B).  Notably, the high intensity of 
phosphacan  staining within the granule cell layer was reduced on the 
deafferented side (asterisk). 
 While Western blot results revealed a persistent increase in sRPTPβ 
protein over the first 2 weeks after UEC, we chose to focus our IHC analysis of 
sRPTPβ at 7d post lesion, the period corresponding to robust sprouting and 
synaptic reorganization in the ML.  Although our RPTPβ antibody recognizes an 
intracellular domain common to both RPTPβ receptors, the low expression of full 
  67
length RPTPβ in adult brain (Sakurai et al., 1996; Dobbertin et al., 2003) and lack 
of detectable signal for the full length receptor in our WB studies strongly 
suggests that our immunostaining with anti-RPTPβ primarily represents 
distribution of sRPTPβ.  We found a punctate staining pattern for sRPTPβ over 
the entire ML, which appeared more intense on the deafferented side compared 
to the contralateral control region (Figures 2.2 C, D). 
 When MAB5210 was used to localize phosphacan family members at the 
ultrastructural level, we observed DAB reaction product in contralateral granule 
cell cytoplasm (arrows; Figure 2.2 E), consistent with the distribution of both 
proteins seen with confocal IHC.  This label was verified as positive signal in 
parallel unstained thin sections (see arrows in Figure 2.2 F).  To investigate 
whether astrocytes might express phosphacan/RPTPβ after UEC, we also 
performed co-localization experiments with 3F8 or anti-RPTPβ and GFAP 
antibody.  Neither phosphacan nor sRPTPβ immunostaining were present within 
astrocyte cell bodies and major processes (Figure 2.2 G, H), suggesting a 
potential neuronal source, rather than glial, for these proteoglycans within the 
deafferented dentate gyrus.  
Since the distribution of sRPTPβ suggested potential synaptic localization, 
we also performed double-label IHC for sRPTPβ and the post-synaptic density 
marker PSD-95 at 7d after UEC.  A subset of sRPTPβ positive puncta were 
found adjacent to sites stained with PSD-95 (arrows in Figures 2.3 A, B), a  
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Figure 2.2  Phosphacan/RPTPβ immunohistochemistry.  (A) 3F8 
immunostaining in contralateral hippocampus shows diffuse phosphacan 
reactivity in the ML and denser aggregates surrounding granule cell bodies 
(arrows).  (B) Ipsilateral to lesion at 2 dpl, phosphacan staining intensity appears 
reduced within the GCL (asterisk) and clearly increased in the outer ML (arrows). 
(C) Anti-RPTPβ immunostaining reveals a diffuse distribution of sRPTPβ over the 
contralateral ML, while ipsilateral to lesion (D) at 7dpl this immunoreactivity 
appeared increased.  In (E) MAB5210 was used to localize phosphacan/RPTPβ 
at the ultrastructural level in the contralateral GCL 2 dpl.  Reaction product can 
be seen in granule cell cytoplasm, consistent with the distribution of phosphacan 
in (A).  In (F) a parallel thin section processed without uranyl acetate or lead 
citrate counter-stain demonstrates specificity of the MAB5210 signal.  Double-
labeling for phosphacan (green) and GFAP (red) at 2 dpl (G), and for sRPTPβ 
(green) and GFAP (red) at 7dpl (H), shows that neither one of these 
proteoglycans co-localizes with astrocytes in the deafferented zone after UEC.  
In (I) a parallel section processed without primary antibodies demonstrates the 
specificity of immunolabeling in these studies. ML=molecular layer; GCL=granule 
cell layer; dpl=days post lesion. A-D bar=50µm; E,F bar=0.5µm; G-I bar=100µm. 
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pattern suggesting contiguous distribution of the two proteins rather than co-
localization.  Moreover, the relative density of sRPTPβ again appeared greater in 
the deafferented ML region when compared with the contralateral side  (compare 
Figure 2.3 B to 2.3 A).  In order to further investigate whether this pattern might 
represent pre- or post-synaptic localization of sRPTPβ, we performed electron 
microscopic IHC on parallel 7d cases.  At the ultrastructural level, sRPTPβ was 
found within dendrites (asterisk in Figure 2.3 C), as well as in spines 
(arrowhead) and adjacent to post-synaptic profiles (arrow), both illustrated in the 
inset of Figure 2.3 C.  This pattern of sRPTPβ  distribution near synaptic 
junctions was similar to that previously observed by Hayashi and colleagues in 
embryonic cortical cells (2005).  Post-synaptic localization in our experiments, 
illustrated from a contralateral control molecular layer, was seen in both injured 
and control ML at 7d post lesion. 
 
Expression of Phosphacan/RPTPβ mRNA after UEC 
 Specific mRNA levels of phosphacan, RPTPβ, and sRPTPβ were 
measured in deafferented and contralateral control tissue at 2, 7, and 15d post 
lesion using qRT-PCR.  Initially, we tested four commonly applied reference 
genes for our hippocampal UEC samples and found that cyclophilin A transcript 
was the most stably expressed (see Chapter 3).  However, prior methodological 
analysis of qRT-PCR shows that normalization to total RNA mass, rather than to 
a specific reference gene, may be more accurate when assessing subtle shifts in  
  71
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.3  sRPTPβ immunostaining indicates postsynaptic localization.  
Double-labeling of sRPTPβ (green) and post-synaptic density marker PSD-95 
(red) was performed at 7dpl. A subset of sRPTPβ positive puncta within the 
contralateral ML (A) and the ipsilateral ML (B) are located adjacent to PSD-95 
positive sites (arrows), suggesting a contiguous but non-overlapping distribution 
of the two proteins. (C) In parallel 7dpl cases processed for ultrastructural 
immunostaining, sRPTPβ is localized within dendrites (asterisk) and spines (see 
inset) within the outer ML. Immunoreactivity was seen both near  the base of 
spines (arrowhead) and at the synaptic active zone (arrow).  ML=molecular layer; 
dpl=days post lesion; EM=electron microscopy. A,B bar= 25µm; C bar=0.5µm; 
Inset bar=0.2µm. 
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gene expression (Tricarico et al., 2002; Meldgaard et al., 2006).  Given these 
observations, we chose to analyze our qRT-PCR data in two ways: 1) normalized 
to cyclophilin, and 2) normalized to total RNA content (Figure 2.4).  Results with 
the two normalization strategies show similar overall trends, but several 
differences in the detection of significant effect were observed.  When normalized 
to cyclophilin, phosphacan mRNA was significantly increased at 7d (120.4 ± 
3.0%; p<0.05), while mRNA for each transmembrane RPTPβ splice variant was 
elevated at only at 15d (138.6 ± 20.8%, p<0.01 for RPTPβ; 134.6 ± 20.1% for 
sRPTPβ, p<0.01).  When mRNA expression was normalized to total RNA mass, 
similar results were obtained for phosphacan, with significant transcript elevation 
occurring only at 7d (113.6± 8.7%, p<0.05).  By contrast, additional differences in 
transcripts for both RPTPβ forms were detected.  Specifically, full length RPTPβ 
was significantly elevated at both 2 and 15d (122.8 ± 5.3% and 122.6 ± 7.8%; 
p<0.001), while sRPTPβ was significantly elevated at 2, 7, and 15d post lesion 
(111.7 ± 10.0% and 112.8 ± 5.6%, p<0.05; 118.8 ± 6.9%; p<0.01).  These results 
suggest that small shifts in cyclophilin gene expression following UEC introduce 
enough variance into the reference gene normalization analysis to cause the loss 
of some group differences.  Interestingly, Bustin and colleagues (2006) have 
proposed that reference gene normalization may not be necessary if RNA 
sample quality is high (avoiding contamination effects on PCR reaction 
dynamics), and if total RNA load concentration is accurately measured.  Since 
we rigorously assessed RNA quality by Experion LabChip analysis (see 
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Appendix D) and confirmed sample concentrations by Nanodrop 
spectrophotometry, we feel that these conditions are met in our protocol, and 
predict that low variability of the PCR reaction was achieved in our experiments.  
Based upon these criteria, and the fact that the temporal pattern of protein and 
transcript are most closely matched using normalization to total RNA mass, we 
believe that our results without reference gene normalization (Figure 2.4, right 
column) are the more biologically relevant data. 
 
Local Expression of Phosphacan in the Deafferented Molecular Layer  
 Given that observed shifts in phosphacan protein and mRNA at 2 and 7d 
postlesion were not temporally matched, we investigated whether these 
differences might be explained by sampling method.  Our time course profiles for 
phosphacan/RPTPβ were determined from whole hippocampal extracts, which 
could potentially dilute injury effects specific to the deafferented ML.  In fact, our 
IHC results suggested that phosphacan within the ipsilateral dentate gyrus was 
reduced over the granule cell layer and increased in the deafferented ML 
following UEC.  We examined phosphacan protein level in Western blots for both 
2 and 7d samples enriched in the ML.  At 7d, when qRT-PCR showed elevated 
transcript, but no increase in whole hippocampal phosphacan, the isolated 
deafferented zone revealed  a significant increase in phosphacan protein 
(129.9±4.9%;  p<0.05; Figure 2.5). Interestingly, we found that phosphacan was 
not increased in 2d ML enriched samples (3.7±3.6%; p>0.05), as compared with 
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a clear increase seen in the whole hippocampal extracts (see also Figure 2.1).   
This result might be explained by the observation that UEC appears to shift 
phosphacan signal from granule cell layer to the deafferented outer ML (see 
again Figure 2.2 A, B).  Given that our ML enriched extracts are also likely to 
contain some granule cell bodies (see dissection methods above), then the ML 
enriched extracts from the ipsilateral and contralateral sides would have similar 
overall amounts of phosphacan and show no relative change in WB signal.   
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Figure 2.4  Phosphacan/RPTPβ mRNA after UEC.  RNA samples extracted from 
whole hippocampi at 2, 7, or 15d post lesion were analyzed for expression of 
phosphacan, RPTPβ, or sRPTPβ transcript using qRT-PCR.  The data were either 
normalized to expression of the reference gene cyclophilin (left column) or normalized 
to equal starting amounts of total RNA (right column).  When normalized to cyclophilin, 
phosphacan mRNA is significantly increased at 7dpl (120.4 ± 3.0%; *p<0.05), while 
RPTPβ and sRPTPβ transcripts are each increased at 15dpl (138.6 ± 20.8% for 
RPTPβ; 134.6 ± 20.1% for sRPTPβ; **p<0.01).  Normalizing to equal total RNA 
showed similar overall trends but revealed additional significant effects of injury.  When 
normalized to total RNA, phosphacan was increased at 7dpl (113.6± 8.7%, *p<0.05), 
while RPTPβ showed significant elevation at both 2 and 15d (122.8 ± 5.3% and 122.6 
± 7.8%; **p<0.001) and sRPTPβ showed persistent increase at 2, 7, and 15dpl (111.7 
± 10.0% and 112.8 ± 5.6%, *p<0.05; 118.8 ± 6.9%; **p<0.01). Since the criteria for 
accurate normalization to total RNA are met in our experiments (see text for details) we 
propose that the qRT-PCR results normalized to total RNA represent the more 
biologically relevant data.    
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Figure 2.4 
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Figure 2.5  Phosphacan protein in the deafferented molecular layer.  Protein 
was extracted from ML-enriched hippocampal dissections at 2 and 7 dpl and 
probed for phosphacan with the 3F8 antibody.  Representative lanes show 3F8 
Western blotting results from ipsilateral and contralateral hippocampi at 2 and 
7dpl.  At 7dpl, when whole hippocampal protein showed no change in 
phosphacan compared to contralateral control (see also Figure 2.1A), ML-
enriched samples showed a significant increase in phosphacan (129.9±4.9%; 
*p<0.05).  This pattern is supported by the increase in phosphacan transcript we 
observed at 7dpl (see Figure 2.4). Interestingly, the increase in whole 
hippocampal phosphacan at 2 dpl (see also Figure 2.1A) is lost in the ML-
enriched dissection, suggesting differential distribution of phosphacan protein 
within the hippocampus at 2 and 7d after UEC.  I = ipsilateral; C= contralateral; 
dpl = days post lesion.  
  79
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.5
  80
 Discussion 
The present study describes the expression of phosphacan/RPTPβ 
isoforms during the time course of reactive synaptic plasticity in the deafferented 
hippocampus.  We focused on post-injury time intervals of synaptic degeneration 
(2d), sprouting and synapse formation (7d), and synapse stabilization (15d).  We 
report that the protein and mRNA for phosphacan, full length RPTPβ, and 
sRPTPβ are differentially expressed following UEC deafferentation.  In whole 
hippocampal tissue extracts, phosphacan protein was acutely upregulated 2d 
after UEC, while transcript showed a later increase at 7d.  When samples 
enriched in the deafferented molecular layer were probed for phosphacan 
protein, an increase was observed at 7d, showing that the injury response is sub-
region specific.  By contrast, both protein and transcript for sRPTPβ were 
persistently elevated at all three post injury time points.  The mRNA for full-length 
RPTPβ also increased after UEC lesion, but this change was limited to 2 and 15d 
survival, and was not accompanied by detectable signal for the translated 
protein.  Phosphacan and sRPTPβ were each localized within granule cell bodies 
and over the deafferented neuropil of the dentate ML, and increased in label 
intensity at 2 and 7d post-lesion.  Co-localization studies showed that reactive 
astrocytes were not labeled for either phosphacan or sRPTPβ protein, 
suggesting that they are not a primary source of the increased levels observed in 
the deafferented zone.  We also found that sRPTPβ and PSD-95 were expressed 
in adjacent loci within the ML neuropil, and EM immunostaining showed sRPTPβ 
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localization in ML dendrites and spines, suggesting post-synaptic proteins may 
be targets of the tyrosine phosphatase during synaptogenesis.  Taken together, 
these results support the participation of phosphacan and its membrane bound 
tyrosine phosphatase variants in each phase of reactive synaptogenesis.  
 
Time Course of Phosphacan/RPTPβ Expression During Synaptogenesis 
Our study provides new detail regarding the expression of extracellular 
phosphacan and the transmembrane tyrosine phosphatase sRPTPβ during the 
time course of reactive synaptogenesis.  Overall, phosphacan showed increased 
mRNA and protein expression in the earlier phases of synaptogenesis (2 and 
7d), while the membrane bound sRPTPβ transcript and protein were elevated at 
all time points examined, covering the degenerative, sprouting, and stabilization 
phases.  Notably, sRPTPβ showed a correlated rise in both transcript and 
protein, while phosphacan did not.   
Prior to the present study, two other investigations have explored 
expression of phosphacan isoforms at single time points after UEC.  First, Deller 
and colleagues (1997) reported an increase in phosphacan immunostaining 6d 
after UEC.  However, this study used an antibody directed toward a CS epitope 
attached to phosphacan.  Since post-translational modifications may alter CS 
epitopes, causing them to be regulated independently from the core protein 
(Rauch et al., 1991; Meyer-Puttlitz et al., 1995; Dobbertin et al., 2003), changes 
detected by this antibody may not fully reflect the impact of UEC on phosphacan 
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protein level.  The second study employed in situ hybridization to show induction 
of phosphacan and full-length RPTPβ mRNA in hippocampus 20d after a 
combined UEC and fimbria/fornix lesion (Snyder et al. 1996).  Unfortunately, the 
single long-term time point examined did not allow for conclusions to be drawn 
about the specific role(s) of these transcripts during the full time course of 
hippocampal synaptic reorganization.    
In our study we sampled three key postinjury intervals and report an 
increase in both sRPTPβ and full-length RPTPβ transcript after UEC.  For 
sRPTPβ, protein and mRNA were concurrently elevated at 2, 7, and 15d survival, 
remaining remarkably stable throughout the different phases of reactive 
synaptogenesis.   Transcript for the long form of RPTPβ was increased at the 
acute 2d and later 15d period.  Notably, the increase in full-length RPTPβ mRNA 
reported by Snyder and colleagues is consistent with our 15d data showing 
transcript elevation for both long and short receptor forms during the synaptic 
stabilization phase.  Because full-length RPTPβ is primarily a developmental 
isoform, and the protein is not routinely detectable in our adult samples, the 
functional significance of UEC-induced changes in RPTPβ transcript remains 
unclear.  Since we have applied the standard curve method for relative transcript 
quantification (Bond et al. 2002), we could not derive an absolute copy number of 
RPTPβ mRNAs.  Given that qRT-PCR is a sensitive technique capable of 
detecting mRNAs with very low copy number, it is possible that the significant 
increases in full-length RPTPβ detected in the present study reflect a low copy 
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number shift, which may or may not be directly relevant to the process of reactive 
synaptogenesis.  Further examination of this RPTPβ isoform will be required to 
establish its possible role in the acute and long-term phases of synaptic 
reorganization.   
  In addition, our results differ from those of Snyder and colleagues in that 
we did not observe increased hippocampal phosphacan message at 15d after 
UEC.  As we found with phosphacan protein analysis, this may be due to dilution 
of effect by sampling whole hippocampus rather than enriched ML zones.  In fact, 
the study by Snyder et al. (1996) showed that increased tissue signal was 
focused over the stratum lacunosum-moleculare and stratum radiatum, dendritic 
regions targeted by their combined injury paradigm.  It is also possible that 
hippocampal deafferentation produces elevation of phosphacan message at both 
7 and 20d postinjury, indicating a biphasic transcriptional response, and 
suggesting multiple roles for this proteoglycan during synaptic recovery.   
 While more recent studies have included phosphacan in a detailed 
analysis of CSPG family transcription during reactive synaptogenesis (Schafer et 
al., 2008), we believe that the present study is the first to report the pattern of 
both protein and transcriptional regulation for three major phosphacan splice 
variants over the time course of reactive synaptogenesis leading to adaptive 
recovery.  Our current findings with respect to UEC lesion add to the 
understanding of how phosphacan and sRPTPβ contribute to synaptic 
reorganization within the injured CNS.  
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Asynchrony of Phosphacan Expression During Synaptogenesis 
In the current study some interesting differences in phosphacan 
expression were revealed from whole hippocampal extracts.  Specifically a 2d 
increase in protein was not matched by mRNA elevation, while a 7d increase in 
transcript was not accompanied by a rise in protein.  While less frequently 
observed, differing patterns of transcript versus protein expression have been 
reported for proteoglycans in other studies of CNS injury.  For example, spinal 
cord contusion caused an increase in phosphacan protein while transcript 
remained essentially unchanged (Iaci et al., 2007).  Conversely, experimental 
stroke caused an induction of phosphacan mRNA while staining for phosphacan 
protein was reduced in peri-infarct cortical regions (Carmichael et al., 2005).   
Such differences between phosphacan protein level and mRNA 
transcription might be explained in several ways.  When increased protein is 
observed without transcript change, as we have shown for phosphacan at 2d 
after UEC, one possibility would be that a stable pool of mRNA is translated at an 
accelerated rate after injury.  One mechanism by which this effect might occur 
could be through the induction of elongation factor 1α (EF1α), a key component 
of the translational machinery, in granule cell dendrites when reactive plasticity is 
induced.  Increased EF1α has been demonstrated in association with the 
hippocampal plasticity produced by LTP of the medial perforant path (Huang et 
al., 2005).  Molecules like EF1α are also upregulated by mGluR activation, 
mediating protein expression by driving dendritic mRNA translation without new 
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transcription (Huang et al., 2005; Huber et al., 2000).  Changes in proteins which 
regulate translation have also been reported following fluid percussion injury 
(FPI).  For example, mammalian target of rapamycin (mTOR) and cytoplasmic 
polyadenylation element-binding protein (CPEB), both mediators which help 
promote protein translation, are reported to be transiently increased after FPI 
(Atkins et al., 2006; Chen et al., 2007).  Clearly, multiple pathologies which 
constitute focal brain lesion might activate molecules which alter the rate of 
protein translation.  Alternatively, the difference we report in phosphacan protein 
and transcript at 2d could be due to an injury-induced effect on antibody binding.  
In this case, the efficacy of antibody recognition could be altered by injury-
induced changes in the target protein, including changes in binding partners, 
protein conformation, or post-translational modifications.  Such post-injury 
changes in phosphacan conformation or post-translational modifications could 
potentially enhance detection of protein by immunological methods, in the 
absence of change in transcript.  
 In contrast to 2d post injury, at 7d we observed an elevation in 
phosphacan transcript without concurrent increase in protein.  Several different 
scenarios could explain this type of difference.  First, despite the evidence 
suggesting accelerated protein translation at 2d, it is possible that post-injury 
conditions at the 7d time point could cause translation of phosphacan protein to 
be suppressed.  On the other hand, the observed transcript elevation without 
change in protein levels could occur if the protein products of new mRNA 
  86
transcripts are successfully translated, but then rapidly degraded in vivo.  This 
could result from activation of one or more extracellular proteases known to 
degrade phosphacan.  In particular, the metalloproteinase MMP-3 has been 
shown to cleave phosphacan in vitro (Muir et al., 2002) and its expression is 
upregulated in hippocampus after UEC (Falo et al., 2006).  The tPA/plasmin 
proteolytic pathway could also degrade phosphacan during injury-induced 
synaptogenesis, since plasmin has been shown to degrade phosphacan in the 
hypothalamus during physiologically induced synaptic plasticity (Miyata et al., 
2005).  
 Our exploration of the role of tissue sampling revealed a more direct 
potential explanation for these differences between phosphacan mRNA and 
protein expression.  In extracts from whole hippocampus, phosphacan protein 
increased only at 2d post lesion.  When the deafferented ML was more directly 
examined using dentate-enriched protein fractions, phosphacan was no longer 
elevated at 2d, but rather at 7d post lesion, the period when sprouting and 
synapse formation is initiated.  This ML result was consistent with our 
observation that increased transcription of hippocampal phosphacan mRNA was 
restricted to 7d after UEC.  With careful examination of correlative phosphacan 
IHC (describe in detail below), the absence of ML increase in protein expression 
at 2d appears to be associated with phosphacan redistribution from the granule 
cell body lamina to dendritic zones (see again Figure 2.2 A, B).  Thus, 
comparison of our lesioned and control extracts would produce no detectable 
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differences.  By contrast, at 7d, when ipsilateral ML expresses higher levels of 
phosphacan by WB analysis, the IHC pattern shows uniform elevation of the 
protein over the entire deafferented dentate ML (see again Figure 2.2 C, D).  In 
this case, our ML enriched extracts revealed significant elevation of phosphacan 
on the lesioned side.  Given the differences between whole hippocampal and ML 
enriched extracts, it is clear that UEC produces a complex phosphacan response 
and that accurate interpretation of phosphacan expression requires sampling of 
tissue sites specific to the biological process being investigated. 
 Finally, we cannot rule out the possibility that the examination of other 
time points not included in the present study would provide tighter correlation 
between mRNA and protein profiles.  For example, phosphacan transcript levels 
may be elevated prior to 2d and their translation may be responsible for the 
significant increase in phosphacan protein we find at 2d. The asynchrony in 
phosphacan mRNA and protein levels after UEC illustrates the fact that transcript 
does not always accurately predict changes in protein content.  In fact, others 
have urged caution in interpreting studies of proteoglycan expression after CNS 
trauma, particularly where mRNA quantification is the sole endpoint (Iaci et al. 
2007). 
 
Distribution of Phosphacan/RPTPβ During Synaptogenesis 
We also investigated the in vivo localization of phosphacan splice variants, 
to address whether the changes observed in protein extracts were supported by 
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a tissue distribution consistent with the adaptive synaptogenesis induced by 
UEC.  IHC for hippocampal phosphacan and sRPTPβ was performed focusing 
on 2 and 7d post injury, intervals when differences in protein expression for each 
splice variant were detected by Western blot.   
IHC for phosphacan revealed a diffuse, uniform staining of the neuropil in 
the control samples, consistent with its role as a matrix proteoglycan.  We also 
observed a dense staining pattern surrounding neuronal somata in the 
hippocampal GCL.  At 2d post lesion, immunoreactivity for phosphacan appeared 
as a strong band in the deafferented outer ML and was notably decreased in the 
GCL compared to contralateral controls.  At 7d post lesion the same relative 
distribution of phosphacan between ML and GCL was observed, however the 
intensity of antibody signal was reduced overall (data not shown).  A similar 
pattern of elevated proteoglycan over the deafferented outer ML was reported 
using antibodies to tenascin-C and a CS epitope on phosphacan (Deller et al., 
1997).  However, one notable difference shown in our study was a strong GCL 
localization of phosphacan which appeared to shift into the deafferented dendritic 
regions after UEC.  It is possible that 3F8 antibody recognition of the phosphacan 
protein core revealed cell body sites not recognized with the DSD-1-PG IgM 
antibody used by Deller’s group. 
By contrast, IHC with antibody to sRPTPβ revealed a punctate staining 
pattern, which at 7d showed elevation over the hippocampal ML compared to 
contralateral controls.  Anti-RPTPβ targets an intracellular epitope common to 
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both receptor variants, so that this staining could represent the long as well as 
short receptor form of the protein.  However, since other studies have 
demonstrated that full-length RPTPβ is primarily a developmental isoform 
(Sakurai et al. 1996; Dobbertin et al 2003), and we failed to detect it in our 
Western blot samples from adult brain, it seems likely that our anti-RPTPβ IHC 
signal represents primarily the short receptor form.  Thus, the enhanced IHC 
signal observed at 7d supports the increase in ML sRPTPβ detected at that same 
time interval with Western blotting.  Furthermore, the increased sRPTPβ tissue 
signal is located in the region of active synaptogenesis at 7d after UEC, the 
period when the rate of collateral sprouting and synapse formation is most rapid.  
This supports the hypothesis that sRPTPβ may interact with the local ML 
environment to influence the development of presynaptic terminals and the 
reorganization of postsynaptic dendrites after UEC.  A similar role for RPTPβ has 
been proposed during dendritic morphogenesis of cerebellar Purkinje cells in 
vitro, where direct inhibition of RPTPβ results in aberrant, disoriented dendritic 
structure (Tanaka et al., 2003).  It would be interesting to examine such 
manipulations of sRPTPβ in UEC or other TBI models to establish a direct link 
between the tyrosine phosphatase and synaptic recovery following brain injury. 
Because the punctate pattern of sRPTPβ staining was suggestive of a 
potential synaptic distribution, we performed co-localization studies with the post-
synaptic density marker PSD-95.  We found that a subset of sRPTPβ puncta in 
the outer ML were localized immediately adjacent to, but not overlapping with, 
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PSD-95 signal, suggesting that this tyrosine phosphatase is positioned near the 
reorganizing postsynaptic sites to regulate protein phosphorylation in tandem 
with local synaptic kinases.  A similar patchy localization of RPTPβ along 
dendritic shafts and cell body membranes of cerebellar Purkinje cells was 
reported by Fukazawa et al. (2008) using both confocal and EM methods.  In the 
present study we have also used EM immunohistochemistry, and our results 
confirm the localization of sRPTPβ within ML postsynaptic spines and dendrites.  
Such a pattern is consistent with the postulated role for sRPTPβ in modulating 
postsynaptic protein distribution (Kawachi et al., 1999; Fukazawa et al., 2008) 
and in the regulation of phosphorylation-directed positioning of receptors in the 
postsynaptic membrane (Tezuka et al., 1999).  Supporting this interpretation, 
other EM studies also show anti-RPTPβ immunostaining on dendrites and 
postsynaptic profiles of pyramidal neurons in cortex and hippocampus (Miyata et 
al., 2004; Hayashi et al., 2005).   
Finally, we have utilized dual label confocal IHC combining antibody to 
phosphacan or sRPTPβ with antibody to GFAP, to determine whether reactive 
astrocytes contribute significantly to the increased expression of these proteins in 
the deafferented ML.  Surprisingly, we failed to find co-localization of either of 
these phosphacan splice variants within the cell bodies and primary processes of 
ML reactive astrocytes, either at 2 or 7d after lesion.  This observation contrasts 
with documented astrocytic expression of phosphacan following spinal cord 
contusion (Vitellaro-Zuccarello et al., 2008), ischemic brain injury (Beck et al., 
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2008), and a filter implant-induced model of chronic glial scarring (McKeon et al., 
1999).  Our results suggest that such a pattern is not reproduced in the UEC 
model, where astrocytes do not appear to be the primary source for phosphacan 
or sRPTPβ production during reactive synaptogenesis.  Neurons themselves 
may be the major regulators of phosphacan response during adaptive synaptic 
recovery.   
 
Phosphacan/RPTPβ Expression Differs as a Function of Injury Type 
 Based on previous studies in multiple models of brain and spinal cord 
injury, phosphacan regulation in the injured CNS appears to be quite complex.  
While many other CSPGs such as neurocan (Asher et al., 2000), versican (Asher 
et al., 2002), and NG2 (Tang et al., 2003), all undergo rapid upregulation after 
CNS injury, phosphacan appears to be unique in that its response to injury may 
be mixed.  For example, acute reductions in phosphacan (1-4 days) have been 
documented after cortical stab injury (Dobbertin et al., 2003; Matsui et al., 2002), 
kainic acid induced seizures (Matsui et al., 2002; Okamoto et al., 2003), spinal 
cord contusion (Jones et al., 2003), and spinal cord stab injury (Tang et al., 
2003).  On the other hand, increased phosphacan expression has been reported 
as well, generally at later time points (2 weeks - 2 months), after spinal cord 
contusion, spinal cord stab injury, and seizures induced by intra hippocampal 
glutamate agonist injection (Jones et al., 2003; Tang et al., 2003; Heck et al., 
2004).  In some cases, both increases and decreases in phosphacan occur 
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concurrently within different sub-regions after injury.  For example, phosphacan 
immunostaining 2d after spinal cord stab injury is reduced in the lesion core but 
increased at the lesion margins (Tang et al., 2003).  Additionally, in a rodent 
model of stroke, phosphacan immunostaining was increased in the region of glial 
scarring closely bordering the infarct, but was markedly reduced in a broader 
band of peri-infarct tissue where axonal sprouting is known to occur (Carmichael 
et al., 2005).  Clearly injury-induced changes in phosphacan expression can 
depend upon the type and severity of tissue damage, the location sampled, and 
the post-injury interval examined. 
The present results serve as a good example of how assessment of 
phosphacan expression can be dependent on multiple factors.  We found that, 
during UEC-induced synaptogenesis, the temporal profile of phosphacan: 1) 
differs from other types of cortical injury, 2) may exhibit asynchronous mRNA and 
protein change, and 3) will show significant increase or decrease depending 
upon the proximity to the site of synaptic plasticity.  It seems likely that variance 
in phosphacan expression after CNS injury can be attributed, in large part, to 
physical differences between the injuries induced.  Compared to other injury 
paradigms, one unique feature of the UEC model is that the lesion site is some 
distance away from the deafferented region, allowing separation between 
processes associated with tissue degeneration and those associated with 
adaptive synaptic plasticity (Deller et al., 2000).  In particular, the lack of 
extensive cell death and typical glial scarring (as would be generated by lesions 
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such as stab wounds) might contribute to the novel pattern of phosphacan 
regulation we have observed in the UEC deafferented hippocampus.  Since 
neurons express phosphacan, lower expression would be expected following 
injuries with more extensive cell loss, as has been observed in spinal cord 
contusion (Jones et al., 2003) and stab injury (Tang et al., 2003).  Conversely, 
paradigms like UEC  lesion, which reduce neuronal activity in the deafferented 
region, might lower expressional inhibition for proteins like phosphacan/RPTPβ.   
Studies which apply systemic stimuli to activate supraoptic magnocellular 
neurons have shown an inverse relationship between cell activity and levels of 
phosphacan/RPTPβ  expression (Miyata et al., 2004).  
Differences in the extent of reactive gliosis across injury models could also 
affect phosphacan since reactive astrocytes have been shown to alter their 
expression of phosphacan splice variants after experimental brain injury, 
including knife lesion of the perforant path (Snyder et al., 1996), and cortical stab 
lesions (McKeon et al., 1999; Dobbertin et al., 2003).  With focal brain lesions like 
stab wounds, phosphacan may be more closely linked to the local astrocytic 
scarring response than other CSPGs.  This possibility is supported by a recent 
study where experimental attenuation of the astroglial response to spinal cord 
contusion reversed the injury-induced rise in phosphacan, while elevated 
expression of other CSPGs (e.g. versican, neurocan, and brevican) remained 
unaltered (Vitellaro-Zuccarello et al., 2008).  Further, astrocyte expression of 
phosphacan splice variants is influenced by a number of soluble growth factors 
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and cytokines (Dobbertin et al., 2003; Smith and Strunz, 2005), many of which 
are altered with CNS injury.  Two of these molecules, epidermal growth factor 
(EGF) and transforming growth factor α (TGFα), both EGF receptor ligands, 
enhance astrocytic phosphacan expression in vitro.  Astrocytes have also been 
shown to up-regulate EGF receptors and ligands including TGFα in vivo after 
lesions to the anterior hypothalamus or hypoglossal nerve (Junier et al., 1991; 
Junier et al., 1993; Lisovoski et al., 1997).  Thus, activation of EGF receptors on 
astrocytes may be one pathway responsible for increased phosphacan protein 
levels in some types of injury.  Interestingly, after UEC we found no evidence of 
significant astroglial phosphacan synthesis, at least during the 2-7d postinjury 
period.  While it remains possible that astrocytes produce and release 
phosphacan prior to 2d after UEC, this seems unlikely since the ML reactive 
astrocytic response peaks between 2-4d post lesion without appreciable scar 
formation.  Given these conditions, our results suggest that induction of astrocytic 
phosphacan may depend upon whether or not a barrier scar interface is required 
after injury.  
Phosphacan may be degraded by matrix metalloproteinase 3 (MMP-3), 
part of a family of extracellular enzymes (Muir et al. 2002).  Therefore, 
differences between injury models in activation of MMPs (Kim et al 2005; Falo et 
al. 2006) could also account for some of the variance in phosphacan expression 
levels seen after different types of injury.  Specifically, these studies have shown  
a significant increase in MMP-3 transcript, protein, and enzyme activity at 2d 
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after UEC, with reduction toward control values at 7d postlesion.  If MMP-3 
contributes to the regulation of phosphacan protein levels after injury, the 
temporal pattern of early activation and later reduction would fit with the ML 
profile of phosphacan expression observed in our study.   
 Compared to the extensive literature on phosphacan and other 
extracellular  proteoglycans, studies describing the response of receptor splice 
variants RPTPβ or sRPTPβ to CNS injury are rare.  In one of these studies, 
Dobbertin and colleagues (2003) described the expression of both receptor 
variants after cortical stab injury in rodents.  There, injury did not alter expression 
of sRPTPβ protein or transcript, and caused a reduction in full-length RPTPβ 
mRNA.  A different result was found with the evaluation of sclerotic hippocampal 
tissue from epileptic patients, where an increase in anti-RPTPβ immunoreactivity 
was associated with gliosis and mossy fiber sprouting in the inner molecular layer 
(Perosa et al. 2002).  Our results after UEC also showed an elevation in sRPTPβ 
mRNA and protein, which persisted throughout the period of reactive plasticity.  
Similar to temporal lobe epilepsy, UEC induces axonal sprouting in the 
hippocampus.  The present results support an association between this sprouting 
response and increase of sRPTPβ mRNA and protein, as well as full-length 
RPTPβ mRNA.  Again, it appears that this splice variant is associated with 
neuronal structures, as we see little evidence of significant astrocytic production 
of sRPTPβ.  A stab injury, in contrast, would likely be associated with more 
discrete tissue damage, blood-brain barrier disruption, astroglial scarring, and 
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notably less compensatory plasticity.  If sRPTPβ is supportive for synaptic 
remodeling, then this lack of plasticity following stab lesion correlates well with 
the lack of change in sRPTPβ.  Thus, as with phosphacan, it appears that the 
expression of RPTPβ after injury is sensitive to differences in injury pathogenesis 
across different models.   
 
Mechanisms of Phosphacan/RPTPβ Regulation of Synaptic Plasticity 
How might phosphacan/RPTPβ isoforms influence synaptic reorganization 
after brain injury?  These proteoglycans are large molecules with many functional 
domains which may carry out different and even opposing functions depending 
on the presence of specific binding partners in the immediate proximity.  We 
propose that the effects of phosphacan on plasticity are due to interactions 
occurring in the extracellular compartment, while sRPTPβ effects on plasticity 
can be attributed largely to interactions within the intracellular domain.  For 
phosphacan, relevant binding partners may include cell adhesion molecules 
(CAMs), ECM molecules, and growth factors.  For sRPTPβ, functional 
intracellular targets may include a number of post-synaptic scaffolding proteins 
and regulators of the neuronal cytoskeleton. 
 It is well established that endogenous growth factors can promote 
sprouting and plasticity in the injured CNS (Nieto-Sampedro & Bovolenta, 1990; 
Cui 2006; Deller et al., 2006).  Similar to other ECM molecules, phosphacan 
binds to a unique array of growth factors including basic fibroblast growth factor 
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(FGF-2), pleiotrophin, amphoterin, and midkine (Milev et al., 1998a; Milev et al., 
1998b; Maeda et al., 1999).  This binding may help localize these signals to sites 
of sprouting, or to sequester them for mobilization at the appropriate point during 
regeneration.  In particular, FGF-2 has been shown to be important for 
synaptogenesis induced by hippocampal deafferentation, since antibodies 
against FGF-2 caused a marked reduction in compensatory cholinergic sprouting 
(Fagan et al., 1997).   
 CAMs are another class of molecules known to regulate the sprouting and 
outgrowth of axon collaterals after injury (Deller et al., 2006).  Phosphacan may 
block neuronal binding to CAMs, which would be adaptive during the early phase 
of reactive synaptogenesis, when axons must “release” their contacts with 
adjacent cells in order to reorganize.  The acute (2d) shift in phosphacan to 
deafferented dendritic regions and the overall elevation of phosphacan within the 
dentate gyrus at the initiation of sprouting (7d) could serve as mechanisms to 
generate an open and permissive environment for adaptive synaptic 
reorganization in the ML. 
 In contrast to phosphacan, sRPTPβ may affect injury-induced plasticity 
primarily through its interactions with binding partners in the intracellular domain.  
sRPTPβ has a cytosolic tyrosine phosphatase domain, and binding of 
extracellular ligands such as pleiotrophin and midkine has been shown to induce 
a conformational change which regulates phosphatase activity and triggers signal 
transduction (Maeda et al., 1996; Maeda et al., 1999; Sakaguchi et al., 2003).  A 
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role for the receptor splice variants in the morphogenesis of post-synaptic 
structures has been proposed in the context of cerebellar Purkinje cell 
development (Tanaka et al., 2003).  In that study, disruption of 
pleiotrophin/RPTPβ signaling by RPTPβ antibodies, chondroitinase treatment, 
exogenous CS, or inhibition of phosphatase activity resulted in aberrant dendritic 
morphology.  The cellular mechanisms underlying structural plasticity in 
development, and in learning and memory in adults, share many similarities with 
those that drive reactive plasticity after brain injury.  Therefore, these 
developmental studies offer further support for our hypothesis that sRPTPβ is 
involved in regulating the structural plasticity of dendrites after UEC.   
RPTPβ knockout mice have also provided additional insight into the role of 
sRPTPβ during synaptic plasticity in the uninjured adult brain.  While the 
knockouts (lacking all splice variants derived from the RPTPβ gene) showed no 
gross anatomical abnormalities, they did display abnormal synaptic plasticity as 
evidenced by enhanced LTP and impaired spatial learning (Niisato et al. 2005). 
One mechanism to explain the observed effects on learning, memory, and LTP in 
RPTPβ-null mice proposes that structural plasticity is impaired due to altered 
phosphorylation of p190 RhoGAP (Niisato et al., 2005).  This GTPase activating 
protein is a substrate of sRPTPβ in wild-type mice, and is known to regulate 
neuronal morphogenesis and synaptic plasticity through its downstream effectors 
Rho and ROCK.  In addition to p190 RhoGAP, the sRPTPβ phosphatase also 
targets a number of other proteins involved in cytoskeletal regulation and spine 
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morphogenesis, including β-catenin, β-adducin, Fyn, GIT1, PSD-95, and ErbB4 
(Meng et al., 2000; Pariser et al., 2005a; Pariser et al., 2005b; Kawachi et al., 
2001; Kawachi et al., 1999; Fujikawa et al., 2007; see full list in Appendix E).  Of 
these sRPTPβ  targets, at least two are directly associated with cell damage in 
TBI paradigms.  Dying neurons show an elevation in ErbB4  after closed head 
injury (Erlich et al., 2000) and regions of cortical contusion exhibit reduced PSD-
95 expression up to 4d postinjury (Ansari et al., 2008).  Together, these 
observations suggest that sRPTPβ can act through multiple signaling pathways 
after brain injury to alter the phosphorylation state of synaptic proteins and 
influence synaptic structural plasticity.   
 
 In summary, the data presented here provide new evidence that 
phosphacan and sRPTPβ play a role in the reactive synaptic plasticity that 
occurs after brain injury.  These two isoforms are differentially regulated over 
time after UEC.  Phosphacan protein is increased at 2 and 7d as a function of 
sampled subregion, with transcript increasing only at 7d.  By contrast, 
hippocampal sRPTPβ protein and transcript are both elevated throughout the 
time course of reactive synaptogenesis.  These changes appear to be primarily 
associated with neuronal structures.  The earlier increase in extracellular 
phosphacan could be adaptive if it helps concentrate plasticity-promoting growth 
factors in the outer ML, or it could modulate the physical aspects of synaptic 
structural reorganization by blocking neuronal binding to CAMs.  The prolonged 
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increase in sRPTPβ after UEC suggests that this isoform may be involved in 
spine morphogenesis and/or stabilization of new synapses, acting through 
intracellular substrates that control cytoskeletal reorganization.  In order to 
promote recovery after TBI, it will be essential to gain a better understanding of 
the many interacting signals in the extracellular environment which contribute to 
the inhibition, or to the promotion, of axonal regeneration and synaptogenesis in 
the injured CNS.  Understanding how components of brain ECM influence 
synaptic reorganization will be key to defining the difference between injuries 
where recovery is successful, and those where recovery fails. 
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CHAPTER 3 
QUANTIFYING GENE EXPRESSION IN RODENT 
MODELS OF TBI: NORMALIZATION STRATEGIES  
 
 
 
 
Introduction 
 Real-time quantitative RT-PCR (qRT-PCR) has come to be a widely 
preferred method for the sensitive measurement of mRNA in tissue.  The number 
of studies using real-time to quantify gene expression after injury to the central 
nervous system (CNS) has grown immensely over the past decade.  Technical 
details have been described elsewhere (Heid et al., 1996; Gibson et al., 1996) 
but the basic concept of qRT-PCR is centered, like traditional endpoint RT-PCR, 
around the design of forward and reverse oligonucleotide probes to anneal to a 
specific mRNA of interest.  Unlike traditional RT-PCR however, TaqmanTM qRT-
PCR also uses a TaqmanTM probe designed to anneal to the target mRNA 
downstream of one of the primers.  This probe contains a fluorescent reporter 
dye and a quencher dye, whose proximity suppresses the fluorescent emission 
through fluorescence resonance energy transfer (FRET).  When the target 
sequence is replicated, both dyes are released by the 5’ endonuclease activity of 
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Taq DNA polymerase, terminating FRET and allowing the reporter dye to 
fluoresce.  Thus each time a target mRNA is replicated, one fluorophore is 
released.  The increase in total fluorescence intensity is proportional to the 
amount of amplicon produced, and can be measured in “real time.” 
 Considering the many sequelae of a traumatic brain injury (TBI)—reactive 
gliosis, inflammation, activation of cell death pathways, neuroplasticity, 
regeneration—it can be said that every one of these processes relies on altered 
gene expression.  The quantitative assessment of specific mRNAs is therefore 
an essential tool in TBI research, and an important complement to techniques 
which measure protein expression.  There are several advantages of using qRT-
PCR to assess mRNA transcripts, compared to other techniques (Reviewed in 
Giulietti et al., 2001; Bustin, 2002; Nolan et al., 2006).  It offers rapid, high-
throughput screening of genes with less opportunity for RNA contamination than 
other quantification methods.  It also enables the use of small amounts of starting 
material, an advantage which is not only critical for analysis of precious biopsy 
tissue from patients, but which may also present new opportunities for TBI 
studies in animals.  For example, Dash and colleagues (2004) used qRT-PCR to 
assess mRNA from small ‘punches’ of cortical tissue harvested at varying 
distances from the injury core, permitting high spatial accuracy in their analysis of 
injury-induced gene expression.  Further, qRT-PCR is a more sensitive approach 
for measuring gene expression levels than other semi-quantitative assays (e.g. 
northern blots, microarrays, or in situ hybridization), in that it permits detection of 
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smaller changes in genes of interest.  Real-time RT-PCR was recently shown to 
be more accurate than microarrays for determining <2-fold changes in gene 
expression (Wang et al., 2006).  This sensitivity may be especially important in 
the field of TBI research, where significant differences in gene expression can 
often occur within a <2-fold range.  One study by Li et al. (2004) used microarray 
to screen for transcript changes after TBI and compared results for selected 
genes with qRT-PCR assessment.  This comparison showed that the two 
approaches produce comparable results for many genes, but for some genes 
measurement by real-time was far more sensitive, detecting for example a 1.5-
fold increase in HSP70 while microarray showed no change. 
 Despite the many advantages of qRT-PCR, the increasingly frequent use 
of this technique in neuroscience research has brought to light certain technical 
issues and concerns.  In particular, the identification of suitable reference genes 
has been an topic of focus in recent reviews (Dheda et al., 2004; Bustin et al., 
2005; Huggett et al., 2005; Meldgaard et al., 2006; Johansson et al., 2007; 
Coulson et al., 2008).  qRT-PCR data are typically normalized to a 
“housekeeping” or reference gene, to control for nonspecific variation due to 
sample-to-sample differences in RNA quality and reaction efficiency.  Some 
commonly used reference genes include cyclophilin A (also known as PPIA), β-
actin, glyceraldehyde phosphate dehydrogenase (GAPDH), and 18s or 28s 
rRNA.  In order to serve as a reliable nonspecific control, an ideal reference gene 
should be stably expressed across all tissues, developmental stages, and 
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experimental conditions.  Of course, such an ideal does not exist in real practice.  
Prior studies have shown that expression of widely used reference genes is 
altered in models of hypoxia/ischemia (Zhong et al., 1999; Bond et al., 2002; 
Kobayashi et al., 2004), seizure activity (Chen et al., 2001), hippocampal 
deafferentation (Phillips et al., 1987; Phillips & Steward, 1990), and 
demyelination (Meldgaard et al., 2006).  On the other hand, in some 
experimental contexts these same reference genes are invariant and can serve 
as reliable standards for data normalization.  For example, GAPDH and 
cyclophilin were found to be stably expressed in the first 24 hours after middle 
cerebral artery occlusion in rats (Harrison et al., 2000).   
 Normalization to total RNA mass has also been considered as an 
alternative to the use of a reference gene control (Bustin 2005).  This approach 
depends on the ability to recover high quality RNA from tissue, and to accurately 
measure its concentration and integrity.  Several studies have shown that if these 
conditions are met, normalization to total RNA can produce viable experimental 
results (Tricarico et al., 2002; Dheda et al., 2004; Bustin 2005; Meldgaard et al., 
2006).  Normalization to multiple reference genes is another option, and several 
mathematical approaches to this strategy have been proposed (Vandesompele 
et al., 2002; Pfaffl et al., 2004; Anderson et al., 2004).  However, the identification 
of three or more best reference genes requires testing the suitability of many 
candidate genes—a process which requires more time, resources, and tissue 
sample than may be practically feasible. 
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 While two recent articles have critically examined the practice of qRT-PCR 
normalization in acute post traumatic analyses (Thal et al., 2008; Rhinn et al., 
2008), the unique issues surrounding the application of this technique to the 
range of pathology generated in rodent TBI models have not been fully 
considered.  TBI presents a particular challenge for the accurate and reliable 
quantification of mRNA due to heterogeneous cell populations in injured tissue, 
multiple components of TBI pathology (primary tissue damage, progressive 
secondary degeneration, ischemic/hypoxic damage, edema, hemorrhage, 
inflammation, etc.), and variability of individual animal responses to brain injury.  
Each of these parameters may impact the expression of common qRT-PCR 
reference genes.  
 In this study we have examined the expression of four widely used 
reference genes in two rodent models of brain injury.  Moderate central fluid 
percussion injury (cFPI) was used to model diffuse closed-head trauma, while  
unilateral entorhinal cortex lesion (UEC) served as a model of targeted 
deafferentation and reactive plasticity induced by traumatic axonal injury.  
Transcripts for β-actin, cyclophilin A, GAPDH, and 18s ribosomal RNA were 
measured at long term survival intervals (2, 7, or 15 days) in order to investigate 
the pattern of reference gene expression during these well-defined periods of 
synaptic recovery.  We examined RNA extracted from hippocampus after UEC, 
and from both hippocampus and parietotemporal cortex after cFPI.  Results were 
analyzed for gene expression at each time point, comparing injured samples to 
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contralateral control tissue (for UEC), or to sham control tissue (for cFPI).  
Change in expression relative to controls was also assessed over time post-
injury.  Finally, the within-group variability of gene expression was measured by 
calculating the coefficient of variation (CV) for each experimental group.  
 Here we show that none of the four common reference genes tested was 
invariant across all tissues, time points, and types of experimental injury.  For 
studies focusing on the rodent hippocampus after UEC, cyclophilin may be an 
appropriate reference gene.  In the hippocampus subjected to cFPI, β-actin was 
the most stable control gene.  Within the parietotemporal cortex, each of the 
tested reference genes showed significant alteration over time after cFPI, making 
them unsuitable controls for time course studies.  However, some of the 
reference genes tested may be appropriate for investigations confined to a single 
post-injury time point.  We further suggest that normalization to total RNA content 
may be a reasonable approach, particularly where measurement of smaller 
changes in gene expression is desired.  The present data provide a starting point 
for the identification of appropriate reference genes in studies of postinjury 
recovery following experimental TBI.  In this context, we outline considerations 
for validating a qRT-PCR normalization strategy in models of brain injury, and we 
stress the importance of reference gene validation for each TBI paradigm and 
each set of experimental conditions. 
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Methods 
Experimental Animals  
Adult male Sprague-Dawley rats (300-390g) were used for each injury 
model in this study.  Rats were randomly divided into three experimental groups:  
unilateral entorhinal lesion (UEC; n = 17), central fluid percussion injury (cFPI; n 
= 30) and sham-injured (n = 16).  Rats were housed in pairs within individual 
cages having food and water ad libitum, subjected to a 12hr dark-light cycle at 
22°C.  All protocols for injury and use of animals were approved by the 
Institutional Animal Care and Use Committee of Virginia Commonwealth 
University. 
 
Unilateral Entorhinal Cortex Lesions 
Rats were subjected to unilateral entorhinal cortex lesion (UEC) after the 
method of Loesche and Steward (1977).  All animals were surgically prepared 
under isoflurane anesthesia delivered via nose cone (2.25% in carrier gas of 70% 
N2O, 30% O2).  During all surgical procedures, body temperature was maintained 
at 37°C via a thermostatically controlled heating pad (Harvard Apparatus, 
Holliston MA).  Rats were placed in a stereotaxic frame, and an area of skull was 
removed above the entorhinal cortex of the right hemisphere. Lesion current was 
passed through a Teflon-insulated wire electrode angled at 10o from vertical.  
Current was delivered (1.5 mA for 30 sec) at a total of eight stereotaxic sites: 1.5 
mm anterior to the transverse sinus, 3mm lateral to midline, at 2mm, 4mm, and 6 
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mm ventral to the brain surface; then 4mm lateral to midline at 2mm, 4mm, and 
6mm ventral; and finally 5 mm lateral to midline at 2mm and 4 mm ventral (see 
Figure 1.4).  After lesions were completed, the electrode was removed, the scalp 
was sutured closed over the surgical site, and topical antibiotic was applied.  
Animals were placed in a warmed holding cage and monitored during recovery 
from anesthesia, after which they were returned to their home cages. 
 
Central Fluid Percussion Injury 
Adult male Sprague-Dawley rats (300-390 gm) were subjected to central 
fluid percussion injury (cFPI) as previously described (Dixon et al., 1987).  24 
hours before cFPI, each animal was surgically prepared under isoflurane 
anesthesia delivered via nose cone (2.25% in carrier gas of 70% N2O, 30% O2).  
During all surgical procedures, body temperature was maintained at 37°C via a 
thermostatically controlled heating pad (Harvard Apparatus; Holliston, MA).  Rats 
were placed in a stereotaxic frame and an incision was made to expose the skull 
from bregma to lambda.  A fluid percussion injury hub was prepared as follows.  
Two shallow 1 mm holes were drilled in the left frontal and right occipital bones, 1 
cm rostral and caudal to bregma and lambda respectively.  A 4.8 mm circular 
craniotomy was then made, centered on the sagittal suture midway between 
lambda and bregma, taking care not to disturb the underlying dura.  A Luer-Loc 
syringe hub was cut away from a 20-gauge needle and affixed to the craniotomy 
site with cyanoacrylate glue.  After verifying the integrity of the seal between the 
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hub and the skull, two fixation screws were inserted into the 1 mm holes (round 
machine screws, 3/16 in. long).  Dental acrylic (Coltene/Whaledent, Inc.; 
Cuyahoga Falls, OH) was then applied around the hub and over the screws to 
provide stability during induction of the injury.  After solidification of the dental 
acrylic, skin over the hub was sutured and the animal was placed in a warmed 
recovery cage and monitored until fully recovered from anesthesia.  The animal 
was then returned to the home cage and allowed to recover for 24 hours.  Prior 
to the induction of fluid percussion injury, anesthesia was induced by placing the 
animal in a bell jar with 4% isoflurane in 70% N2O and 30% O2 for 4 min.  An 
incision was quickly made to expose the craniotomy site, and the male end of a 
connector tube was inserted into the hub.  After filling the hub-spacer assembly 
with 0.9% normal saline, the female end of the spacer was inserted into the male 
end of the fluid percussion apparatus, taking care to ensure that no air bubbles 
were introduced into the system.  The animal was then injured at a magnitude of 
2.00 ± 0.10 ATM, representing an injury of moderate severity (Dixon et al., 1987).  
The pressure pulse measured by the transducer was displayed on an 
oscilloscope (Tektronix 5111; Beaverton, OR) and the peak of the pressure curve 
was recorded.   
Following injury, the hub was removed and scalp incision rapidly sutured, 
prior to recovery of consciousness.  Animals were monitored for spontaneous 
respiration, and if necessary, artificially ventilated to ensure adequate postinjury 
oxygenation until spontaneous respiration was recovered.  Recovery of 
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consciousness was monitored by recording the length of time it took for each 
animal to recover the following reflexes: tail pinch, toe pinch, corneal blink, 
pinnal, and righting.  Following recovery of the righting reflex, animals were 
placed in a warmed holding cage and monitored during recovery, after which 
they were returned to their home cages.  For animals in the sham injury group, all 
of the above procedures were followed with the exception of the release of the 
pendulum for actual transduction of fluid percussion injury.   
 
RNA isolation and quantitative real time RT-PCR 
Rats were sacrificed 2d (n = 6), 7d (n = 5), and 15d (n = 6) after UEC 
lesion, or 2d (n = 6), 7d (n = 5) and 15d (n = 3) after cFPI.  Sham-injured animals 
for cFPI comparison were sacrificed at 7d (n = 5).  Fresh brains were rapidly 
removed from the skull and a mid-sagittal cut was made to separate the two 
hemispheres.  For UEC rats, whole hippocampi (including dentate gyrus and 
Ammon's horn) were dissected  from each hemisphere.  For cFPI animals, both 
hippocampi and tissue blocks of parietotemporal cortex were removed (see 
Appendix C).  Tissue samples (~100mg) were homogenized in 1ml Trizol 
Reagent (Invitrogen; Carlsbad, CA), mixed with 0.2 ml chloroform, and 
centrifuged for 15 min at 12,000 x g.  RNA in the upper phase was removed and 
precipitated with 0.5 ml isopropyl alcohol.  After centrifugation for 10 min at 
12,000 x g, supernatant was removed and RNA pellets were washed in 75% 
ethanol.  The pellets were then dissolved in PCR-grade water (Ambion; Austin, 
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TX) and incubated at 55°C for 10 min.  All samples were rigorously treated with 
the DNA-free DNase kit (Ambion; Austin, TX) according to the manufacturer’s 
protocol in order to remove residual DNA contamination.  DNase treated RNA 
samples were stored at -80°C.  Total RNA concentration and integrity were 
assessed with the Experion automated electrophoresis system (Bio-Rad 
Laboratories; Hercules, CA).  Electropherogram traces for all samples indicated 
good quality RNA, with clear peaks for 18s and 28s rRNA and very low signal 
indicative of sample degradation (see example in Appendix D).  RNA 
concentrations measured with Experion were further verified with 
spectrophotometry (ND-1000, NanoDrop Products; Wilmington, DE).  Equal 
amounts of total RNA were prepared in PCR-grade water for quantitative real 
time RT-PCR on the ABI prism 7900 Sequence Detection system (Applied 
Biosystems; Foster City, CA).  Taqman primers for all reference genes and two 
test transcripts of interest (phosphacan and sRPTPβ) were designed with Primer 
Express software (Applied Biosystems; Foster City, CA) to span exon-exon 
boundaries.  Sequences for specific primers and Taqman probes are listed in 
Table 3.1.  Reactions were run in triplicate and relative mRNA quantity values 
were derived from CT values by the standard curve method.  Reactions were 
found to have an efficiency of >88% as determined by the slope of the standard 
curves.  Negative controls on each plate included no-amplification and no-
template control conditions.   
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Table 3.1 Taqman sequences 
 
gene Oligo sequence
GAPDH forward 5' AATGTATCCGTTGTGGATCTGACA 3'
GAPDH reverse 5' CTCGGCCGCCTGCTT 3'
GAPDH probe 5' CCTGGAGAAACCTGCCAAGTATGATGACATC 3'
cyclophilin forward 5' CTGTTTGCAGACAAAGTTCCAAA 3'
cyclophilin reverse 5’ AGGAACCCTTATAGCCAAATCCTT 3'
cyclophilin probe 5’ CAGCAGAAAACTTTCGTGCTCTGAGCACT 3'
β-actin forward 5' CCCTGGCTCGCACCAT 3'
β-actin reverse 5' GAGCCACCAATCCACACAGA 3'
β-actin probe 5' ATCAAGATCATTGCTCCTCCTGAGCGC 3'
18s rRNA
18S rRNA was measured using a Taqman pre-developed assay 
reagents kit containing 18s primers and probe (Applied 
Biosystems)
phosphacan forward 5' GGGCATTCAGGAGTATCCAACA 3'
phosphacan reverse 5' TCCGTGACTCTTCTATTTTTACTTTCAT 3'
phosphacan probe 5' TCAGCACATCTCGTTCTATCCCTTTGCTCA 3'
sRPTPβ forward 5' ACAATGAGGCCAGTAATAGTAGCCAT 3'
sRPTPβ reverse 5' TAGATGAGAATACCAACAAGAACCACTAG 3'
sRPTPβ probe 5' AGACACGATCACAAGGGGTATAACCGCCT 3'  
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Protein Extraction and Western Blotting  
 Rats were sacrificed 2d (n = 6), 7d (n = 6), or 15d (n = 4) after cFPI, and 
paired sham-injured controls at 2d (n = 4), 7d (n = 4), or 15d (n = 3).  Whole 
hippocampi (including dentate gyrus and Ammon's horn) were dissected from 
fresh brain, rapidly homogenized in a 250 μl volume of T-PER (Thermo Scientific; 
Rockford, IL) and centrifuged for 5 min at 8,000xg and 4°C.   Supernatant was 
removed and stored at -80°C.  Protein concentration of each sample was 
determined using the Bio-Rad Protein Assay Reagent and spectrophotometry 
(Shimadzu UV-160; Shimadzu Scientific Instruments).  5 μg of protein from each 
sample was mixed with reduced sample buffer and electrophoresed on 4-12% 
Bis-Tris Criterion XT gels (200V, 45 min.) and subsequently transferred to PVDF 
membrane.  Membranes were blocked in 5% milk-TBST (Tris buffered saline 
containing 0.05% Tween 20) for 1h before being probed with mouse monoclonal 
antibody raised against phosphacan (3F8; Developmental Studies Hybridoma 
Bank, University of Iowa) in milk-TBST (1.5 μg/mL) overnight at 4°C.  Blots were 
subsequently washed with milk-TBST and then incubated for 1h at room 
temperature in peroxidase conjugated goat anti-mouse secondary antibody 
(1:20,000; Rockland; Gilbertsville, PA).  The blots were then washed in TBST 
and immunopositive signal visualized using Super Signal West Dura Extended 
Duration Substrate (Thermo Scientific; Rockford, IL) and imaged digitally with the 
G:Box ChemiHR system for densitometric analysis using GeneSnap software 
(SynGene; Frederick, MD).  Measurements from tissue ipsilateral to UEC were 
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compared to homologous contralateral control regions and results expressed as 
percent of contralateral value.   
 
Statistical Analysis 
For all qRT-PCR data, group means were analyzed using specific planned 
comparisons between experimental groups, implemented using simple main 
effects tests (SPSS v11 MANOVA syntax). The significance of densitometric 
values from Western blots were analyzed using the Student’s t-test.  A probability 
of less than 0.05 was considered statistically significant for all tests.  In order to 
assess within-group variability of reference gene expression, the coefficient of 
variation (CV) was calculated for each group, generated from the ratio of 
standard deviation to group mean.  CV is a dimensionless parameter which 
permits the comparison of variability of gene expression between groups with 
different  mean values. 
 
 
Results 
Reference gene expression is differentially altered after UEC and cFPI   
Transcripts for β-actin, GAPDH, 18s ribosomal RNA, and cyclophilin A 
were measured in tissue collected 2, 7, or 15 d after UEC or cFPI.  We examined 
RNA from whole hippocampi following UEC, and compared relative gene 
expression ipsilateral to lesion to gene expression in contralateral controls.  β-
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actin was significantly increased in ipsilateral hippocampus at 2d after UEC 
(145.1 ± 25.4%, p<0.05; Table 3.2; Figure 3.1).  GAPDH expression was highly 
variable after UEC in both ipsilateral and contralateral hippocampi (see CV 
values in Table 3.2; scatterplot in Figure 3.1).  While 18s rRNA showed lower 
variability and no significant difference between ipsilateral and contralateral 
expression at any post-injury time point (Table 3.2), there was increase of 61± 
28% in 18s rRNA between 2 and 15d after UEC (Figure 3.1).  Only cyclophilin 
showed stable expression after UEC and relatively low variance (Figure 3.1; 
Table 3.2), making this the best choice of reference gene among the four we 
tested in this injury paradigm. 
Following cFPI, we examined reference gene expression in both 
hippocampus and parietotemporal cortex, two brain regions known to be affected 
in this injury model.  Because of the midline injury location, hippocampi or cortical 
blocks dissected from both hemispheres were pooled for analysis.  Reference 
gene expression was assessed at each time point, comparing injured samples to 
sham control tissue.  β-actin was significantly increased in cortex at 2 and 7d 
after cFPI (173.9 ± 36.0%; 153.9 ± 38.5%, p<0.05).  By contrast, expression of β-
actin in hippocampus remained remarkably stable after injury at all time points 
sampled (Figure 3.2; Table 3.2).  Thus β-actin may be a good reference gene 
choice in hippocampus but not in cortex following cFPI.  GAPDH expression was 
increased in both cortex and hippocampus 7d after injury (132.5 ± 6.8% and 
128.7 ± 6.5%, p<0.05; Table 3.2).  18s rRNA was lower than control values in 
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both hippocampus and cortex 2d after cFPI (84.0 ± 8.2%; 82.9 ± 17.3%) and 
later increased in hippocampus and cortex 7d after cFPI (138.7 ± 16.4%; 190.0 ± 
26.6%, p<0.01).  However because of group differences in variability, these 
changes only reached statistical significance for hippocampus and for cortex at 
7d (Table 3.2).  Finally, cyclophilin mRNA was reduced in both hippocampal and 
cortical tissue at 2 and 7d post-injury (84.5 ± 13.4%, p<0.01, and 90.6 ± 4.6%, 
p<0.05 for hippocampus; 87.3 ± 13.5%, p<0.01, and 76.2 ± 4.6%, p<0.05 for 
cortex; Table 3.2). 
 We believe the reference gene regulation we have described represents 
specific changes in gene expression following injury, since the four candidate 
reference genes are differentially altered in the same tissue samples.  If 
expression differences were due to a nonspecific factor (for example, if some 
tissue samples contained a higher concentration of an endogenous PCR-
inhibiting compound), then we would expect to see a parallel shift in expression 
of all genes measured in these samples.  However our results do not show 
parallel changes; for instance in hippocampus 7d after cFPI we have observed 
an increase in GAPDH, a reduction in cyclophilin, and no change in expression of 
18s or β-actin compared to sham controls.  This supports the conclusion that 
these findings represent specific, injury-induced alterations in expression of each 
reference gene. 
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Table 3.2  Reference genes after experimental brain injury: variability and 
change relative to control.  Where present, arrows represent significant change 
in expression of a reference gene compared to contralateral control hippocampus 
for UEC, or compared to sham injured tissue for cFPI (p < 0.05).  Numerical 
values represent coefficient of variation (CV; standard deviation divided by mean) 
for expression of each reference gene at 2, 7, or 15 days after injury.  These 
provide a measure of within-group variability of gene expression at a given time 
point, tissue, and injury type.  An ideal reference gene should not be altered with 
injury, and should have a low CV value indicating stable expression among 
individuals in a group.  We emphasize however that CV is a relative measure; an 
acceptable level of variance cannot be defined a priori but must be determined 
for each particular experiment.   
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Table 3.2 
  
UEC hippocampus                  
  2d 7d 15d 
β-Actin ↑    0.175 0.144 0.233 
GAPDH 0.317 0.415 0.454 
18s  0.149 0.151 0.235 
Cyclophilin 0.145 0.120 0.256 
  
cFPI hippocampus                  
  2d 7d 15d 
β-Actin 0.149 0.092 0.114 
GAPDH 0.159 ↑    0.051 0.071 
18s  0.092 0.120 0.108 
Cyclophilin ↓    0.201 ↓   0.050 0.123 
  
cFPI cortex                         
  2d 7d 15d 
β-Actin ↑    0.207 ↑    0.250 0.018 
GAPDH 0.154 ↑    0.061 0.046 
18s  0.209 ↑    0.138 0.054 
Cyclophilin ↓    0.213 ↓    0.051 0.160 
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Figure 3.1  Reference gene expression after UEC.  Each point represents the 
mean hippocampal gene expression for one animal, while bars represent group 
means.  Y-axes show arbitrary quantity units based on the standard curves 
generated for each set of primers.  18s rRNA shows no significant difference 
between ipsilateral and contralateral expression at any time point.  However, the 
overall level of gene expression increases over time post-injury, so 18s is not a 
suitable control.  β-actin is both increased ipsilateral to lesion at 2 days after UEC 
(145.1 ± 25.4%, p < 0.05) and shows high variance at 15d, and is thus is also a 
poor control.  The variability of GAPDH expression is very high, particularly at 7 
and 15d after UEC, so GAPDH is not a suitable control.  Only cyclophilin is a 
good candidate reference gene in this injury paradigm, showing both stable 
expression at all time points after UEC and low variability within groups. 
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Figure 3.1
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Figure 3.2  Regional differences in reference gene expression after cFPI.   
Compared to a sham-injured control group, β-actin shows increased expression 
in parietotemporal cortex 2 and 7 days after central fluid percussion injury (173.9 
± 36.0% and 153.9 ± 38.5%; p < 0.05).  By contrast, β-actin expression in 
hippocampus remains stable over time after cFPI.  However it should be noted 
that sham control variance in hippocampus is relatively high, possibly 
contributing to the lack of detectable difference between groups.  These results 
suggest that in this injury model β-actin is a poor choice of reference gene for 
studies of cortical tissue, but could be an appropriate choice for studies of 
hippocampus. 
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Normalization approach can affect qRT-PCR study conclusions  
 To investigate the effect of different normalization approaches, we ran 
qRT-PCR for two genes of interest, phosphacan and sRPTPβ, in hippocampus 
following UEC.  We compared results for phosphacan and sRPTPβ when 
normalized to 18s rRNA (a poor control in this injury model due to increased 
expression over time; see Figure 3.1), normalized to cyclophilin (a stable control 
in this injury model), or normalized to total RNA content.  Results show that the 
choice of reference gene may significantly affect qRT-PCR results for a gene of 
interest (Figure 3.3).   
Phosphacan normalization to cyclophilin and to total RNA produce a 
similar overall pattern of regulation, showing no change relative to contralateral 
control at 2d and 15d, but significantly elevated expression at 7d, (120.4 ± 3.0%, 
p<0.05 with cyclophilin; 113.6 ± 8.8%, p<0.05 with total RNA; Figure 3.3).  By 
contrast, normalizing phosphacan to 18s shows trends toward elevation at all 
three postinjury intervals, however none of the differences reached statistical 
significance.  Since phosphacan normalized to cyclophilin or total RNA 
corresponds to the temporal changes in phosphacan after UEC detected by 
immunohistochemistry (IHC; Harris et al., 2006; see also Chapter 2), this 
suggests that either of these normalization strategies may be acceptable for 
phosphacan analysis.   
For the analysis of sRPTPβ expression, all three normalization strategies 
produced somewhat different results.  Analysis with cyclophilin showed no 
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change at 2d, and a trend toward elevation over control at 7d, which reached 
significance at 15d (134.6 ± 20.0%; p<0.01; Figure 3.3).  Normalizing sRPTPβ 
expression to total RNA showed a steady significant increase over control at 2, 7, 
and 15d post injury (111.7 ± 10.0% , p<0.05;112.8 ± 5.6%, p<0.05; 118.8 ± 6.9%; 
p<0.01).  By contrast, 18s normalization showed significant increase only at 15d 
(151.1± 5.4%; p<0.05).  Here the pattern of sRPTPβ transcript normalized to total 
RNA best reflects the changes in sRPTPβ protein observed after UEC by 
Western blotting (WB; Harris et al., 2008), suggesting that total RNA may be the 
most accurate normalization approach for sRPTPβ analysis.  
Even when a potential reference gene meets initial criteria for stability over 
time postinjury and low CV,  normalization using that reference gene may not be 
optimal if there is high variance in the control group against which it is compared.   
We compared hippocampal phosphacan transcript after cFPI, normalized to β-
actin and normalized to total RNA.  We show that phosphacan normalized to β-
actin shows no change after cFPI, while the same data using total RNA as a 
standard reveals a significant elevation in phosphacan transcript at 7d postinjury 
(138.9 ± 6.02%, *p<0.05; Figure 3.4 A, B).  When these results are compared 
with hippocampal phosphacan levels determined by Western blotting (Figure 3.4 
C), the increase in transcript at 7d seen with total RNA normalization is 
supported by a 3-fold rise in phosphacan protein at 7d (2d- 144.3 ±14.3%, 
*p<0.05; 7d- 370.2 ± 53.4%, **p<0.01; 15d- 61.7 ± 4.0 %, **p<0.01).  The 
difference in phosphacan qRT-PCR results depending on normalization 
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approach is most likely a result of variance of β-actin expression in the sham 
control group (see Figure 3.2).  When considering selection of a reference gene, 
variability of gene expression under control conditions may be just as important 
as variability after injury.  Even in the absence of reference gene change under 
experimental conditions, when qRT-PCR data are compared to a variable control 
group, differences in subsequent injury to control comparisons may be lost.  
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Figure 3.3  Normalization approach can significantly affect experimental 
conclusions.  Expression data for two genes of interest, phosphacan and 
sRPTPβ, are compared when normalized to cyclophilin, 18s rRNA, or total RNA 
content.  18s is a poor choice of reference gene dues to increasing expression 
after UEC, while cyclophilin is stably expressed and may be an appropriate 
reference gene (see Figure 3.1).  These comparisons show that the applied 
normalization strategy can significantly affect experimental results.  We suggest 
that, beyond initial consideration of reference gene changes with injury and CV 
values, consideration of correlative data on the gene of interest can help guide 
selection of a normalization approach.  In (A) phosphacan normalized to either 
cyclophilin or total RNA shows peak transcript elevation at 7d postinjury, a result 
which best matches the temporal elevation of phosphacan protein in the 
deafferented hippocampus detected by IHC (see Chapter 2).  In (B) the 
consistent increase in sRPTPβ transcript normalized to total RNA best reflects 
the consistent increase in sRPTPβ protein seen in WB analysis of hippocampus 
after UEC (see again Chapter 2).   
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Figure 3.3 
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Figure 3.4  Reference gene choice must consider variance in all groups 
sampled.  Even when a potential reference gene meets initial criteria for stability 
over time postinjury and low CV,  normalization using that reference gene may 
not be optimal if there is high variance in the control group against which it is 
compared.   In (A) hippocampal phosphacan mRNA normalized to β-actin shows 
no change after cFPI, while the same data using total RNA as a standard (B) 
reveals a significant elevation in phosphacan transcript at 7d postinjury (138.9 ± 
6.02%; *p<0.05).  When these results are compared with hippocampal 
phosphacan levels determined by WB (C), the more than 3-fold rise in 
phosphacan protein at 7d (370.2 ± 53.4%; *p<0.05) supports the increase in 
transcript at 7d with total RNA normalization.  These differences between A and 
B are most likely a result of variance of β-actin expression in the sham control 
group (see Figure 3.2).  When considering selection of a reference gene, 
variability of gene expression under control conditions may be just as important 
as variability after injury.  Even in the absence of reference gene change under 
experimental conditions, when qRT-PCR data are compared to a variable control 
group, differences in subsequent injury to control comparisons may be lost.   
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Figure 3.4
  130
Discussion 
In the present study we describe the postinjury time course of mRNA 
expression for four common reference genes (GAPDH, β-actin, cyclophilin A, and 
18s rRNA) in two models of brain injury, (UEC and cFPI).  Nearly all qRT-PCR 
studies of TBI have used one of these reference genes for quantitative evaluation 
of gene expression (Rhinn et al., 2008).  When a reference gene is used to 
normalize RT-PCR data, it is often assumed that the expression of this gene in 
the target tissue is unchanged by experimental treatments.  Any variations 
observed in reference gene levels should then only reflect differences in sample 
quality and technical differences in RT-PCR runs (Bond et al., 2002; Wilson, 
1997).  However, we report that every one of the four reference genes we tested 
was specifically altered following focal deafferentation and/or diffuse brain injury, 
demonstrating that CNS trauma does result in reference gene modulation.  First, 
18s rRNA expression increases over time after UEC in both deafferented 
ipsilateral and contralateral control hippocampi.  Further, 18s expression is 
increased in parietotemporal cortex following cFPI.  Second, GAPDH expression 
is increased in hippocampus and cortex 7d after cFPI.  Third, the commonly used 
reference gene β-actin showed an increase in mRNA transcript in cortex after 
cFPI (2d and 7d), and in hippocampus after UEC (2d).  Finally, cyclophilin is 
decreased in both hippocampus and cortex 2d and 7d after cFPI.  Together, 
these results show that selection of appropriate qRT-PCR reference genes in the 
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context of experimental TBI must take into consideration model type, brain region 
sampled, and postinjury survival interval.  
 
Reference gene expression may be altered under numerous physiological 
or pathological conditions in the CNS  
 
 Accumulating evidence has indicated that physiological and pathological 
events in the brain are capable of influencing the expression of traditional 
reference genes.  One recent report showed that normal aging and dietary 
restriction altered expression of reference genes including 18s rRNA in the 
rodent hippocampus and cortex (Tanic et al., 2007).  Synaptic plasticity also 
appears to be associated with altered expression of traditional control genes.  
The hippocampal dentate gyrus is known to exhibit a robust synaptic 
reorganization during the time points we sampled following UEC.  Our finding 
that 18s rRNA is elevated during this period of synaptic plasticity is supported by 
a previous study which showed increased rRNA after UEC by in situ hybridization 
(Phillips et al., 1987).  The widely used reference gene cyclophilin A is also 
altered during synaptic plasticity, showing reduced expression during 
reorganization of the feline visual cortex following retinal lesions (Arckens et al., 
2003).  We have similarly observed reduced cyclophilin in hippocampus following 
cFPI; however we did not see significant changes in hippocampal cyclophilin 
expression after UEC.  Differences in species or region-specific cell types may 
account for these results.  The precise role of cyclophilin A in lesion-induced 
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plasticity remains to be clarified.  GAPDH may also be altered during injury-
induced plasticity, though the details of its regulation are not yet clear.  A 
previous study showed reduced GAPDH expression during synaptic 
reorganization of mouse hippocampus after a mechanical lesion of the perforant 
path (Meldgaard et al., 2006).  In the denervated rat hippocampus, we have 
identified GAPDH as a poor choice of reference gene due to high variability of 
expression after UEC.     
It has also been reported that the expression of β-actin and GAPDH is 
rapidly upregulated in rodent models of cerebral ischemia (Harrison et al., 2000; 
Kobayashi et al., 2004).  Secondary ischemia is frequently a component of TBI 
pathogenesis, and in our FPI studies β-actin was acutely increased in cortex but 
not hippocampus at the earliest time point we assayed (2d).  The lack of change 
in β-actin in hippocampus was surprising, since hippocampal regions such as 
CA3 are selectively vulnerable to global TBI and ischemic injury.  Notably, the 
variability of β-actin gene expression in sham-injured hippocampus was relatively 
high (see Figure 3.2), which may have contributed to the failure to detect injury-
induced expressional changes. 
Finally, two recent studies have both explored reference gene regulation 
in the acute response to mouse models of brain trauma.  In the first study, Thal 
and colleagues (2008) examined expression of candidate reference genes at the 
site of contusion over the first 24 hours after controlled cortical impact (CCI).  
This study identified cyclophilin A and β-2-microglobulin as the best controls, 
  133
while GAPDH and β-actin were among the worst normalization factors due to 
increased and highly variable expression in injured tissue.  Interestingly, in the 
second study by Rhinn et al. (2008) GAPDH was one of the least variable genes 
at the site of injury over the first 48 hours after weight drop TBI, and was 
identified as a top choice for normalization of gene expression.  This group also 
reported that 18s rRNA and total cDNA content were good normalization choices 
following weight drop injury.  As in the CCI model, β-actin expression was 
increased after weight drop injury, and thus was identified as an inappropriate 
control.  Both of these studies focused on the early post-injury period, compared 
to the more protracted postinjury time course we report here, which may help 
account for the differences between these studies and our results.  Furthermore, 
both previous studies examined gene expression at the site of tissue lesion, 
while we have sampled hippocampus and cortical regions in a diffuse head injury 
model which does not cause frank contusion and cavitation.  Species differences 
could also potentially contribute to the differences in our results in rodents and 
theirs in mice.  In contrast to the two mouse TBI studies, we have shown β-actin 
to be stably expressed in hippocampus after cFPI.  However, β-actin may not be 
a good control because of variable expression in sham controls (see Figure 3.2).  
Like the conclusions of Thal et al. with CCI, our results showed cyclophilin to be 
a good reference gene choice after UEC, while GAPDH expression was 
regulated and highly variable in our injured tissues.   
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Given the many examples of physiological and pathological changes that 
can influence reference gene expression, our present finding that traditional 
controls are differentially regulated following UEC and cFPI is not surprising.  The 
present study in combination with the two recent reports on reference genes in 
mouse TBI models should underscore the fact that choice of appropriate qRT-
PCR controls is specific to the brain region, survival time, and specific 
pathological components of a given TBI paradigm.   
 
Validation of candidate reference genes  
 The question remains for researchers wishing to use the present 
investigation as a starting point for selecting reference genes in future TBI 
studies: what are the criteria for reliable validation of a candidate reference 
gene?  First, a valid reference gene is one which remains unaltered under the 
varying experimental conditions of a study.  In the specific context of TBI studies, 
this means no difference in injured tissues versus sham-injured (or other control) 
at any single time point, no changes over time post-injury, and no changes 
between experimental treatment groups (i.e. drug-treated) and controls.  
Additionally, researchers should bear in mind that injury effects on gene 
expression may be tissue specific; a reference gene which is deemed 
appropriate for studies of one brain region cannot be assumed to be stably 
expressed in a different region under the same injury paradigm.   
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Second, our results suggest that expressional differences between 
experimental groups are not the only concern in identifying a valid reference 
gene.  Variability of reference gene expression within each group (CV value) is 
also an important consideration, and this has received somewhat less attention in 
recent studies and reviews.  For example we show that after UEC, mean GAPDH 
expression is no different between ipsilateral and contralateral hippocampi, and 
that expression levels do not change over time.  However, GAPDH expression is 
highly variable in both ipsilateral and contralateral groups (Figure 3.1) and thus 
GAPDH is not a good reference gene choice after UEC.  We emphasize that the 
acceptable level of variability cannot be defined a priori but must be dictated by 
the degree of resolution required for each particular experiment.  This will 
primarily depend on the magnitude of injury effect on the gene of interest.  If a 
gene of interest exhibits a large change, study conclusions may only be 
minimally impacted by control gene variability.  However, for a gene of interest 
showing lower levels of change, study conclusions are more likely to be seriously 
affected by the additional noise introduced to the analysis by a variable reference 
gene.  Variability of reference gene expression should be considered not only in 
injured groups, but in control groups as well.  We have shown that β-actin 
expression remains stable in hippocampus following cFPI, and considering this 
information alone, one might conclude that β-actin is an appropriate control in 
this injury paradigm.  However, the high variability of β-actin mRNA in sham-
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injured tissue causes significant effects in injured-to-sham comparison to be lost 
(see Figure 3.2; Figure 3.4).  
 
Potential outcomes of using an unvalidated reference gene 
 Results of qRT-PCR studies can depend heavily on the choice of 
reference gene (Dheda et al., 2005; Thal et al., 2008; Bonefeld et al., 2008).  
Three types of errors can potentially be introduced when an unvalidated 
reference gene is used: the first two arise from use of a poor control which is 
altered by experimental treatments, while the third can arise from a poor control 
which exhibits highly variable expression.  First, if the reference gene and the 
gene of interest are both altered by injury in the same direction (i.e. both are 
increased or both are decreased), normalization can produce a false negative 
result, since one cancels out the effect of the other.  Second, if the reference 
gene is altered after injury but the gene of interest is not, normalization can lead 
to a false positive result (Bond et al., 2002).  For example if the gene of interest is 
stably expressed while the reference gene increases, normalized expression 
(gene of interest divided by reference gene) would indicate an apparent decrease 
in the target gene.  Third, when expression of a reference gene is highly variable 
(high CV) then normalization will introduce additional noise to the assay so that 
relatively small changes in the gene of interest lose statistical significance 
(Dheda et al., 2005; also see Figure 3.4).  Depending on the overall distribution 
of data, small increases or decreases in a gene of interest may be no less 
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biologically significant than large quantitative changes (Bond et al., 2002).  
Therefore careful validation of a normalization strategy is especially crucial for 
genes of interest which undergo smaller quantitative changes following TBI. 
 
Experiment-specific considerations can help in selecting a qRT-PCR 
normalization approach 
 
Specific knowledge about the biology of an injury paradigm could be used 
to help guide candidate reference gene selection.  For example, in injuries known 
to induce a significant increase in the population of non-neuronal cells, a 
neuronally expressed gene might be a good choice of reference (e.g. Chen et al., 
2001).  Conversely, in an injury known to induce selective neuronal loss, a 
reference gene expressed by glial cells might be a more attractive candidate.  
However, most brain injuries are likely to exhibit both neuronal loss and 
significant influx of astrocytes and microglia, rendering the identification of 
suitable control genes particularly challenging.  In tissues undergoing complex 
changes associated with TBI pathology and recovery, total RNA levels may be 
less volatile than expression of most individual genes (Bustin et al., 2002; Bustin 
& Nolan, 2004).  We propose that future TBI studies consider the possible use of 
total RNA as a normalizing factor, when high quality of RNA samples (lacking 
significant degradation or contaminating DNA) can be demonstrated and when 
total RNA concentration can be accurately measured.   
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Additionally, we suggest that correlative experiments such as measuring 
protein expression are likely to help complete the 'biological picture' and assist in 
the interpretation of meaningful qRT-PCR data following experimental TBI.  
Protein expression levels may often predict similar alterations in mRNA.  In 
Figure 3.4, we show hippocampal phosphacan expression normalized to β-actin 
and normalized to total RNA content after cFPI.  β-actin was the most stable of 
the four reference genes we tested in this injury paradigm, while total RNA is a 
reasonable alternative normalization approach given the low degradation of our 
RNA samples.  We show that phosphacan transcript normalized to total RNA is 
supported by the profile of phosphacan protein regulation after UEC, but 
phosphacan transcript normalized to β-actin follows a very different pattern.  
Thus the protein data strongly supports the use of total RNA rather than β-actin 
as a normalization factor in this experimental context.  The different result seen 
with β-actin normalization is probably due to high variance of β-actin expression 
observed in the sham control group, as described above.  While correlative 
studies cannot substitute for thorough validation of reference gene selection as 
detailed above, they can provide valuable additional information which may 
further support a chosen normalization approach. 
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Recommendations for qRT-PCR normalization in studies of experimental 
TBI  
 Based on the results presented here, we propose that cyclophilin A may 
be a good candidate reference gene for studies of injury-induced plasticity in the 
deafferented rodent hippocampus.  For studies of hippocampal response to fluid 
percussion brain injury, β-actin may be an appropriate reference gene provided 
that other correlative outcome measures are concurrently applied.  However, in 
cortical tissue following fluid percussion, none of the four genes we tested was 
stably expressed.  Additional research is needed to identify suitable reference 
genes for TBI time course studies and analyses of different brain regions.  
Microarrays might be a useful tool to initially screen a broad array of mRNA 
transcripts to identify those which change the least under the conditions of the 
proposed experiment.  Finally, since we have shown that 18s rRNA was 
significantly altered in each of the brain regions we examined after UEC and 
cFPI, we recommend that 18s, although commonly used as a reference gene in 
qRT-PCR studies, may not be an appropriate control for brain injured tissues.   
 Conclusions from real-time RT-PCR data can be highly dependent on the 
reference gene selected for normalization (Dheda et al., 2005; Bonefeld et al., 
2008).  The results presented here are meant to establish a groundwork for 
guiding the selection of controls in future TBI studies using real-time RT-PCR.  
However for each new set of experimental conditions it is essential that validation 
of one or more candidate reference genes be performed.  Knowledge about the 
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pathobiology of specific injury paradigms may be used to help guide selection of 
candidate reference genes for validation.  A validated reference gene will be 
stably expressed across all experimental conditions (sham vs. injury, treatment 
vs. control, between survival time points) and will have low CV within each group 
(defined as low enough not to introduce confounding noise to study results). 
 In addition, researchers should bear in mind that in some cases 
normalization to a single reference gene may not be the only valid approach.  If 
quality of extracted RNA is high and concentration can be accurately measured, 
normalization to total RNA mass can be a good alternative (Tricarico et al., 2002; 
Meldgaard et al., 2006; see also Chapter 2 Results).  If time and resources 
permit, normalization to multiple reference genes may also be a preferable 
alternative to use of a single control gene (Kobayashi et al., 2004; Bonefeld et al., 
2008).  In conclusion, qRT-PCR is a powerful and essential tool for TBI research, 
but it will be most useful only when technical considerations such as data 
normalization are carefully addressed.  Data from qRT-PCR assays will always 
provide the most meaningful biological picture when combined with other 
approaches such as in situ hybridization and measures of corresponding protein 
expression. 
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CHAPTER 4 
 
sRPTPβ AND REACTIVE PLASTICITY: EVIDENCE FOR EFFECTS 
ON POSTSYNAPTIC STRUCTURES THROUGH SUBSTRATE  
β-CATENIN 
 
 
 
Introduction 
 Two chief components of the pathobiology of traumatic brain injury (TBI) 
are neuronal cell death and traumatic axonal injury.  Both of these have the 
important downstream effect of deafferenting target tissues.  Injury-induced 
deafferentation in the CNS is known to induce axonal sprouting and structural 
reorganization of neuronal connections in many brain regions (Raisman 1969; 
Lund & Lund, 1971; Steward 1976).  However, in many cases, naturally occurring 
plasticity after brain trauma is limited, and varies with injury type and severity.  
Since reactive plasticity after brain injury may contribute to functional recovery 
(Ramirez 2001; Stein & Hoffman, 2003; Nudo 2007), elucidating the factors that 
control injury-induced plasticity is of particular interest.   
 Injury-induced neuronal restructuring is supported by the dynamic 
regulation of cytoskeletal proteins.  One important mechanism for regulating the 
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interactions of cytoskeletal proteins is their phosphorylation and 
dephosphorylation via the coordinated activity of tyrosine kinases and 
phosphatases.  Short receptor protein tyrosine phosphatase beta (sRPTPβ) is a 
neuronal tyrosine phosphatase which appears well positioned to potentially 
regulate plasticity of post-synaptic structures after TBI.  An alternative splice 
variant of the proteoglycan phosphacan/RPTPβ, sRPTPβ is a transmembrane 
receptor protein primarily localized on dendrites and spines in the mature brain 
(Kawachi et al., 1999; Hayashi et al., 2005; see also Chapter 2).  We have 
recently provided evidence that sRPTPβ may be involved in synaptic 
reorganization following brain injury, reporting that sRPTPβ expression is 
persistently upregulated following unilateral entorhinal cortex lesion (UEC), a 
classic model of injury-induced axonal sprouting and synaptogenesis.  sRPTPβ 
protein and mRNA expression were increased in the denervated rat 
hippocampus at 2, 7 and 15 days after UEC (Harris et al., 2008; see also 
Chapter 2).  Since the tyrosine phosphatase domain of sRPTPβ is constitutively 
active (Meng et al., 2000), we hypothesized that increased protein expression 
might correspond to a more dynamic regulation of intracellular sRPTPβ 
substrates important for the reactive plasticity process. 
A number of intracellular substrates of sRPTPβ have been identified, 
including both cytosolic proteins and transmembrane receptors (reviewed in Paul 
& Lombroso, 2003). Notably, many of these substrates are enriched at 
postsynaptic sites, and all of them have been functionally linked to processes 
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important to successful synaptogenesis.  For example, β-catenin, β-adducin, 
Fyn, and P190Rho/GAP are cytoskeletal regulators involved in neuronal 
morphogenesis (Takeichi & Abe, 2005; Pariser et al., 2005a; Pariser et al., 
2005b; Brouns et al., 2000), the neuregulin receptor ErbB4 plays a role in the 
maturation of excitatory synapses (Li et al., 2007), and PSD-95 is important for 
synapse stabilization (Ehrlich et al., 2007).  Moreover, the actions of several 
sRPTPβ substrates are known to be regulated by phosphorylation on tyrosine 
residues.  One of the best-studied examples is β-catenin.  β-catenin is a 92 kD 
intracellular protein which orchestrates structural changes in dendritic spines by 
reversibly linking surface cadherins to the actin cytoskeleton.  When 
dephosphorylated, β-catenin binds to α-catenin and the resulting complex 
associates with both cadherin and actin filaments.  However when tyrosine-
phosphorylated, β-catenin dissociates from this complex and relocates to the 
base of spines (Murase et al., 2002).  sRPTPβ is one of several tyrosine 
phosphatases which may balance the actions of kinases to maintain a dynamic 
regulation of β-catenin in spines (Lilien & Balsamo, 2005).  Since excitatory 
projections from the entorhinal cortex terminate almost exclusively on spines in 
the hippocampal molecular layer, spine retraction and reformation is a central 
part of reactive plasticity after UEC (Matthews et al., 1976; Reeves & Steward, 
1986).  Given the role of β-catenin in spine morphogenesis, we chose to explore 
this sRPTPβ target during injury-induced synaptogenesis. 
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 In the present study we examined whether β-catenin might play a role in 
injury-induced synaptic restructuring.  We used Western blotting to track β-
catenin protein in hippocampus after UEC, selecting survival intervals which 
correspond to three phases of reactive plasticity: degeneration of perforant path 
axon terminals (2d), afferent sprouting and synapse regeneration (7d), and 
synapse stabilization (15d).  We show that the profile of β-catenin protein shifts in 
kD during the three post injury time intervals examined, generating fragments 
which may be consistent with calpain proteolysis.  Moreover, when phosphatase 
activity was inhibited within parallel tissue extracts, the same β-catenin fragments 
produced during reactive synaptogenesis were not detected by Western blot 
analysis.  We discuss the implications of this finding for understanding the role of 
sRPTPβ in reactive synaptogenesis. 
 
 
Methods 
Experimental Animals  
Adult male Sprague-Dawley rats (300-390g) were used for each injury 
model in this study.  A randomly selected group of rats (n = 19) were subjected to 
unilateral entorhinal cortex lesion under isoflurane anesthesia delivered via nose 
cone (2.25% in carrier gas of 70% N2O, 30% O2).  During all surgical procedures 
body temperature was maintained at 37°C.  Rats were housed in pairs within 
individual cages having food and water ad libitum, subjected to a 12hr dark-light 
  145
cycle at 22°C.  All protocols for injury and use of animals were approved by the 
Institutional Animal Care and Use Committee of Virginia Commonwealth 
University. 
 
Unilateral Entorhinal Cortex Lesion  
 Adult male Sprague-Dawley rats (300-390g) were subjected to unilateral 
entorhinal cortex lesion (UEC) after the method of Loesche and Steward (1977).  
All animals were surgically prepared under isoflurane anesthesia delivered via 
nose cone (2.25% in carrier gas of 70% N2O, 30% O2).  During all surgical 
procedures, body temperature was maintained at 37°C.  Rats were placed in a 
stereotaxic frame, and an area of skull was removed above the entorhinal cortex 
of the right hemisphere.  Lesion current was passed (1.5 mA for 30 sec) through 
a Teflon-insulated wire electrode angled at 10o from vertical.  Current was 
delivered at a total of eight stereotaxic sites: 1.5 mm anterior to the transverse 
sinus, 3mm lateral to midline, at 2mm, 4mm, and 6 mm ventral to the brain 
surface; then 4mm lateral at 2mm, 4mm, and 6mm ventral; and finally 5 mm 
lateral at 2mm and 4 mm ventral (see also Figure 1.4).  After lesions were 
completed, the electrode was removed and the scalp was sutured closed.  
Topical antibiotic was applied to the surgical site, and animals were placed in a 
warmed holding cage and monitored during recovery.  Following recovery from 
anesthesia animals were returned to their home cages. 
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Protein Extraction and Western Blotting  
  Rats were sacrificed at 2d (n = 7), 7d (n = 8), or 15d (n = 4) after lesion.  
Brains were rapidly removed from the skull and a mid-sagittal cut was performed 
to separate the hemispheres and expose hippocampi.  Whole hippocampi 
(including dentate gyrus and Ammon's horn) were dissected from each 
hemisphere, homogenized in a 125 μl volume of T-PER (Thermo Scientific), and 
centrifuged for 5 min at 8,000xg and 4°C.  Supernatant was removed and stored 
at -80°C.  Protein concentration of each sample was determined using the Bio-
Rad Protein Assay Reagent and spectrophotometry (Shimadzu UV-160; 
Shimadzu Scientific Instruments).  20 μg of protein from each sample was mixed 
with reduced sample buffer and electrophoresed on 4-12% Bis-Tris Criterion XT 
gels (200V, 1h) and subsequently transferred to PVDF membrane.  Membranes 
were blocked in 5% milk-TBST (Tris buffered saline containing 0.05% Tween 20) 
for 1h before being probed with mouse monoclonal antibody raised against β-
catenin (BD Transduction Laboratories; Franklin Lakes, NJ) in milk-TBST 
(1:1000) overnight at 4°C.  Blots were subsequently washed with milk-TBST and 
then incubated for 1h at room temperature in secondary antibody (peroxidase 
conjugated goat anti-mouse IgG; Rockland).  The blots were washed in TBST 
and immunopositive signal visualized using Super Signal West Dura Extended 
Duration Substrate (Thermo Scientific) and imaged digitally with the G:Box 
ChemiHR system for densitometric analysis using GeneSnap software 
(SynGene).  Measurements from tissue ipsilateral to UEC were compared to 
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homologous contralateral control regions and results expressed as percent of 
contralateral value.   
 
Protein Extraction with Phosphatase Inhibition  
In a subset  (n = 2) of the 2d UEC samples , whole hippocampi were 
homogenized in the same buffer system as indicated above, except that 
PhosStop (1:10 dilution; Roche Applied Science; Indianapolis, IN) and complete 
protease inhibitor cocktail (1:25 dilution; Roche Applied Science) were added to 
the 125 μl volume of T-PER.  After protein determination, 20 μg volumes were 
separated on the same 4-12% Bis-Tris Criterion XT gel system and transferred to 
PVDF membranes.  Blots were then subjected to the same protocol for β-catenin 
Western blotting and visualization as described above.  Densitometric analysis of 
band intensity was again determined with SynGene software and injury effect 
expressed as percent of contralateral control.    
 
Statistical Analysis   
 The significance of percent change in densitometric values from Western 
blot immunobinding was analyzed using the Student’s t-test.  A probability of less 
than 0.05 was considered statistically significant for all tests. 
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Results 
Expression of β-catenin During Time Course of Reactive Synaptogenesis 
Western blot analysis was performed on hippocampal homogenates from 
2, 7 and 15d post lesion using anti-β-catenin antibody.  In contralateral control 
tissues we observed a primary band at 92 kD at all time points sampled.  In 
ipsilateral hippocampus, signal intensity for this 92 kD band was reduced at 2 
and 7d (Figure 4.1; 39.1 ± 2.9%, p<0.01 and 37.8 ± 6.5%, *p<0.05) returning to 
control levels by 15d.  By contrast, two lower bands at 90 kD and 75 kD were 
barely detectable in contralateral control tissue and were significantly increased 
after UEC (Figure 4.1; 90 kD-2d 270.5 ± 19.1%, *p<0.01; 7d 258.8 ± 32.0%, 
*p<0.05; 15d 157.6 ± 13.8%, *p<0.05; 75 kD-2d 379.6 ± 69.5%, *p<0.05; 7d 
390.1 ± 29.5%, *p<0.05; 15d 175.3 ± 11.4%, *p<0.05).  These results show that 
reactive synaptogenesis alters the protein profile of β-catenin in hippocampus.  
The shift in molecular weight of β-catenin may reflect increased proteolytic 
processing and/or a shift in phosphorylation due to altered balance of 
phosphatase and kinase activity following injury. 
 
Expression of β-catenin is Altered by Phosphatase Inhibition 
 We added PhosStop phosphatase inhibitor (Roche) to a small subset of 
hippocampal homogenates extracted at 2d.  When we performed Western 
blotting on these tissues, the injury-induced shift in β-catenin was abolished 
(Figure 4.2).  In contrast to untreated ipsilateral samples, PhosStop treated  
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Figure 4.1  The protein profile of β-catenin is altered in hippocampus after 
UEC.  Western blotting of β-catenin revealed a primary band at 92 kD in 
contralateral control tissue.  In ipsilateral hippocampus, UEC produced a shift in 
molecular weight of β-catenin, with reduced signal in the 92kD band and 
increased signal in additional bands at 90kD and 75 kD.  These changes were 
evident at 2 and 7dpl.  At 15dpl there was a trend toward return to contralateral 
baseline, with the 92kD band equal to control levels and expression of the lower 
bands still elevated, but markedly reduced compared to earlier post-injury time 
points (i = ipsilateral; c = contralateral). 
  150
 
 
 
Figure 4.1 
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Figure 4.2  Phosphatase inhibition abolishes the UEC-induced shift in β-
catenin.  In a small subset of animals, hippocampi were collected at 2d post 
lesion and PhosStop phosphatase inhibitor was added to the protein 
homogenates.  Compared to untreated samples at 2d, PhosStop treated samples 
no longer showed reduction in the 92 kD band ipsilateral to UEC.  Appearance of 
the lower 90kD and 75 kD bands ipsilateral to injury was also abolished in the 
PhosStop treated samples.  (I = ipsilateral; C = contralateral). 
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Figure 4.2 
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samples ipsilateral to injury showed no reduction in the 92kD band and a 
disappearance of the lower 90 and 75 kD bands.  This finding suggests that the 
shift in β-catenin after UEC is dependent on phosphatase activity, and suggests 
a potential role for sRPTPβ or other phosphatases (such as calcineurin) in 
regulating β-catenin function during reactive synaptogenesis. 
 
 
Discussion 
 In the present study we have examined the post-injury expression profile 
of β-catenin, a substrate which may mediate the downstream effects of sRPTPβ 
on injury-induced structural reorganization of synapses.  Western blotting of 
hippocampal β-catenin after UEC revealed a shift in the molecular weight of β-
catenin bands.  Compared to contralateral controls, a 75kD and 90kD band were 
each enhanced at 2, 7, and 15d postinjury, while the primary 92kD band was 
reduced at 2 and 7d after UEC.  Inhibiting phosphatases in the tissue 
homogenates abolished the injury-induced shift in β-catenin bands, supporting 
the hypothesis that phosphatase activity may regulate the function of β-catenin 
during reactive synaptogenesis.   
 
β-catenin Cleavage After UEC 
From our initial experiments it is clear that different forms of β-catenin are 
generated during the time course of UEC reactive synaptogenesis.  While the 
  154
cellular mechanism(s) responsible for producing these fragments cannot be 
determined from the present data, at least three possibilities are suggested. 
These include either a shift in phosphorylation state, proteolytic cleavage, or 
some combination of the two.  If sRPTPβ is directly altering the profile of β-
catenin, it would most likely be involved with the generation of the 90kD 
fragment, resulting in a 2kD shift due to extensive dephosphorylation of tyrosine 
residues.  It is also possible that sRPTPβ activity might indirectly alter the 
structure of β-catenin to facilitate specific proteolysis, similar to what  has been 
suggested for the interaction of β-catenin and other protein tyrosine 
phosphatases with the Wnt signaling pathway (Welters et al., 2008).  If sRPTPβ 
and other enzymes work in concert after UEC, then the 75 and 90 kD bands 
immunoreactive for β-catenin would most likely represent cleavage products of 
the full-length 92kD form.  Calpain cleaves β-catenin after NMDA receptor 
activation in hippocampal neurons (Abe & Takeichi, 2007), generating stable 
truncated forms at 85 and 75 kD.  Since UEC has been shown to induce calpain 
activity in the denervated regions (Seubert et al., 1988), one or both of the 
fragments we have observed could be calpain cleavage products.   
Alternatively, β-catenin can also be degraded by caspase-3, though in this 
case several different fragment sizes have been reported (Steinhusen et al., 
2000; Brancolini et al., 1997; Van de Craen et al., 1999).  Because of this 
variability, it is generally concluded that the pattern of β-catenin breakdown 
products generated by caspase-3 may depend on cell type and/or the extent of 
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enzyme activation.  Peptides at 90 kD and 76 kD were among the caspase-
mediated fragments observed in cultured epithelial cells undergoing apoptosis 
(Steinhusen et al., 2000), which were of similar molecular weight as those we 
observed following UEC.  Furthermore, since entorhinal lesion has been shown 
to induce acute caspase-3 activation (24-36 hours) in a subset of dentate granule 
cells (Kovac et al., 2004), the β-catenin fragments we find in our hippocampal 
extracts could be generated by caspase-3, within a population of granule cell 
neurons undergoing transneuronal cell death after UEC. 
 
Potential Injury Effects on β-catenin Function in Spines 
β-catenin is known to influence the structural integrity of spines depending 
on its tyrosine phosphorylation (Takeichi & Abe, 2005).  Dephosphorylated β-
catenin associates with α-catenin, and stabilizes synapses by linking surface 
cadherins to the actin cytoskeleton.  By contrast, tyrosine-phosphorylated β-
catenin dissociates from this complex and accumulates in dendritic shafts 
(Murase et al., 2002).  In neurons, multiple tyrosine kinases and phosphatases 
work together to control β-catenin phosphorylation, and their relative 
contributions in regulating the cytoskeletal role of β-catenin are not yet fully 
understood (Lilien & Balsamo, 2005).  However, the neuronal phosphatase 
sRPTPβ is ideally positioned to influence the plasticity of dendritic spines through 
β-catenin after UEC.  sRPTPβ dephosphorylates β-catenin on tyrosine, is 
specifically enriched at postsynaptic sites, and expression of sRPTPβ is 
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increased over the same post-injury time course described in the present study 
(Harris et al., 2008; see also Chapter 2).  Since the intracellular phosphatase 
domain of sRPTPβ is constitutively active, it can reasonably be presumed that 
increased protein expression corresponds to increased dephosphorylation of 
sRPTPβ substrates.  During reactive plasticity, enhanced sRPTPβ activity may 
modulate the effects of tyrosine kinases in dendritic spines, resulting in a more 
dynamic regulation of β-catenin.  This would be consistent with the active 
cytoskeletal reorganization that underlies spine retraction (2d) and reformation 
(7d) after UEC (Steward 1989).   
In addition to the morphological effects, an increased rate of sRPTPβ-
mediated dephosphorylation could have several additional consequences in 
postsynaptic spines.  For example, tyrosine-phosphorylated β-catenin is known 
to dissociate from N-cadherin, rendering N-cadherin more susceptible to 
ubiquitination and degradation (Huber et al., 2001; Lilien & Balsamo, 2005).  
Thus, increased sRPTPβ activity could promote the association of β-catenin and 
N-cadherin, reducing N-cadherin turnover and protecting the stability of cadherin 
mediated synaptic adhesions.  Further, recent evidence has suggested a novel 
role for β-catenin in maintaining excitatory synaptic strength by regulating the 
abundance of functional postsynaptic AMPA receptors (Okuda et al., 2007).  This 
raises the possibility that sRPTPβ effects on β-catenin could modulate 
physiological responses of deafferented ML dendrites after UEC.   
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It is unclear whether the β-catenin fragments generated after UEC would 
have implications for altered cytoskeletal stability.  Steinhusen et al. (2000) 
showed that fragments generated by caspase-3 in MCDK cells could still interact 
with both α-catenin and cadherin.  On the other hand, Brancolini et al. (1997) 
reported that caspase-cleaved β-catenin did not associate with α-catenin in 
apoptotic NIH3T3 and MDCK cell lysates.  Also Abe and Takeichi (2007) showed 
that fragments generated by NMDAR-dependent calpain cleavage in neurons 
could not stably associate with cadherin.  In order to determine the impact of β-
catenin cleavage on injury-induced plasticity, future studies will first have to 
determine whether the β-catenin fragments that appear in hippocampal 
homogenates after UEC are generated in intact, reorganizing dentate granule 
cells (DGCs) or in apoptotic DGCs.   
 
Potential Injury Effects on the Transcriptional Function of β-catenin 
In addition to its role as cytoskeletal regulator, β-catenin also plays an 
important role in the neuronal cell body as a transcription factor.  This 
transcriptional function can be activated through the canonical Wnt pathway 
(Moon et al., 2002), or through an activity-dependent NMDAR-calpain pathway 
(Abe & Takeichi, 2007).  If the β-catenin fragments generated in the denervated 
hippocampus after UEC are the product of calpain, then these may retain 
transcriptional activity and potentially alter gene expression to influence synaptic 
recovery (Abe & Takeichi, 2007).  Conversely, if these are caspase-derived 
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fragments, they may have reduced or inactivated transcription potential 
(Steinhusen et al., 2000).  To date, it remains unclear whether these 
transcriptional modifications would positively or negatively affect synaptogenesis 
after brain injury.  The complexity of such transcriptional change is illustrated by 
a recent study, where calcineurin, a serine-threonine phosphatase which can 
also target tyrosine (Chernoff et al., 1984; Pallen et al., 1985), has been shown to 
mediate nuclear translocation of the transcription factor proline-rich tyrosine 
kinase 2 (Faure et al., 2007).  Following TBI, calcineurin inhibition is 
neuroprotective, suggesting that, in certain cases, attenuation of phosphatase-
induced transcriptional change would be beneficial.  Future studies will need to 
define whether β-catenin and other phosphatase substrates indeed act as 
transcription factors after TBI and what genes they may target to affect synaptic 
plasticity. 
As discussed above, when β-catenin in spines is tyrosine-phosphorylated, 
it dissociates from α-catenin and cadherin and moves away from the synapse to 
the base of spines.  Is this pool of unbound β-catenin then available to move to 
the nucleus and act as a transcription factor?  Recent reviews have posed the 
question of whether the cytoskeletal and transcriptional functions of β-catenin are 
served by two separate pools of proteins, or a single common pool (Nelson & 
Nusse, 2004; Harris & Peifer, 2005).  A study from Brembeck and colleagues 
(2004) suggested that in cultured fibroblasts, β-catenin can translocate from the 
plasma membrane to the nucleus to serve either function, with the switch 
  159
mediated by tyrosine phosphorylation and the co-factor BCL9-2.  When 
dephosphorylated on Y142, β-catenin binds α-catenin and cadherin to stabilize 
cell adhesions.  When phosphorylated, β-catenin dissociates from α-catenin, and 
is then able to bind BCL9-2 and translocate to the nucleus.  It is yet unclear 
whether a similar mechanism might work in neurons.  If so, this raises the 
possibility that changes in the balance of kinase and phosphatase activity after 
injury could affect not only the cytoskeletal function of β-catenin, but also its 
transcriptional activity.  Specifically, increased phosphatase activity could 
decrease β-catenin availability to move to the nucleus and activate transcription. 
 
In conclusion, the results presented here lend support to the hypothesis 
that sRPTPβ may function through its intracellular substrates to influence 
reorganization of postsynaptic structures after injury.  We have focused on β-
catenin, showing that the protein profile of this substrate is altered after UEC at 
the same post-injury time points when sRPTPβ is upregulated.  Exactly how the 
observed generation of β-catenin fragments may be related to the presumed 
increase in sRPTPβ-mediated dephosphorylation after injury is still 
undetermined.  However it is clear that changes in proteolysis and 
phosphorylation can influence the structural and transcriptional functions of β-
catenin, and we propose that sRPTPβ is ideally positioned to affect these 
changes. 
  160
Notably, β-catenin is just one of several candidate sRPTPβ substrates 
which could potentially direct synaptic reorganization after brain injury.  Like β-
catenin, the role of other substrates (e.g. β-adducin, P190 RhoGAP) in regulating 
cytoskeletal structure can be directly altered by tyrosine phosphorylation and 
dephosphorylation (Pariser et al. 2005; Tamura et al., 2006).  Further 
investigation of additional substrates will help better elucidate the mechanism by 
which elevated sRPTPβ could affect cytoskeletal fluidity during spine retraction, 
spine regeneration, establishment of new synaptic contacts with sprouted axons, 
and stabilization of these newly formed synapses.  It is our hope that a better 
understanding of the factors which control reactive synaptogenesis will help to 
identify therapeutic approaches which will support adaptive plasticity after TBI, 
and ultimately, will enhance recovery. 
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CHAPTER 5 
GENERAL DISCUSSION 
 
 
Summary of Results 
 In these studies we have investigated the role of phosphacan/RPTPβ 
variants, major components of brain ECM, in synaptic plasticity following brain 
injury.  In Chapter 2, we provided a detailed characterization of the spatial and 
temporal expression of three phosphacan splice variants (phosphacan, RPTPβ 
and sRPTPβ) during reactive synaptogenesis.  We used unilateral entorhinal 
cortex lesion (UEC), a well-characterized rodent model of reactive plasticity 
which leads to successful functional recovery.  UEC allowed us to track mRNA 
and protein throughout the course of reactive sprouting and synapse formation in 
the ipsilateral dentate gyrus (DG) during the first two weeks post-lesion.  We 
focused on three post-injury time points corresponding to three distinct phases of 
the adaptive plasticity response: degeneration of perforant path axon terminals 
(2d), afferent sprouting and establishment of new synaptic contacts (7d), and 
stabilization of newly formed synapses (15d).  We show for the first time that 
hippocampal sRPTPβ protein and mRNA are persistently elevated during all 
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three phases of synaptogenesis after UEC.  In contrast, we have demonstrated 
that hippocampal phosphacan protein is elevated during the acute degenerative 
phase (2d in whole hippcampus) and during sprouting and synapse formation (7d 
in isolated molecular layer).  Phosphacan transcript was also increased at 7d 
post injury.  Immunolocalization studies suggested that sRPTPβ is localized on 
dendrites and spines in the OML, while phosphacan is found more diffusely in the 
neuropil, particularly in spaces surrounding granule cell bodies.  These results 
support a role for phosphacan/RPTPβ splice variants in both the degenerative 
and regenerative phases of injury-induced synaptogenesis.   
 As we began our study to measure mRNA levels of phosphacan/RPTPβ 
after UEC, we turned our attention to the technical limitations of qRT-PCR for 
resolving the small-but-consistent changes we observed in our genes of interest.  
In particular, we had some initial difficulty identifying a suitable reference gene 
which was stably expressed and unaffected by the applied brain lesion.  Chapter 
3 therefore sought to systematically compare the expression of four widely used 
reference genes (β-actin, GAPDH, cyclophilin, 18s rRNA) in hippocampus after 
UEC, in order to determine their suitability as normalization factors.  Beyond the 
immediate applicability of these results to our qRT-PCR studies following UEC, 
selection of a normalization strategy is a critical issue for TBI researchers in 
general.  qRT-PCR is now the method of choice for measuring mRNA, and the 
choice of reference gene can significantly affect final experimental results.  
Unfortunately, many currently published studies still fail to appropriately validate 
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their qRT-PCR normalization strategy.  Therefore we have also evaluated these 
candidate reference genes in hippocampus and cortex following central fluid 
percussion injury (cFPI), a widely used model of brain trauma in rodents.  Nearly 
all TBI studies using qRT-PCR in the last 5 years have utilized one of these four 
genes for data normalization (Rhinn et al., 2008).  In Chapter 3 we report that 
none of the reference genes we tested shows invariant expression across all 
tissues, time points, and experimental injury models.  However, we have 
identified certain reference genes which may be reasonable choices for 
normalization within a defined experimental context (for example, cyclophilin in 
hippocampus after UEC).  From these studies it is clear that endogenous 
reference gene expression can be modulated by injury-induced tissue 
denervation and closed-head trauma.  Since our findings regarding appropriate 
normalization choices differ significantly from the findings of two recent studies of 
reference genes in mouse TBI models (Rhinn et al., 2008; Thal et al., 2008) we 
emphasize the critical importance of reference gene validation for each new TBI 
model and each set of experimental conditions.  We define a 'validated' reference 
gene as one whose expression does not change under the varying experimental 
conditions of a study and whose intrinsic variability of expression (within-group 
coefficient of variation) is low.  Normalization to multiple reference genes may be 
preferable to a single control, when resources permit extensive screening of 
reference gene candidates.  Normalization to total RNA is another alternative, 
which may be the best option in cases when extensive screening of reference 
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genes is not practically feasible or when a suitably stable reference cannot be 
found.   
In Chapter 4, we began to investigate the potential functional significance 
of the increased sRPTPβ expression observed during the course of reactive 
synaptogenesis.  These studies have shown for the first time that β-catenin, a 
substrate of sRPTPβ and a critical cytoskeletal regulator protein, is altered during 
reactive plasticity after UEC.  We have described a shift in the protein profile of β-
catenin on Western blots, including reduced signal for full-length β-catenin and 
increased signal for two shorter immunoreactive bands.  These may reflect 
proteolytic degradation by calpain or caspase.  Exactly how these β-catenin 
fragments may be related to the presumed increase in sRPTPβ-mediated 
dephosphorylation of β-catenin remains to be determined.  However sRPTPβ is 
known to target β-catenin, and is specifically enriched on postsynaptic spines 
where β-catenin regulates the stability of the actin cytoskeleton.  Since 
expression of sRPTPβ is increased after injury at time points when dendritic 
reorganization is known to occur, we suggest that sRPTPβ is ideally positioned to 
influence the reactive plasticity of dendritic spines through β-catenin.   
 
Source of Elevated Phosphacan Expression 
 While these studies have provided a detailed characterization of 
phosphacan/RPTPβ expression at the protein and mRNA levels during injury-
induced synaptic plasticity, some key questions remain.  For instance, the source 
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of increased phosphacan expression after UEC is still undetermined.  While a 
number of studies have described phosphacan expression by astrocytes in vivo 
and in vitro (Canoll et al.,1993; Milev et al.,1994; Engel et al., 1996; Meyer-
Puttlitz et al., 1996; McKeon et al., 1999; Beck et al., 2008), we did not detect 
any co-localization of astrocytic marker GFAP and 3F8 immunostaining for 
phosphacan in our tissues.  It is still possible that astrocytes are the source of the 
increased phosphacan expression after UEC, but that the redistribution of 
phosphacan once secreted into the extracellular space precludes detection of 
colocalization by immunohistochemical means.  Astrocytes have been shown to 
contain phosphacan mRNA (Engel et al., 1996; Canoll et al., 1996; McKeon et 
al., 1999) and probing for phosphacan with in situ hybridization after UEC could 
be a straightforward way to answer this question. 
 Neurons could also be the source of elevated phosphacan following UEC.  
We did not try co-localization of 3F8 immunostaining with neuron-specific 
markers, but it is possible that as with astrocytes, phosphacan antibodies would 
not co-localize with neuronal markers because of diffusion or redistribution once 
it is secreted.  Phosphacan mRNA has been detected in granule and pyramidal 
neurons of the hippocampal formation in adult rodents (Snyder et al., 1996).  Our 
IHC results with confocal microscopy showed phosphacan staining in the granule 
cell layer, while qualitative EM analysis showed reaction product for 
phosphacan/RPTPβ in granule cell bodies.  Again, in situ hybridization of the 
denervated dentate gyrus could definitively address whether neuronal 
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populations increase production of phosphacan after injury.  Notably, the DG is 
one of the few brain regions known to undergo continued neurogenesis 
throughout adult life, and EC lesion enhances neurogenesis in the DG (Gama 
Sosa et al., 2004).  Since neural progenitor cells (NPCs) express high levels of 
CSPGs including phosphacan (Kabos et al., 2004), dividing neural progenitors 
could be another potential source of increased phosphacan after UEC, at least 
within the GCL.   
 
Signals Responsible for Phosphacan/RPTPβ Induction 
Another question which remains unresolved is the nature of the upstream 
signals which induce the observed changes in phosphacan and sRPTPβ with 
injury.  A recent study by Beck et al. (2008) demonstrated that the transcription 
factor Egr-1 binds to the phosphacan promoter and activates phosphacan 
transcription both in primary astrocyte cultures and in vivo.  In a mouse model of 
experimental stroke, Egr-1 expression was increased as early as 12 hours post-
injury and co-localized with increased phosphacan in the zone of infarct.  Also 
Egr-1-null mice expressed less phosphacan and sRPTPβ after stroke than wild-
type animals.  This is the first transcription factor which has been shown to 
directly influence expression of phosphacan splice variants.  Egr-1 is considered 
an immediate-early gene which undergoes rapid, transient activation in response 
to growth factors, vascular injury, hypoxia, or mechanical perturbation 
(Khachigian et al., 1996).  It would be interesting to examine the expression of 
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Egr-1 in different brain injury paradigms, and the extent to which this correlates 
with induction of phosphacan/RPTPβ expression.  If the concentration of Egr-1, 
or the mechanical or molecular signals which induce its expression, prove to vary 
in different injury models, this could potentially account for the range of 
phosphacan responses to different types of injury which have been reported by 
different groups (see discussion in chapters 1 and 2). 
 
Function of Phosphacan May Depend on the Presence of  
Co-factors 
 
Whereas some previous studies have reported reduced phosphacan after 
injury (Jones et al., 2003; Dobbertin et al., 2003; Tang et al., 2003), we have 
observed increases in phosphacan expression after UEC, including an increase 
in whole hippocampal protein at 2d, an increase in ML protein at 7d, and an 
increase in mRNA transcript at 7d.  Thus our results, along with those from 
previous studies, suggest that the role of phosphacan in CNS injury is complex, 
and may be dependent on injury type, severity, and location.  Given that 
phosphacan can interact with so many extracellular binding partners, the 
functional role of phosphacan after injury may be contextual; that is, it may 
depend on an array of co-factors whose concentration might vary considerably in 
different microenvironments.  Growth factors (GFs) and cell adhesion molecules 
(CAMs) are two groups of phosphacan ligands of particular interest in this 
respect.   
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GFs are known to promote sprouting and adaptive structural plasticity 
after brain injury (Nieto-Sampedro & Bovolenta, 1990; Cui 2006; Deller et al., 
2006).  The binding of phosphacan to GFs including FGF-2, pleiotrophin, 
amphoterin and midkine, may help to localize or sequester these molecules 
during tissue reorganization and synaptogenesis.  In particular, FGF-2 is known 
to be important for normal reactive plasticity in the dentate gyrus.  FGF-2 mRNA 
was increased in hippocampus during the degenerative and regenerative phases 
of reactive synaptogenesis, while intracerebroventricular (ICV) infusion of FGF-2 
antibodies attenuated the sprouting response (Fagan et al., 1997).  Furthermore, 
intravenous infusion of FGF-2 after entorhinal lesion led to enhanced sprouting of 
the septodentate fibers (Ramirez et al., 1999).  Importantly, the increase in FGF-
2 staining observed by Fagan and colleagues was confined to the OML after the 
denervating lesion and apparently associated with astrocytes.  Since the 
plasticity-promoting function of FGF-2 requires secretion and extracellular 
binding to FGF receptors (Reuss et al., 2003), it is possible that once astrocytes 
secrete this factor, phosphacan, enriched in the OML after UEC, binds to it and 
helps ensure its strict confinement to the region of sprouting.  
 CAMs mediate neuronal adhesion, and these molecules are important 
regulators of structural reorganization and synaptogenesis after brain injury.  
Phosphacan/RPTPβ interaction has been reported for several neuronal CAMs 
including contactin/F3 (Peles et al., 1995), axonin-1/TAG-1 (Milev et al., 1996), 
Nr-CAM (Sakurai et al., 1997), Ng-CAM/L1, and N-CAM (Milev et al., 1994).  
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Binding of the transmembrane RPTPβ variants to CAMs may directly mediate 
cell adhesion (Peles et al., 1995; Sakurai et al., 1996).  By contrast, binding of 
phosphacan to CAMs may interfere with cell adhesion by competing with the 
receptor forms or with other CAMs for binding sites (Milev et al., 1994; Sakurai et 
al., 1997).  This hypothesis has been supported by cell culture experiments, but it 
is unclear whether such interactions occur in the dentate gyrus after EC lesion.  
We have observed sRPTPβ localization on granule cell dendrites and spines 
within the OML.  Axons in the molecular layer have been shown to express Ng-
CAM/L1, while reactive astrocytes in the denervated region increase N-CAM 
expression after UEC (Styren et al., 1995; Jucker et al., 1995, 1996).  It is 
therefore possible that sRPTPβ on dendrites mediates adhesion to CAM-
expressing axon terminals and/or glial cells in the deafferented hippocampus, 
and that phosphacan in the extracellular space serves to modulate these 
interactions.  Such a scenario would place great importance on the temporal 
regulation of phosphacan protein levels after injury.  The enhanced phosphacan 
expression we have observed at 2d (in whole hippocampal tissue) and 7d (in 
molecular layer enriched samples) could represent an adaptive response to 
injury.  During these early post-injury phases, sprouting terminals and dendritic 
spines must release their contacts with neighboring cells in order to allow 
structural reorganization and establishment of new synaptic contacts.  Increased 
extracellular phosphacan might bind to adhesion molecules to facilitate such a 
release.  In contrast, a more prolonged phosphacan elevation (which we have 
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not observed after UEC, but which has been reported in some other studies, e.g. 
Carmichael et al., 2005) could be maladaptive, since prolonged interference with 
cell adhesion would impair synapse stabilization and maturation.  Future studies 
which manipulate sRPTPβ binding in vivo could test these hypotheses.  For 
example, infusion of purified phosphacan should increase competition for CAM 
binding and enhance synaptic reorganization if administered early after injury, 
while later treatment should impair successful synapse formation.  Treatment 
with antibodies to the CAM-binding region of sRPTPβ would also disrupt 
sRPTPβ-CAM interactions and should have a similar effect. 
 
Multiple Intracellular Targets of sRPTPβ May Be Involved at 
Different Post-Injury Stages 
 
In Chapter 4 we evaluated post-injury changes in β-catenin, a substrate of 
sRPTPβ known to play an important role in cytoskeletal regulation and spine 
morphogenesis.  However β-catenin is just one of several sRPTPβ substrates 
which could potentially influence structural reorganization after brain injury.  Like 
β-catenin, the functional interactions of other substrates have been shown to be 
directly altered by tyrosine phosphorylation and dephosphorylation.  One 
example is β-adducin, a neuron-specific cytoskeletal regulator also targeted for 
dephosphorylation by sRPTPβ (Pariser et al., 2005).  β-adducin caps actin 
filaments and works with α-adducin to promote stabilization of actin-spectrin 
junctions near the plasma membrane (Gardner & Bennett ,1987).  Tyrosine 
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phosphorylation of β-adducin alters its subcellular distribution, suggesting 
changes in its association with the actin-spectrin complex (Gotoh et al., 2006).  
Interestingly, β-adducin-deficient mice show abnormalities in LTP maintenance 
and generalized learning deficits on spatial and cued memory tasks, supporting 
the idea that β-adducin is involved in the synaptic plasticity underlying learning 
and memory (Rabenstein et al., 2005).   
p190 RhoGAP is another sRPTPβ substrate which has been implicated in 
plasticity required for hippocampus-dependent learning.  In behavioral studies 
comparing wild-type mice with RPTPβ knockouts, fear conditioning induced 
dephosphorylation of p190 RhoGAP in wild-types, while RPTPβ-deficient mice 
showed no change in phosphorylation of p190 and impaired learning ability 
(Tamura et al., 2006).  Tyrosine dephosphorylation of p190 RhoGAP is known to 
inhibit its interaction with Rho, thus promoting Rho GTPase activity.  Therefore in 
the absence of sRPTPβ-mediated dephosphorylation, the learning defects in 
knockout mice were attributed to reduced activation of Rho GTPase.  Rho 
GTPases are known to be important for neuronal morphogenesis and structural 
plasticity (Luo 2002).  It would be interesting to examine whether RPTPβ 
knockout animals exhibit altered capacity for reactive plasticity after brain injury, 
and whether this could be correlated with differences in substrate 
phosphorylation.  Tamura and colleagues (2006) have developed an antibody 
specific to tyrosine-phosphorylated p190 RhoGAP which would be useful for this 
kind of investigation.  If such a correlation could be established, this would 
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provide strong evidence that sRPTPβ influences structural plasticity following 
injury at least in part through targeting the substrate p190 RhoGAP. 
 The most recently identified sRPTPβ substrate is the receptor tyrosine 
kinase TrkA (Shintani & Noda 2008).  Unlike the intracellular proteins discussed 
above, this substrate is a transmembrane receptor which mediates signaling for 
outgrowth and plasticity of both axons and dendrites in response to nerve growth 
factor (NGF; Huang & Reichardt, 2001).  Shintani and Noda showed that 
sRPTPβ dephosphorylates TrkA and inhibits its activation, leading to attenuated 
neurite outgrowth in NGF-stimulated PC12D cells.  The fact that sRPTPβ 
reduced but did not completely attenuate neurite outgrowth in these studies 
suggests a modulatory role for sRPTPβ in growth factor-induced plasticity.  
Importantly, NGF expression is increased in the OML after EC lesion (Conner et 
al., 1994) and intraventricular treatment with NGF antibodies inhibits regenerative 
sprouting (Van der Zee et al., 1992).  If sRPTPβ interacts with TrkA in the 
denervated hippocampus, then it is possible that elevated sRPTPβ expression 
after injury could modulate growth factor-induced synaptic reorganization.   
Altogether, it is likely that change in expression of sRPTPβ after injury 
coordinately regulates the function of multiple intracellular substrates, by altering 
their steady-state tyrosine phosphorylation.  Since we have shown that sRPTPβ 
is persistently upregulated in the zone of sprouting and synaptogenesis after 
UEC, actions of different downstream targets may mediate distinct functions of 
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sRPTPβ during the early, intermediate, and later phases of injury-induced 
plasticity.   
 
sRPTPβ in the Context of Other Phosphatases and Kinases 
The tyrosine phosphorylation state of proteins in the nervous system is 
typically maintained by the balanced activity of multiple kinases and 
phosphatases (Johnson & Van Vactor, 2003; Paul & Lombroso, 2003).  While 
injury-induced sRPTPβ changes have the capacity to alter the steady-state 
tyrosine phosphorylation of intracellular targets, we cannot rule out the possibility 
that changes in other tyrosine phosphatases and kinases after brain injury could 
counteract or augment the effect of sRPTPβ alone.  Other neuronal tyrosine 
phosphatases share partially overlapping substrate specificity with sRPTPβ.  For 
example PTP1B and LAR-PTP also act on β-catenin (Balsamo et al., 1998; 
Kypta et al., 1996) and PTPσ dephosphorylates TrkA (Faux et al., 2007).  
Neuronal tyrosine kinases which may work to counteract the effects of sRPTPβ 
activity include the EGF family of receptor tyrosine kinases and the Src family of 
intracellular kinases, e.g. Fyn, Src, and Abl (Murase et al., 2002; Roura et al., 
1999).  Interestingly, Fyn is itself dephosphorylated by sRPTPβ (Pariser et al., 
2005).  This raises the possibility that sRPTPβ may regulate steady-state levels 
of tyrosine phosphorylation both directly (by dephosphorylating substrates), and 
indirectly by altering tyrosine kinase activity.   
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 While it is difficult to directly assess activity changes in an individual 
phosphatase protein after injury, it would be interesting to perform a phosphatase 
assay to investigate overall changes in tyrosine phosphatase activity in brain 
tissue at different post-injury time points.  This would determine whether the 
expressional changes we have observed in sRPTPβ occur in parallel with 
generalized changes in tyrosine phosphatase activity after brain injury.  Clearly 
the factors controlling tyrosine phosphorylation after injury are complex, and 
understanding the contributions of multiple kinases and phosphatases to the 
structural reorganization that occurs after brain injury remains a major challenge 
for the future. 
 
Potential Modulation of sRPTPβ Phosphatase Activity 
We have thus far assumed that increased expression of sRPTPβ would 
directly correspond to increased effects of the constitutively active intracellular 
phosphatase.  However, there are at least two ways in which this constitutive 
enzymatic activity may be modulated following TBI.  First, sRPTPβ phosphatase 
activity can be regulated by interaction with the growth factor pleiotrophin (PTN).  
PTN has been shown to inactivate the phosphatase upon binding to the 
extracellular domain of sRPTPβ (Meng et al., 2000).  In normal adult brain PTN is 
expressed by a subset of neurons, but its expression by astrocytes and 
macrophages is greatly upregulated after acute ischemic injury (Yeh et al., 1998).  
If PTN is also increased following traumatic brain injury, this could potentially 
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suppress activity of the sRPTPβ phosphatase and its downstream effects on key 
intracellular substrates.  Second, a recent study has reported that reactive 
oxidative species (ROS) specifically target the conserved cysteine residues in the 
catalytic domain of protein tyrosine phosphatases, rendering them inactive (Wu & 
Terada, 2006).  Brain injury is well known to induce oxidative stress in surviving 
neurons (Juurlink & Paterson, 1998; Bayir et al., 2006).  Thus, even if sRPTPβ 
protein levels are increased following injury, this might not correspond to 
increased phosphatase activity if the phosphatase is inactivated in cells 
undergoing oxidative stress.  Alternatively, in the face of phosphatase 
inactivation by PTN and/or ROS, the increase in sRPTPβ expression we have 
observed after brain injury could be an adaptive response in order to maintain 
homeostasis. 
 
Clinical Considerations 
Relevance of Findings in UEC to Clinical TBI 
 Each year, TBI affects at least 1.5 million people in the U.S and millions 
more around the world.  There is mounting evidence to indicate that TBI induces 
axonal sprouting of spared axons and subsequent synaptogenesis, and that 
these processes can support functional recovery.  However the natural extent of 
reactive synaptic plasticity achieved after most brain injuries is limited.  
Identifying the factors that regulate injury-induced sprouting and synaptogenesis 
is an important challenge of current TBI research.  UEC, as applied in the 
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present studies, is a targeted lesion known to induce robust, localized sprouting 
and synaptogenesis which can be directly examined.  The discrete nature of EC 
lesion allows researchers to identify molecules and define mechanisms involved 
in adaptive synaptic reorganization after injury.  However, it is important to 
recognize that UEC also has its limitations.  In particular, its relative lack of many 
complicating pathologies common to human TBI (e.g. neuroexcitatory insult, 
vascular damage, edema, hypoxia, inflammation) could lead to difficulty in 
translating research findings and experimental treatments to successful 
application in brain-injured patients.   While other TBI models which more 
specifically reproduce the pathologic features of human closed-head injury do 
induce a limited degree of post-injury sprouting (Erb & Povlishock, 1991; 
Christman et al., 1997), the diffuse nature of reactive synaptogenesis in these 
models makes further study difficult.  One reasonable strategy would be to 
contrast the adaptive response to a targeted UEC lesion with that generated in a 
TBI model which does not lead to successful synaptic recovery.  This approach 
has been taken in studies which compare UEC to a combined insult model which 
pairs bilateral UEC lesion with central fluid percussion injury, generating a 
maladaptive synaptic plasticity consistent with clinical TBI outcome (Phillips et 
al., 1994; Phillips et al, 1997; Zhu et al., 2000; Phillips & Reeves, 2001; Falo et 
al., 2006).  Thus, having the option to design studies which compare the adaptive 
synaptogenesis following UEC with insults which do not lead to successful 
recovery is another powerful benefit of the UEC injury paradigm.   
  177
 
ECM Manipulations Can Promote Sprouting and Recovery after Injury   
 Exciting new studies have garnered much attention by showing that in vivo 
treatment with chondroitinase ABC (chABC), an enzyme which digests the CS-
GAG side chains of matrix CSPGs, can promote axon sprouting and recovery 
after CNS injury.  These studies provide important proof-of-concept that the ECM 
influences plasticity following injury, and that manipulations to render the 
extracellular environment more permissive can significantly affect anatomical, 
physiological, and behavioral measures of recovery (Reviewed in Crespo et al., 
2007; Del Rio & Soriano, 2007).  However, chABC is a non-specific treatment; it 
degrades both hyaluronan and the CS portion of all extracellular CSPGs.  The 
functional significance of hyaluronan (HA) digestion by chABC is just beginning 
to be appreciated.  Since HA serves to link many ECM components, it has been 
suggested that its degradation leads to a more widespread disruption of ECM 
structure than digestion of CS alone, and this may be important for the effect of 
chABC on plasticity and recovery (Crespo et al., 2007).   
In addition, the mechanism(s) by which degradation of CS on CSPGs can 
enhance recovery are not well understood.  It is well documented that the 
expression of CSPGs is upregulated by reactive glia in response to CNS injury 
and that this contributes to inhibition of adaptive axon growth and plasticity 
(McKeon et al., 1991; Davies et al., 1999).  As discussed in Chapter 1, CSPGs in 
the nervous system constitute a large group of molecules which exhibit 
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substantial structural and functional diversity.  The removal of CS is therefore 
likely to reduce the inhibitory effects of some, but not all, CSPGs.  Notably, one in 
vitro study reported that chABC-mediated digestion of CS on phosphacan 
significantly enhanced its inhibitory effect on neurite outgrowth from retinal 
ganglion cells (Inatani et al., 2001).  This increased inhibition of neurite outgrowth 
after CS removal from phosphacan could be due to a loss of interaction with 
growth and plasticity-promoting factors, since CS chains are the sites where 
several GFs bind to phosphacan (Milev et al 1998; Maeda et al 1999).  We have 
hypothesized that the increased phosphacan observed in reorganizing OML after 
UEC could support recovery by concentrating GFs in the denervated region.  If 
this is the case, then treatment with chABC after UEC would eliminate GF 
binding and possibly impair recovery.  chABC has been successfully 
administered in vivo by intracerebroventricular infusion, and it would be 
interesting to examine the effect of this enzyme on sprouting and recovery after 
UEC.   
Thus while chABC clearly shows promise as a potential therapeutic 
approach to promote plasticity and recovery after CNS injury, its nonspecific 
mechanism of action may also present some drawbacks.  Although degradation 
of CS may reduce inhibitory effects of many CSPGs, it could also increase 
inhibition of axonal outgrowth and plasticity by other CSPGs like phosphacan.  
Gaining a better understanding of the contributions of specific ECM components 
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in the CNS injury response is an essential first step for developing the next 
generation of more specific and effective ECM-manipulating therapies.   
 
Concluding Remarks 
In conclusion, the present studies have characterized the expression of 
phosphacan/RPTPβ splice variants over the course of reactive plasticity following 
brain injury.  Protein expression of sRPTPβ, the primary receptor isoform in 
mature brain, is persistently increased during the first two weeks after 
hippocampal denervation.  By contrast, post-injury increases in phosphacan, the 
primary extracellular isoform, were limited to the early degenerative phase (2d, 
whole hippocampal homogenates) and the later phase of synaptic reorganization 
(7d in molecular layer enriched fractions).  Using a rigorously validated approach 
to our qRT-PCR analysis (as detailed in chapter 3), we show that mRNA for 
sRPTPβ is also persistently elevated, while mRNA for phosphacan is increased 
during the phase of active tissue reorganization and synaptogenesis (7d).  The 
protein profile of the sRPTPβ substrate β-catenin, an important regulator of spine 
morphogenesis, shows a shift after injury which temporally correlates with the 
changes seen in sRPTPβ.  We propose that sRPTPβ could promote postsynaptic 
structural plasticity after brain injury by controlling the phosphorylation of β-
catenin and possibly other intracellular substrates. 
In sum, our findings support the hypothesis that phosphacan and sRPTPβ 
play a role in the adaptive reactive plasticity and synaptogenesis that occur 
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following TBI.  It is our hope that the results and discussion presented herein will 
contribute to a better understanding of the complexity of ECM responses to brain 
injury.  It has been scarcely two decades since the concept of a substantial, 
functionally significant ECM in the nervous system truly gained widespread 
acceptance (Celio 1999).  In that time, great progress has been made in defining 
which matrix molecules serve adaptive roles and which serve maladaptive roles 
after brain and spinal cord injury.  Moreover it has been demonstrated that these 
roles are not at all static, but are likely to vary with injury type, severity, location, 
and post-injury time interval.  Since pioneering experiments have recently begun 
to show the promise of therapeutic interventions which manipulate ECM, gaining 
a better understanding of how different matrix molecules contribute to the 
success—or the failure—of recovery from brain injury is now all the more 
important.  This information will improve our understanding of how such 
interventions work, and it will be critical for developing the next generation of 
more effective, targeted therapies to improve outcomes for brain injured patients. 
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Appendix A 
 
 
 
 
 
A Representative lanes (3F8)        B Representative lanes (anti-RPTPβ) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Serial extraction of soluble and membrane-associated proteins from brain 
tissue homogenates.   Because the 3F8 antibody may recognize both 
phosphacan and full-length RPTPβ, we followed serial extraction protocol to 
separate soluble protein-enriched and transmembrane protein-enriched fractions, 
as previously described by Dobbertin et al. (2003).  Phosphacan should be 
enriched in the 'saline' fraction, while both transmembrane forms should be found 
in the 'detergent' fraction.  The representative samples shown here were 
extracted from hippocampus 7d after UEC and treated with chondroitinase ABC 
(see also Appendix B and detailed methods in Chapter 2).  (A) shows that 
phosphacan protein is enriched in the saline (detergent-free) tissue fraction, 
while (B) shows that sRPTPβ protein is enriched in the detergent tissue fraction.  
Consistent with the report by Dobbertin, we did not detect any bands in the 
detergent fraction representing the developmentally prominent full-length RPTPβ.  
Therefore we believe that the 3F8 signal in our samples represents phosphacan 
immunobinding alone.  i = ipsilateral; c = contralateral. 
450 kD
|-----saline-----|  |---detergent---|
i         c         i         c
250 kD
i         c         i         c
|-----saline-----|  |---detergent---|
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Appendix B 
 
 
 
 
 
 
 
Chondroitinase treatment of protein samples for Western blotting.  In order 
to expose antigenic sites and maximize antibody detection of phosphacan and 
sRPTPβ, all protein samples were treated with chondroitinase ABC (chABC) prior 
to Western blotting, to remove chondroitin sulfate side chains.  540μl aliquots of 
either saline-extracted or detergent-extracted protein samples were buffered to 
pH 8 by addition of 400 mM Tris, and mixed with protease inhibitors (Roche 
complete cocktail plus 2μg/ml Pepstatin).  The resulting preparations (600μl 
volume) were incubated with 0.3 U chABC for 3 h, shaking at 37°C.  Reaction 
was stopped by returning samples to -80°C.  Representative lanes from 
hippocampus 7d after UEC were probed with 3F8, and show that chABC 
treatment enhances the strength of 3F8 signal and causes the high molecular 
weight smear to resolve to a band at around 450 kD.  Representative sample 
from hippocampus 2d post lesion show that without chABC treatment there is no 
detectable signal with anti-RPTPβ.  With chABC, a band appears at 250 kD, 
representing sRPTPβ.  i = ipsilateral; c = contralateral. 
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 Appendix C 
 
 
 
 
 
 
Cortical dissection for qRT-PCR analysis after cFPI.  For qRT-PCR analysis 
of candidate reference genes after central fluid percussion injury (cFPI), RNA 
was extracted from bilateral hippocampi and from parietotemporal cortex. The 
cortical regions, diagrammed above, were selected based on the location of 
cellular damage previously observed after cFPI and visualized by cellular uptake 
of horseradish peroxidase. In our studies, rats were deeply anesthetized with 4% 
isoflurane and sacrificed by decapitation. The brain was rapidly removed from the 
skull, and both cerebral hemispheres were gently rolled outward from the midline 
to expose the subcortical structures.  After hippocampi were collected, the 
cortical laminae were laid flat and tissue blocks corresponding to the boxed 
regions were collected for RNA extraction and analysis. 
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Appendix D 
 
 
 
 
 
 
 
Quality assurance of RNA samples.  Each RNA sample extracted from rodent 
brain after UEC or cFPI was evaluated by microcapillary electrophoresis using 
the Experion LabChip (Bio-Rad Laboratories, Inc.) as shown above, or using the 
Agilent bioanalyzer system (Agilent Technologies, Inc.) according to the 
manufacturer's protocol.  The sample shown is RNA isolated from hippocampus 
ipsilateral to UEC at 7d post lesion, and the electropherogram trace is 
representative of all samples used for our qRT-PCR studies.  Clear peaks can be 
seen for 18s and 28s, and background signal is very low, indicating good quality 
RNA with little breakdown or contamination.  RNA concentrations reported in the 
Experion analysis were verified with spectrophotometry.
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Appendix E 
 
 
Intracellular substrates of sRPTPβ 
PSD-95 AMPA-R trafficking, synapse stabilization Kawachi et al. 1999 
β-catenin cytoskeletal regulator, links actin to surface cadherins Meng et al. 2000 
GIT1/Cat-1 growth cone extension, neuronal migration Kawachi et al. 2001 
β-adducin cytoskeletal regulator, stabilizes actin-spectrin junctions Pariser et al. 2005 
Fyn Src family kinase, regulates cytoskeletal plasticity Pariser et al. 2005 
Magi1 scaffolding protein, also binds β-catenin Fukuda et al. 2005 
P190Rho/GAP neuronal morphogenesis, synaptic plasticity Tamura et al. 2006 
ErbB4 neuregulin receptor, maturation and plasticity of excitatory 
synapses 
Fujikawa et al. 2007 
TrkA growth factor signaling, modulates neurite outgrowth Shintani et al. 2008 
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